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Zusammenfassung
Diese Dissertation trägt zum Bereich der biopharmazeutischen Prozessentwicklung und
Produktion bei. In der Pharmaindustrie gewinnen biopharmazeutische, meist protein-
basierte Medikamente, im Vergleich zu klassischen, niedermolekularen Medikamenten
immer mehr an Bedeutung. Durch ihre hohe Spezifität sind proteinbasierte Medikamente
in der Lage zielgerichtet an Zellen oder Rezeptoren zu binden und dadurch einen komplexen
Wirkmechanismus auszulösen. Dadurch erreichen sie oft eine höhere Wirksamkeit bei
gleichzeitiger Reduzierung der Nebenwirkungen. Die komplexe Wirkungsweise eröffnet
zudem die Möglichkeit neue Krankheiten und solche, die aktuell noch nicht therapierbar
sind, zu behandeln. In den letzten Jahren konnte der Bereich der Krebsimmuntherapie
das größte Wachstum im biopharmazeutischen Markt aufweisen. Vor dem Hintergrund
einer alternden Gesellschaft wird die Herausforderung Krebs zu bekämpfen stetig weiter
wachsen. Darüber hinaus wird auch die Nachfrage nach Behandlungen von Autoim-
munerkrankungen, Diabetes oder Alzheimer weiter steigen. Eine Gemeinsamkeit aller
biopharmazeutischen Produkte sind die hohen Entwicklungs- und Produktionskosten. Der
steigenden Nachfrage nach neuen Produkten und höheren Produktionskapazitäten stehen
die immer knapper werdenden Gesundheitsbudgets gegenüber. Durch die Zulassung der
ersten Biosimilars, generischen Versionen des Originalpräparats, nimmt der wirtschaftliche
Druck auf den biopharmazeutischen Sektor weiter zu. Während für die erste Generation der
biopharmazeutischen Blockbuster kaum eine Verbindung zwischen Produktionskosten und
Verkaufspreisen bestand, erhöht die Entwicklung von Biosimilars den ökonomischen Druck
auf die Produzenten und dadurch auch den Bedarf an einer schnelleren Prozessentwicklung,
sowie an wirtschaftlicheren Prozessen.
Die Entwicklung von Biopharmazeutika lässt sich grob in Upstream-Prozessentwicklung
(USP), der Produktexpression in lebenden Zellen, und Downstream-Prozessentwicklung
(DSP), der Aufreinigung des hergestellten Produktes, unterteilen. In der Vergangenheit
wurden bereits große Erfolge bei der Entwicklung einer effizienteren USP erzielt. Ins-
besondere erhöhte Zellkultur-Titer führten zu höheren Produktkonzentrationen. Um mit
diesen USP Entwicklungen Schritt zu halten, werden neue und kostengünstige Alterna-
tiven zu den bisherigen Aufreinigungsprozessen benötigt. Heutzutage basiert die DSP von
biopharmazeutischen Produkten hauptsächlich auf chromatographischen Auftrennungs-
schritten. Durch die hohe Selektivität der Chromatographie kann eine hohe Produktrein-
heit erziehlt werden. Jedoch sind diese Vorteile mit hohen Adsorberkosten und einem
langsamen volumetrischen Durchsatz verbunden. Somit verursachen chromatographische
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Aufreinigungsschritte die meisten Kosten der DSP. Dennoch basiert die Entwicklung eines
Aufreinigungsprozesses großteils auf chromatographischen Schritten, da dafür bereits Platt-
formprozesse zur Verfügung stehen. Für monoklonale Antikörper (mAb) beispielsweise
basiert diese Aufreinigungsplattform auf der Protein A Affinitätschromatographie als Cap-
ture Schritt. Dieser Schritt ist für alle mAbs generisch, da die Bindung mit dem Adsorber
einer Interaktion mit der Fc-Region zugeschrieben wird, die in allen mAbs vorhanden
ist. Folglich sind, in Abhängigkeit der verwendeten mAbs, nur geringfügige Anpassungen
des Prozesses erforderlich. Dies macht die Prozessentwicklung einfacher, schneller und
effizienter, führt schlussendlich aber auch zu einem Verlust an Flexibilität. Für neue
Biopharmazeutika, wie alternative mAbs, virusähnliche Partikel (VLP) oder Nukleinsäuren
werden die bestehenden Plattformen nicht geeignet sein. Infolgedessen müssen Alternativen
zu den komfortablen, aber teuren Verfahren entwickelt werden. In der Forschung hat die
präparative Proteinpräzipitation bereits gezeigt, dass sie eine einfach anwendbare und
kostengünstige Alternative sein kann. Neben der salz- oder ethanolinduzierten Präzipitation
hat sich Polyethylenglycol (PEG) als wirksames Präzipitationsmittel für die Reinigung
von Proteinen bewährt. PEG ist vergleichsweise günstig, nicht brennbar, ungiftig und
als Hilfsstoff bereits in vielen Medikamenten zugelassen. Allerdings müssen noch einige
Hindernisse überwunden werden, um eine industrielle Anwendung zu ermöglichen.
Um die Akzeptanz der präparativen Proteinpräzipitation in der biopharmazeutischen Indus-
trie zu erhöhen, sind ein tieferes Verständnis des Mechanismus, neue Entwicklungsstrategien
und eine verbesserte Prozessüberwachung notwendig. Prozesskenntnis ist sowohl für eine
erfolgreiche Prozessentwicklung wie auch für die erfolgreiche Genehmigung durch die
zuständigen Behörden von großer Bedeutung. Obwohl auf dem Gebiet der Proteinstabilität
viel Forschung betrieben wird, sind die dabei wirkenden Interaktionen nicht vollständig
verstanden. Die Kenntnis des Mechanismus kann nicht nur dabei helfen die Proteinpräzipi-
tation zu verstehen, sondern auch die Prozessentwicklung zu verbessern. Heutzutage wird
DSP oft expertenbasiert, vor dem Hintergrund eines Plattformprozesses, durchgeführt. Um
bestehende Plattformprozesse zu ersetzen, fehlt es an flexiblen, schnellen und material-
sparenden Prozessentwicklungsstrategien. Darüber hinaus wird bei der Entwicklung eines
Fällungsschrittes dieser Prozessschritt oft eigenständig optimiert, während ein Konzept
zur Integration in den gesamten Produktionsprozess, einschließlich USP und der nachfol-
genden Aufarbeitungsschritte, fehlt. Zudem wird in einem präparativen Fällungsschritt
der Phasenübergang gezielt induziert. Dies führt zu einer Trübung der Lösung, was die
Überwachung des Prozesschrittes erschwert, da gängige Transmissionsmessungen nicht
durchgeführt werden können. Außerdem müssen der Lösung Fällungsmittel zugesetzt
werden, die im folgenden Aufreinigungsschritt unter Überwachung vollständig abgereichert
werden müssen. Die Tatsache, dass diese Komponenten oft nicht UV/Vis aktiv sind, macht
bestehende Prozessüberwachungsmethoden nicht anwendbar.
Das übergeordnete Ziel dieser Arbeit war es, Probleme aus den Bereichen Prozessentwick-
lung, Prozessintegration und Prozessüberwachung zu definieren und zu lösen. Die Rolle
hydrophober Wechselwirkungen auf den Phasenzustand von Proteinen sollte untersucht
werden. Mit den gewonnenen Erkenntnissen über den Präzipitationsmechanismus sollte
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eine mathematische Beschreibung gefunden werden, die eine modellbasierte Prozessent-
wicklung ermöglicht. Für die Prozessentwicklung eines Präzipitationsschrittes komplexer
mAb-Lösungen sollte eine Entwicklungsplattform erarbeitet werden. Dabei sollte der
Einfluss der vorhergehenden wie nachfolgenden Produktionsschritte berücksichtigt werden.
Schließlich sollte eine in-line Überwachungsstrategie entwickelt werden, die in der Lage ist,
das Produkt und die Verunreinigungen, einschließlich der zugesetzten Fällungsmittel, zu
detektieren.
Im dritten Kapitel dieser Arbeit wurde der Einfluss des hydrophoben Effekts auf das
Retentionsverhalten bei der hydrophoben Interaktionschromatographie (HIC), das Kristalli-
sationsverhalten sowie die thermische Stabilität des Modellproteins Glukose-Isomerase
untersucht [1]. Zu diesem Zweck wurde eine Hochdurchsatz-Screening-Plattform im
Mikrobatchmaßstab eingesetzt, die es ermöglichte, ein Proteinphasendiagramm mit Vari-
ation der Salzkonzentration mit gleichzeitiger Änderung des pH-Wertes darzustellen.
Das HIC-Retentionsverhalten konnte erfolgreich mit der Kristallgröße und -form von
Glukose-Isomerase korreliert werden. Die thermische Stabilität wurde verwendet um
Informationen über die Proteinstabilität zu erhalten. Durch eine Kombination aus HIC-
Retentionsverhalten und thermischer Stabilität konnte das Phasenverhalten für die ver-
schiedenen untersuchten Salzarten, Salzkonzentrationen und pH-Werte erfolgreich erklärt
und vorhergesagt werden. Mit Hilfe von HIC wurde ein tieferes Verständnis des Einflusses
hydrophober Wechselwirkungen während der Protein-Protein-Interaktion gewonnen.
Aufbauend darauf wurde in Kapitel vier die Erkenntnisse über den Mechanismus der
hydrophoben Wechselwirkungen während des Präzipitationsprozesses genutzt, um ein
mechanistisches Modell abzuleiten [2]. Die Grundannahme des neuen Modells basiert
auf einer bestehenden Isotherme für HIC. Es wurde angenommen, dass sowohl die Ad-
sorption an einen hydrophoben Liganden als auch die Proteinpräzipitation hauptsächlich
durch eine Reduzierung der hydrophoben Bereiche auf der Proteinoberfläche verursacht
werden. Weiterhin wurde angenommen, dass die treibende Kraft in diesem Prozess eine
Veränderung der Wasserstruktur ist. Folglich wurde Wasser als zusätzliche Komponente
in den Präzipitationsprozess eingeführt und ein Gleichgewicht zwischen strukturiertem
und weniger geordnetem Wasser angenommen. Mit Hilfe einer Hochdurchsatz-Plattform
wurden Präzipitationskurven für Proteine unterschiedlicher Größe, Oberflächenladung
oder Hydrophobizität erzeugt. Die Isotherme konnte die Menge an ausgefälltem Protein
in Abhängigkeit der Ausgangsprotein- und PEG-Konzentration beschreiben. Über den
gesamten Untersuchungsbereich war das Modell in der Lage, die Präzipizationskurve ex-
akt zu beschreiben. Zusammen mit der Fähigkeit, das Präzipitationsverhalten kleiner
Proteine zu beschreiben, ist es bestehenden Modellen, wie der weit verbreiteten Cohn-
Gleichung, überlegen. Da die Isotherme eine mechanistische Grundlage besitzt, ist es
zudem möglich, Daten außerhalb des Kalibrierbereichs zu beschreiben. Dies wurde mithilfe
von Validierungsdaten, die nicht für die Modellbildung verwendet wurden, demonstriert.
Während sich die vorhergehenden Studien vor allem mit Reinsystemen beschäftigten,
konzentrierten sich die Untersuchungen in Kapitel fünf auf den Einfluss der komplexen Pro-
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teinlösungen und des Zellkulturmediums auf das Präzipitationsverhalten von Proteinen [3].
Dafür wurde das Präzipitationsverhalten von zwei verschiedenen mAbs untersucht. In
Hochdurchsatz-Experimenten wurden Präzipitationskurven von reinen mAb-Lösungen mit
Lösungen verglichen, die vor der Präzipitation mit Verunreinigungen versetzt wurden. In
den Lösungen, welche Kontaminanten enthielten, wurde eine Destabilisierung der mAbs und
der Kontaminanten beobachtet. Dies führte zu einer theoretischen Reduktion der Reinheit,
aber auch zu einer Fällung bei niedrigeren PEG-Konzentrationen. Um anschließend den
Einfluss der unterschiedlichen Kontaminanten genauer zu untersuchen, wurden die Verunrei-
nigungen vor Zugabe zu den mAbs umgepuffert. Dabei wurden kleine Moleküle abgereichert
während Makromoleküle, wie Wirtszellproteine (HCP) oder DNA, in der Lösung verblieben.
Mit diesem Versuchsaufbau konnte die Destabilisierung auf mAb-makromolekulare Wech-
selwirkungen zurückgeführt werden. Andererseits konnte eine Stabilisierung der mAbs
und auch der Verunreinigungen, kleinen Molekülen im Zellkulturmedium zugeordnet wer-
den. Dies führte zu höheren Reinheiten, gleichzeitig war aber eine größere Menge PEG
notwendig, um für einen Aufreinigungsschritt akzeptable Ausbeuten zu erzielen. Diese
Ergebnisse zeigten, wie wichtig es ist, den Bedarf der Prozessentwicklung des nachgelagerten
Fällungsschrittes bereits während der USP zu berücksichtigen.
In Kapitel sechs wurde eine Prozessentwicklungsstrategie und die entsprechende Entwick-
lungsplattform für einen integrierten Präzipitations- und Ionenaustauschschritt (IEX)
entwickelt [4]. Durch selektive Präzipitation und selektive Rücklösung wurden prozessbe-
dingte Verunreinigungen wie HCP und DNA reduziert. Der nachfolgende Kationenaus-
tauschchromatographie Schritt (CEX) wurde angewendet, um produktbezogene Verun-
reinigungen, beispielsweise mAb-Aggregate, abzureichern. Darüber hinaus wurde CEX
als Produktkonzentrationsschritt eingesetzt. Durch die Kombination aus Hochdurchsatz-
Prozessentwicklung, empirischer und mechanistischer Modellierung wurde eine schnelle,
flexible und materialsparende Entwicklungsplattform entwickelt. In einer Fallstudie wurde
ein Verfahren zur Aufreinigung eines komplexen mAb-Ausgangsmaterials entwickelt. Es
wurde gezeigt, dass der entwickelte Prozess eine geeignete Alternative zur konventionellen
Protein A Affinitätschromatographie darstellt. Mit der vorgestellten Prozessentwicklungs-
strategie ist es möglich, einen traditionellen Batch-Prozess zu entwickeln. Darüber hinaus
wurde das kalibrierte mechanistische Chromatographie-Modell für eine in silico Opti-
mierung einer periodischen Gegenstromchromatographie (PCCC) verwendet. Dadurch
wurde die Machbarkeit der Entwicklung eines kontinuierlichen Prozesses mit Hilfe der
entwickelten Plattform gezeigt.
Während sich die bisherigen Kapitel mit dem Prozessverständnis und neuen Entwick-
lungsstrategien beschäftigten, war der letzte Teil der Arbeit neuen Kontrollstrategien,
zur Erfüllung der Anforderungen an einen auf Proteinfällung basierenden Prozess, gewid-
met. Im siebten Kapitel wurde die Fourier-Transformations-Infrarot-Spektroskopie (FTIR)
als in-line prozessanalytische Technologie (PAT) zur Überwachung chromatographischer
Prozesse implementiert [5]. In drei Fallstudien wurde das Potenzial der FTIR-Spektroskopie
demonstriert. Die erste Fallstudie zeigte die Möglichkeit, zwei verschiedene Proteine durch
Unterschiede in ihrer Sekundärstruktur zu differenzieren. Mit Hilfe eines Regressionsmo-
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dells der partiellen kleinsten Quadraten (PLS) war es möglich, während der CEX-Elution
zwischen mAb und Lysozym zu unterscheiden. In einer zweiten Fallstudie wurde ein Prozess,
der unterschiedlich PEGylierte Lysozymspezies mittels CEX auftrennt, mit Hilfe der FTIR-
Spektroskopie überwacht. Dies belegt die Möglichkeit, nicht UV/Vis aktive Moleküle wie
PEG nachzuweisen. Im Rahmen eines PEG-induzierten Präzipitationsprozesses ist dies von
großer Bedeutung, da PEG dem Prozess hinzugefügt wird und eine spätere Abreicherung
gewährleistet sein muss. In der letzten Fallstudie wurden die typischen prozessbedingten
Verunreinigungen und die ebenfalls nicht UV/Vis aktive Komponente Triton X-100 selektiv
aus dem FTIR 3D-Feld quantifiziert.
Zusammenfassend liefert diese Arbeit Lösungen für die Entwicklung von neuen, flexibleren
und kostengünstigeren Alternativen zu häufig verwendeten chromatographischen Methoden.
Der Schwerpunkt lag auf der Etablierung von Präzipitationsprozessen im Hinblick auf die
aktuellen Bedürfnisse der DSP. Durch die Untersuchung hydrophober Wechselwirkungen
wurden neue Erkenntnisse über den Präzipitationsschritt gewonnen. Mit Hilfe dieser konnte
ein mechanistisches Präzipitationsmodell entwickelt werden. Dies zeigte die Möglichkeit,
die Prozessentwicklung zu vereinfachen und gleichzeitig den Materialverbrauch zu senken.
Die generierte Prozessentwicklungsplattform ermöglicht eine einfache Prozessentwicklung in
Bezug auf die vorhergehenden und nachfolgenden Prozessschritte. Der entwickelte Prozess
zeigte vergleichbare Ergebnisse in Bezug auf Ausbeute, Reinheit und Aggregatreduktion im
Vergleich zum Industriestandard Protein A Affinitätschromatographie. Mit der Entwicklung
eines in-line-Sensors auf Basis von FTIR-Spektroskopie wurden Strategien entwickelt um
sowohl das Produkt, als auch Additive wie PEG in den nachfolgenden Reinigungsschritten
zu überwachen. Diese ermöglichen die Kontrolle der erfolgreichen Abreicherung.
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Abstract
This PhD thesis contributes to the field of biopharmaceutical process development and
production. In the pharmaceutical industry biopharmaceuticals, mostly protein-based
drugs, are gaining more and more importance compared to classical, small molecule drugs.
They often bind more specifically to the target or receptor. At the same time they trigger
a complex mode of action. This often leads to higher efficacy, while at the same time side
effects are reduced. The complex mode of action also opens up the possibility of treating
new diseases or those for which there is currently no therapy available. In the past, the
biggest growth in the biopharmaceutical market has taken place in the field of cancer
immunotherapy. Against the background of an aging society, the challenge of fighting
cancer will continue to grow. In addition, the demand for therapies for the treatment of
autoimmune diseases, diabetes, and Alzheimer’s disease will continue to rise as well. All
biopharmaceutical products have high development and production costs in common. The
increasing demand for new products and higher production capacities stands in contrast
to the ever scarcer healthcare budgets. With the approval of the first biosimilars, generic
versions of the originator drug, the economic pressure on the biopharmaceutical sector
increases further. While for the first generation of biopharmaceutical blockbusters was
hardly a link between production costs and sales prices, the development of biosimilars
also increases the need for faster process development and more economical processes.
The development of biopharmaceuticals can be roughly divided into the expression of the
product in living cells, the upstream process development (USP) and the purification of
the produced molecule, the downstream process development (DSP). In the past, great
success has been achieved in the development of a more efficient USP. In particular,
higher cell culture titers led to higher product concentrations. In order to keep pace with
these developments, new, and cost-effective alternatives for the purification process are
needed. Today, the DSP of biopharmaceutical products is mainly based on chromatographic
purification steps. These have a high selectivity, which leads to a high purity after the
unit operation. Unfortunately, these advantages are associated with the disadvantage
of high resin costs, and a slow volumetric throughput. Consequently, chromatographic
steps contribute most to the cost of DSP. However, the development of a purification
process is mostly based on chromatographic steps, as platform processes are available. For
monoclonal antibodies (mAb) this purification platform is based on Protein A affinity
chromatography as a capture step. This step is generic for all mAbs since the binding
to the adsorber is attributed to an interaction with the Fc-region present in all mAbs.
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Therefore, depending on the used mAb, only minor adjustments to the process are required.
This makes process development easier, faster, and more efficient. Consequently, this also
leads to a loss of flexibility. New biopharmaceuticals, such as alternative mAbs, virus-like
particles (VLP), or nucleic acids will not fit into existing platforms. As a result, alternatives
to the convenient but expensive methods have to be developed. In academia, preparative
protein precipitation has already shown that it can be an easy-to-use and cost-effective
alternative. In addition to salt-, or ethanol-induced precipitation, polyethylene glycol
(PEG) has proven its suitability as effective precipitating agent for the purification of
proteins. PEG is comparatively cheap, non-flammable, non-toxic, and already approved as
an excipient in many drugs. However, several obstacles still have to be overcome in order
to make industrial application possible.
In order to increase the acceptance of preparative protein precipitation in the biopharma-
ceutical industry, deeper knowledge of the mechanism, new development strategies and an
improved monitoring of the process are necessary. Knowledge of the process is of great
importance for a successful process development, and also for a successful approval by the
relevant authorities. Although much research has been done in the field of protein stability,
the involved interactions are not fully understood. Knowledge of the mechanism can not
only help to understand protein precipitation, but also to improve process development.
Today, DSP is often performed expert based, with the background of a platform process. To
replace existing platform processes, flexible, fast, and material-saving process development
strategies for preparative protein precipitation are missing. Furthermore, when developing
a precipitation step, the purification step is often optimized as a stand-alone operation,
while a concept for integrating the unit operation into the overall production process,
including USP, and other polishing steps, is missing. In a preparative precipitation step,
the phase transition is intentionally induced. This leads to a turbidity in the solution that
makes the process step difficult to monitor. In addition, precipitants are added to the
solution to cause this phase transition. In the following purification step, the complete
degradation of these components must be ensured and monitored. The fact that these
components are often not UV/Vis active makes common techniques inapplicable.
The overall aim of this work was to define and solve problems in the area of process
development, process integration, and process monitoring. The role of hydrophobic
interactions on the phase state of proteins should be investigated. With the knowledge
gained about the precipitation mechanism, a mathematical description that enables model-
based process development should be found. For the process development of a precipitation
step for complex mAb solutions, a development platform should be generated. The influence
of the previous and subsequent production steps should be taken into account. Finally, an
in-line monitoring strategy should be developed that is capable of detecting the product
and impurities, including the added precipitants.
In the third chapter the influence of the hydrophobic effect on the retention behavior
during hydrophobic interaction chromatography (HIC), the crystallization behavior, and
the thermal stability of the model protein glucose isomerase were investigated [1]. For this
xii
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purpose, a high-throughput screening platform in microbatch scale was used, which made
it possible to produce a protein phase diagram with variation of the salt concentration and
simultaneous change of the pH value. The HIC retention behavior could successfully be
correlated to the crystal size and shape of glucose isomerase. The thermal stability was
used to obtain information on the protein stability. Using a combination of HIC retention
behavior and thermal stability, it was possible to successfully explain and estimate the phase
behavior for glucose isomerase for the different investigated salt types, salt concentrations,
and pH values. With the help of HIC, a deeper understanding of the influence of hydropbobic
interactions during protein-protein interaction was obtained.
Based on these findings, in chapter four the mechanism of hydrophobic interaction during
the precipitation process was used to derive a mechanistic model for preparative protein
precipiation [2]. The new model is based on an existing isotherm for HIC. It was assumed
that both, adsorption to a hydrophobic ligand, and protein precipitation are mainly caused
by a reduction of the hydrophobic area on the protein surface. Furthermore, it was assumed
that this was due to a change in the water structure. Consequently, water was introduced
as an additional component into the precipitation process, and an equilibrium between
well-ordered and bulk-like ordered water was assumed. A high-throughput platform was
used to generate precipitation curves for proteins of different size, surface charge, or
hydrophobicity. The isotherm could describe the amount of precipitated protein as a
function of the initial protein and PEG concentrations. The model was able to accurately
describe the precipitation curve over the entire investigated range. Together with the
ability to describe the precipitation behavior of small proteins, it is superior to existing
models, such as the widely used Cohn-equation. Since the isotherm has a mechanistic
foundation it is also possible to describe data beyond the calibration range. This was
demonstrated with validation data that were not included into the model building.
While the previous studies mainly dealt with with pure proteins solutions, the investigations
presented in chapter five concentrated on the influence of complex protein solutions and
the cell culture medium on the precipitation behavior of proteins [3]. Therefore, the
precipitation behavior of two different mAbs was investigated. Using high-throughput
experiments, precipitation curves of pure mAb solutions were compared to solutions, which
were spiked with impurities prior to precipitation. In solutions containing contaminants,
a destabilization of mAbs and the impurities was observed. This led to a reduction of
the purity, but at the same time to an increase of the yield, respectively precipitation at
lower PEG concentrations. In order to investigate the influence of the different components
present in the complex solution, the contaminant solution was re-buffered before spiking.
Thereby, small molecules were depleted while macromolecules, such as host cell proteins
(HCP), or DNA, were still present. Using this experimental setup, destabilization could
be attributed to mAb-macromolecular interactions. On the other hand, a stabilization
of the mAbs, and also of the impurities, could be assigned to small molecules, present in
the cell culture medium. This led to higher purities, but at the same time more PEG was
necessary to achieve acceptable yields. The results showed how important it is to consider
the process development needs of the downstream precipitation step already during the
xiii
Abstract
USP.
In chapter six, a process development strategy, and the corresponding development platform
for an integrated precipitation and ion exchange (IEX) step was developed [4]. By means
of selective precipitation and selective resolubilisation, process-related impurities such as
HCP and DNA were reduced. The subsequent cation exchange chromatography (CEX)
step was used to remove product-related impurities such as mAb aggregates. In addition,
CEX was used as product concentration step. By combining high-throughput process
development, empirical, and mechanistic modeling, a fast, flexible, and material-saving
development platform was designed. In a case study, a process for the purification of a
complex mAb feedstock was developed. It was shown that the developed process is a suitable
alternative to conventional Protein A affinity chromatography. With the presented process
development strategy it is possible to develop a traditional batch process. In addition,
the calibrated mechanistic chromatography model was used for in silico optimization of
periodic counter-current chromatography (PCCC). Thus, the feasibility of developing a
continuous process, using the developed platform, was demonstrated.
While the previous chapters dealt with process understanding, and new development
strategies, the last part of the work was dedicated to new monitoring strategies to meet the
requirements of a protein precipitation based process. In chapter seven, Fourier-transform
infrared (FTIR) spectroscopy was implemented as in-line process analytical technology
(PAT) for monitoring chromatographic processes [5]. The potential of FTIR spectroscopy
was demonstrated in three case studies. The first showed the possibility to distinguish
two different proteins by differences in their secondary structure. Using a partial least
squares (PLS) regression model, it was possible to distinguish between mAb and lysozyme
during CEX elution. In a second case study, a process that separates different types of
PEGylated lysozyme with CEX was monitored by FTIR spectroscopy. This also showed the
possibility to detect the non UV/Vis active molecule PEG. In the context of a PEG-induced
precipitation process this is of great interest, as PEG is added to the process and therefore
a later depletion must be guaranteed and monitored. In the last case study, the typical
process-related impurities and also the non UV/Vis active component Triton X-100 were
selectively quantified from the FTIR 3D field.
In summary, this dissertation provides solutions for the development of new, flexible, and
cost-effective alternatives to frequently used chromatographic based methods. The focus
was set on the establishment of precipitation processes with respect to the current needs of
DSP. By the investigation of the role of hydrophobic interactions, new insights into the
precipitation step were gained. With the help of this, a mechanistic precipitation model
could be developed. This showed the possibility to simplify the process development and to
reduce material consumption at the same time. The generated process development platform
enables a simple process development with regard to the previous and subsequent process
steps. The developed process showed comparable results in yield, purity and aggregate
reduction compared to the industrial standard, Protein A affinity chromatography. With
the development of an in-line sensor based on FTIR spectroscopy strategies were developed
xiv
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to monitor both the product and additives such as PEG, in the subsequent purification
steps.
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1. Introduction
Biotechnology is defined as application of natural or engineered biological organisms for
the use of technical and industrial processes [6]. One of the most important achievements
was the decoding of deoxyribonucleic acid (DNA) by Watson and Crick in 1953 [7]. These
findings enabled the development and application of recombinant DNA technology. Thereby,
targeted manipulation of DNA allows the inserting of specific genes to the cell, and thus,
using the cell as biochemical factory for the production of proteins [8].
With the availability of recombinant proteins, the number of biopharmaceuticals increased.
The term biopharmaceutical refers to pharmaceutical products manufactured by microbio-
logical methods [9]. This definition includes products expressed in living cells, but can also
be applied to the entire living cell as a product, or small molecules produced or modified
by biological systems. Small molecules are defined as drugs with a molecular weight of less
than 500Da, which have usually an oral bioavailability. In contrast, biopharmaceuticals are
typically larger than 5000Da, and have to be administered by injection. Among therapeutic
proteins, insulin was the first recombinant drug to be approved in 1982 [10]. The first mono-
clonal antibody (mAb) product was launched in 1986. Since that time, mAbs have become
the most important drug class on the market. In 2016, approximately 65.6% of therapeutic
protein sales, were achieved with mAbs [11]. Other approved protein-based drugs are
anticoagulants, blood factors, bone morphogenetic proteins, artificial protein scaffolds,
enzymes, growth factors, hormones, interferons, interleukins, and thrombolytics [12].
Biopharmaceuticals have the advantage to bind specifically to a cell or a receptor. This
makes it possible to address a more complex mode of action, compared to small molecule
drugs, leading to a higher efficacy of the biopharmaceutical drug. At the same time
often fewer side effects occur. However, the complex mode of action is usually prone to
changes of the molecule. Small variations can lead to a loss of efficacy, or even raise the
immunogenicity of the drug [13]. This can be a serious problem since biopharmaceuticals
usually tend to be unstable. Changes in temperature, ionic strength, pH value of the
surrounding medium, or concentration of the various molecules involved, may result in
changes, or loss of the product [11]. In addition, the expression of the product in living
cells leads to a high number of impurities. Furthermore, the complexity of the product
leads to several versions of the same protein with only minor variations. Consequently, the
product is never a single molecule, but always a defined profile of several ones. The task of
downstream process development (DSP) is to ensure a high product purity, to meet the
1
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predefined composition of the different protein variants, and to reach an acceptable yield
to ensure an economic process[10].
The complexity of the products and the associated demands on the processes lead to
high development and production costs. However, in the past, there was hardly any
direct correlation between manufacturing costs and selling prices [14]. Starting in 2010,
several biopharmaceutical blockbusters will lose their patent protection in subsequent
years. The phenomenon, known as "patent cliff", has the potential to change the market
and increase economic pressure on the biopharmaceutical industry [15]. One result of
the expiration of many patents is the development of biosimilars. Biosimilars are generic
versions of the originator drug, based on the same DNA sequence [16]. As there is no need
to search for the lead candidate development times, risks, and costs are reduced. The new
competition will also increase the need for new, and more economical downstream processes.
In contrast to the simple copying of an already developed drug, the development of
biobetters is another trend in the biopharmaceutical industry. Biobetters are modifications
of existing drugs, which have superior properties in drug delivery, pharmacokinetics, or
pharmacodynamics [17]. Examples for this are PEGylated proteins, recombinant fusion
proteins, antibody drug conjugates (ADC), or engineered mAbs [18]. A higher efficacy
of biobetters may result in a lower amount of required drug, and consequently a lower
production capacity. Beside mAbs, or mAb-like products, vaccines, gene therapies, and
personalized medicine have a growing impact on the biopharmaceutical market [19]. For
all these products, traditional downstream platform processes are either not efficient or
not applicable at all.
Traditional downstream processes are usually based on a sequence of several chromato-
graphic steps. With these, high resolutions can be achieved, but this is associated with
high adsorber costs, and a slow volumetric throughput. In order to meet the requirements
for more economical, and flexible downstream processes, alternative purification steps,
operating modes, and new integrated process development strategies are necessary [20].
Alternative downstream methods such as preparative protein precipitation, preparative pro-
tein crystallization, aqueous two-phase systems (ATPS), or membrane technology have the
potential to overcome these limitations [21–24]. During crystallization and precipitation, a
phase transition of the protein from the liquid to the solid phase is used to purify the target
protein. The difference between crystallization and precipitation refers to the morphology
of the product. Precipitates often have a poorly defined amorphous structure, whereas
crystals are well-defined large particles formed in a secondary nucleation process [25]. In
particular, the successful applicability of preparative protein precipitation as capture step
has already been demonstrated [26, 27]. However, purities achieved after chromatographic
polishing steps are hardly achievable with alternative methods. Hence, meaningful process
integration is necessary. To develop such processes, the combination of high-throughput
screening (HTS), Design of Experiment (DoE), and model-based approaches have shown
the potential to save development time, cost, and material [28–31]. These methods can also
help to transfer the production process from traditional batch production to a continuous
mode. Continuous production has shown the potential to shorten process times, lead
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to higher productivity, and lower costs for equipment, and consumables. Thereby, new
continuous applications have been developed for classical chromatographic steps, but also
for alternative separation methods [32]. In order to monitor such continuous processes,
and to ensure product quality and safety, academia and industry have focused on the
development of process analytical technologies (PAT). The implementation of multivariate
data analysis (MVDA) in combination with new in-line sensors can help to control processes,
and thus make them more efficient [33, 34].
In order to give an overview of the current state of research, the following chapters deal
with theoretical fundamentals which are necessary for this thesis. Chapter 1.1 introduces
the most relevant intermolecular forces for the understanding of protein phase behavior and
stability. Chapter 1.2 deals with the factors that affect the protein phase behavior, while
chapter 1.3 discusses the basics of downstream process development of biopharmaceuticals.
Chapter 1.4 describes the principles of in-line process monitoring and FTIR spectroscopy.
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1.1. Intermolecular Protein Interactions
In downstream process development, various differences of the physical properties between
the product and the impurities are used to purify the target protein. To understand
the mechanism of the protein phase behavior, as well as adsorption phenomena, the
acting forces between the proteins and their environment need to be understood. At a
molecular level, the interactions of proteins with surfaces, adsorber ligands, other proteins,
or solvents are mainly influenced by weak, non-covalent forces. Therefore, the most
important intermolecular forces and their properties are listed below.
1.1.1. Van-der-Waals Forces
Van-der-Waals (VdW) forces are short-range intermolecular interactions with a weak
binding energy of 0.08 to 42.00 kJ/mol [35]. In general, VdW forces act between all
molecules. In particular, they contribute to the interaction of proteins with other molecules
and with surfaces [36]. The attracting influence results from interactions between fixed or
induced dipoles. These dipoles are caused by short-term electrostatic polarization of the
molecules [37] . The electrostatic potential Ψ and the resulting force F are related to the
distance between two particles z according to Eq. 1.1.
Ψ ≈ 1
z6
F = −∂Ψ
∂z
(1.1)
1.1.2. Electrostatic Interactions
As described above, VdW forces have an electrostatic character resulting from dipole
moments. In addition, most molecules found in biotechnological systems, such as salts,
nucleic acids, or proteins, carry discrete surface charges. Even in pure water one finds the
charged ions OH– and H+. During the separation of biomolecules, charged ligands bound
to chromatographic resins are used to separate, and purify biomolecules [38].
The attractive or repulsive character of stationary charges is defined by Coulomb’s law
(Eq. 1.2). The force F is defined by the signed magnitudes of the charges qp1, and qp2, the
distance between the charges z, and the Coulomb constant ke. An attracting force results
when the charges have an opposite sign and a repulsive force when they are like-signed [35].
F = ke
(qp1qp2)
z2
(1.2)
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If proteins are considered as point charges qp, and they are not disturbed by other charges,
the electrostatic potential Ψ idp , follows Eq. 1.3, depending on the distance between two
charges z, and the permittivity of the medium ε.
Ψ idp (z) =
qp
4piεz (1.3)
The electrostatic potential decreases slowly with the distance, correlating with z−1. There-
fore fixed charges are classified as long-range forces. In contrast, VdW forces are classified
as short-range forces. As described in chap. 1.1.1., the strength of VdW forces correlates
to the distance with z−6 [38]. The combination of the long-range repulsive electrostatic
double layer, and attractive short-range VdW forces is explained in the DLVO theory,
named after their founders Derjaguin, Landau, Verwey, and Overbeek [39]. According to
the DLVO theory the attractive VdW forces are superimposed by the repulsive electrostatic
double layer, resulting in attraction on very short distances and a repulsion on longer
distances. Unfortunately, the DLVO theory is an oversimplification for proteins. For
example, hydrophobic effects of Hofmeister ions, or hydration forces are not considered [40].
1.1.3. Hydrogen Bonds
Similar to VdW forces, hydrogen bonds are induced by dipoles. Hydrogen bonds are formed
when a hydrogen atom, bound to an electronegative atom, especially oxygen, nitrogen,
and fluorine, interacts with an neighboring electronegative atom (Fig. 1.1.). Hydrogen
H
O
H
H
O
H
H
O
H
H N H
H
H N H
H
H F H F
Figure 1.1.: Hydrogen bonds between the molecules NH3, H2O and HF. Illustration adapted
from [41].
bonds are much stronger compared to VdW forces, but have only about 5-10% of the
bond energy of covalent bonds [41]. Theoretically, a water molecule can form up to four
hydrogen bonds. Usually, a water molecule in liquid water is part of one to three bonds, in
frozen water of three to four bonds. Since most protein chemistry takes place in aqueous
solutions, the formation of hydrogen bonds plays an important role in the solution process
of proteins. Thereby, the interaction of charged groups of the protein with the water via
hydrogen bonds enables solvation. The interaction of water molecules with each other via
hydrogen bonds is the source of hydrophobic interaction. The adsorption process towards a
hydrophobic ligand, or a hydrophobic surface, is driven by changes in the water structure.
The same effect explains the aggregation of proteins via hydrophobic patches on the protein
surface. The hydrophobic effect is described in more detail in the following chapter.
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1.1.4. Hydrophobic Interactions
Originally, the hydrophobic effect describes the low solubility of nonpolar solvents in
water [42]. It was extended to also explain the poor water solubility of hydrophobic molecules
or the repulsion of hydrophobic surfaces by the solvent water. Thereby, hydrophobic
interaction is not a real force, but is fundamentally caused by the formation of hydrogen
bonds between water molecules [43]. An important example of the effect of hydrophobic
interactions is the formation of high-order biological structures, such as the formation of
membranes, or the spontaneous folding of proteins [44]. Solvation behavior and aggregation
tendency of proteins can be explained by changes in the Gibbs’ free energy G (Eq. 1.4).
Systems always show a tendency to minimize free Gibbs energy. The two terms ∆H and ∆S
describe the enthalpic and entropic changes that occur during solvation or aggregation [45].
∆G = ∆H − T∆S (1.4)
During an aggregation process of proteins, changes of the intermolecular interaction, like
the formation or solving of bonds, can lead to an increase or a decrease of the enthalpy H.
This term alone would not successfully explain the formation of high-ordered structures.
However, the consideration of water molecules provides an explanation for the spontaneous
formation of complex structures, or the aggregation of proteins. Hydrophobic surface
groups can hardly be solvated, as they cannot form hydrogen bonds with the solvent water.
Therefore, the water molecules can only interact, respectively, form hydrogen bonds with
each other. This leads to a higher-ordered water structure around hydrophobic surfaces.
When two hydrophobic surfaces merge, this leads to a rearrangement of the water molecules.
The change of the water structure, from a higher order to a bulk-like water structure, leads
to an increase of the entropy S, and therefore, an overall decrease of Gibbs free energy.
Following changes in the entropy have to be the driving force for the hydrophobic effect [45,
46].
1.2. Influencing Factors on Protein Phase Behavior
To understand the precipitation process, the nature of the proteins, the forces acting
at the molecular level, and the precipitation mechanism have to be considered. Protein
solubility can be influenced by intrinsic factors, such as protein structure (1.2.1), and
extrinsic factors, such as pH value (1.2.2), ionic strength, or other added components.
In this thesis the influence of inorganic salts as precipitant (chapter 3), respectively as
contaminant (chapter 5) are investigated. Hence, chapter 1.2.3 introduces the fundamentals
of salt induced precipitation. The developed monoclonal antibody (mAb) capture step
(chapter 6) is based on polymer induced precipitation. The fundamentals are explained in
chapter 1.2.4. A methodology for displaying protein phase behavior in the form of protein
phase diagrams is presented in Chapter 1.2.5.
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1.2.1. Protein Structure
Proteins are well-ordered bio-polymers, consisting of amino acids as subunits. Linked by
peptide bonds, the amino acid sequence forms the primary structure. In particular, the
different residues of the amino acids used define the protein character. They influence both
the formation of structural elements of the secondary structure and the folding into the
defined three-dimensional tertiary structure [47].
The residues of amino acids can be divided into three groups: charged; uncharged and
hydrophilic; and hydrophobic. These different properties not only influence protein folding,
but also define protein surface properties. They influence charge distribution, and the
formation of hydrophilic, or hydrophobic patches on the protein surface. Therefore, they
also have a strong influence on protein solubility. In addition to the amino acid sequence,
posttranslational modifications influence the protein character, and solubility. Especially
proteins produced in eukaryotic cells are subject to these changes, such as proteolytic
cleavages, formation of disulfide bonds, or glycosylation [48]. Together they are referred to
as intrinsic factors of protein stability.
Extrinsic factors can also influence the surface character of proteins. During a biophar-
maceutical process in general, and during a preparative precipitation step in particular,
extrinsic factors are altered, and a phase transition is induced [49]. In the following, the
most important extrinsic factors for native protein precipitation or crystallization are listed.
1.2.2. Influence of Solution pH
For the surface net charge of biomolecules such as proteins, or DNA, the pH value of the
solvent plays a significant role. Thereby, the surface net charge of the proteins is defined by
the charge of the amino acid residues, or more precisely, by the pKa of the corresponding
acid or base. At low pH values, the acids and bases are neutral, respectively positively
charged. With increasing pH value the residues are deprotonated and the total surface
net charge of the biomolecules becomes negative. Fig. 1.2. (a) gives a schematic overview
of the surface net charge of DNA, host cell proteins (HCP), and a monoclonal antibody
(mAb). For DNA, an isoelectric point (pI) around pH2.0-3.0 is reported. Proteins have a
wide range of pIs from pH3.5 to pH 11.0 [50]. For example, it is reported that the majority
of HCPs have an pI around the pH5.0, while the mAb used in this paper has an pI of
pH8.5 [51, 52].
Long-range electrostatic forces between equal charged particles are reported to stabilize
molecules, by preventing attraction [53]. Therefore, proteins have the lowest solubility
at their pI, where the total surface net charge is neutral [54]. The influence of surface
net charge on the solubility of biomolecules is shown in Fig. 1.2. (b). The stabilization
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Figure 1.2.: (a) Influence of pH value on the surface net charge of DNA, HCP and mAb.
(b) Influence of the surface net charge on the solubility of biomolecules.
of molecules due to electrostatic repulsion occurs mainly at low salt concentrations. At
higher salt concentrations the electrostatic double layer is completely shielded and specific
salt effects become important.
1.2.3. Influence of Inorganic Salts on Protein Phase Behavior
As unit operation in biotechnological downstream processes, precipitation, or crystallization
of proteins is intentionally caused. In order to avoid harming the protein, it is important
that native protein phase transition takes place. Native precipitation means that the
protein does not unfold before, during or after the precipitation process and thus retains
its tertiary structure. The use of inorganic salts, as precipitants, is one of the oldest ways
to purify proteins [55]. In 1931 Green reported on an approach of selective salt-induced
precipitation of hemoglobin from a complex solution [56]. For a long time it has been
assumed, that during precipitation phase separation between a liquid, salt saturated phase,
and a solid protein phase takes place. More recent studies describe protein precipitation
as separation between two liquid phases with different protein concentrations [57]. Shih
et al. investigated the composition of these two phases and found, that the dense protein
phase still contains a considerable amount of water and salts [58]. They also showed that
for certain proteins, the initial protein concentration has an influence on the amount of
soluble protein in equilibrium after the precipitation.
The influence of salts on the phase behavior of proteins is complex. By dissolving salts,
they dissociate into their charged ions, and thus, influence the electrostatic interactions
between the proteins. Irrespective of the type of ion, shielding of the equally charged
groups on the protein surface can lead to precipitation, or crystallization. The absence of
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long-range repulsive electrostatic interactions can lead to protein-protein attraction, which
is caused by short-range interactions, such as VdW forces, or hydrophobic interactions.
In addition to the influence of salts on electrostatic interactions, specific ion effects are
known as well. At low salt concentrations, a stabilizing "salting-in" effect is reported.
Tanford explained this observation with unspecific interactions depending on the ionic
strength of the medium [59]. In a series of articles, Timasheff and coworkers explained this
behavior in more detail with the preferential interaction theory [60–63]. According to this
theory, a preferential interaction of the ions with the protein leads to a stabilization of the
protein. In contrast, preferential hydration of the water, and thus, preferential exclusion of
the protein, has a destabilizing "salting-out" effect. Specific ion effects were first mentioned
by Franz Hofmeister in 1888 [64]. Accordingly, the influence of anions on the precipitation,
and crystallization behavior of proteins is more pronounced than that of cations. The
empirically ordered anions, which are related to their ability to precipitate proteins, are
shown in Fig. 1.3.. Anions on the left side of Cl– are called kosmotropes, and are known
Figure 1.3.: Empirical order of anions ranked after their ability of precipitating proteins.
to strengthen hydrophobic interactions. This can lead to protein aggregation, but can also
stabilize the tertiary structure of proteins, by strengthening their hydrophobic core. Anions
on the right side of Cl– are called chaotropes. They weaken hydrophobic interactions,
which can prevent proteins from aggregation, but can also lead to protein unfolding. The
effect of the Hofmeister series has been extensively investigated, but the nature of these
effects is not completely understood. Originally, it was assumed, that the ions affect the
water structure both, in the bulk, and around the hydrophobic patches of the protein [65].
Omta and coworkers found out, that only the first hydration shell of the protein and not
the bulk water is affected by the ions [66]. Zhang and Cremer postulated, that the specific
ion effects can be explained by direct interactions between ions, and the protein [67].
1.2.4. Influence of Polymers on the Protein Phase Behavior
Polymer-induced precipitation shows similar effects compared to salt-induced precipitation,
but it is of different nature. The influence on the protein phase behavior of polymer-induced
precipitation in general, and polyethylene glycol (PEG) induced precipitation in particular,
can be explained by two different theories. According to the theory of excluded volume,
introduced by Atha and Ingham, the reduction of protein solubility, in the presence of PEG,
can be explained by steric exclusion of the proteins from the surrounding media [68, 69].
According to Arakawa and Timasheff [70] polymers, like PEG, preferentially interact with
water molecules and are excluded from the surface of the protein. Hence, it is assumed, that
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the polymers trap the solvent and sterically exclude it from the solved proteins. Since this is
a steric effect, proteins with a larger hydrodynamic radius tend to precipitate at lower PEG
concentrations, compared to proteins with a smaller hydrodynamic radius. A schematic
representation of the volume exclusion effect is shown in Fig. 1.4. The theory of attractive
Figure 1.4.: Schematic representation of the accessible and excluded area of a PEG solution
for proteins with different sizes, described by the theory of volume exclusion.
depletion introduced osmotic pressure as additional force to the PEG-induced precipitation
process [71, 72]. According to this theory, each dissolved protein has a depletion zone,
which can not be entered by PEG molecules. If the PEG, or protein concentration is
raising, and two depletion zones are overlapping, a PEG free area is created, and a gradient
towards the bulk is formed. This gradient leads to an attractive force of the order of
osmotic pressure. A schematic representation is shown in Fig. 1.5.. In both theories no
Figure 1.5.: Schematic representation of two proteins in PEG solution and the influence on
the depletion zones, described by the theory of attractive depletion.
direct interaction between the proteins and the polymers is assumed. Consequently, all
other forces between the particles, described in the previous chapters, are still valid, and
must be taken into account.
1.2.5. Protein Phase Diagrams
A protein phase diagram displays the phase state of a protein as a function of the environ-
mental conditions. The most common method, in the biopharmaceutical industry, is to
plot variations in protein concentration as a function of another parameter, e.g. precipitant
concentration, while keeping all other variables constant [73].
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As shown in Fig. 1.6., a schematic protein phase diagram is displayed as a function of the
precipitant and protein concentration. At low precipitant and protein concentrations the
protein is completely dissolved. In the area called the undersaturated zone the repulsion
forces between the proteins dominate and no phase transition occurs [74]. Once the
solubility line is exceeded phase transition takes place. Depending on the underlying
mechanism, crystallization, gelation, precipitation, or liquid liquid phase separation can
occur [75]. In the metastable region of the phase diagram no spontaneous phase transition
in form of crystallization takes place, but crystals can grow if a nucleus is present. In
the region of moderate supersaturation spontaneous nucleation can occur, which can lead
to protein crystallization. In the area of high supersaturation, attraction forces between
the proteins are predominant, and the proteins precipitate. In contrast to amorphous
precipitate, crystals have an ordered structure that depends on specific interactions between
the proteins [76]. To create a protein phase diagram, a large number of data points are
Figure 1.6.: Schematic representation of a protein phase diagram. Shown is the phase state
of a protein in dependency of the protein and precipitant concentration. The phase diagram is
divided into four areas: An undersaturated area, a metastable zone, a nucleation zone, and a
precipitation zone.
required. Therefore, the use of high-throughput experiments (HTE) is very useful. Two
different approaches are commonly used, both in 96-well format. Either sitting, or hanging
drop vapor diffusion, or microbatch experiments [77]. In vapor diffusion experiments, a
protein solution is equilibrated against a reservoir, containing a solution with a higher
precipitant concentration. Over time, this leads to a reduction of the drop volume, and
thus, to a concentration of the protein. At a certain point this can lead to phase transition,
and probably crystallisation [78]. The disadvantage of this methodology is that it is difficult
to define the exact concentrations of the components, at which the phase transition takes
place. In microbatch experiments, different stock solutions containing buffer, precipitant,
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or protein are mixed and subsequently covered with oil, or sealed [51, 79]. This allows
a precise definition of the experimental conditions, but higher amounts of protein are
required, compared to vapor diffusion experiments.
1.3. Downstream Process Development
The following chapters outline fundamentals of biopharmaceutical downstream process
development. In this thesis the chapters 4, 5, and 6 focus on the development of a monoclonal
antibody (mAB) downstream process employing preparative protein precipitation as capture
step. Furthermore, the integration of this step into the further purification strategy based on
chromatographic separation is investigated. Therefore, chapter 1.3.1 gives an introduction
to preparative protein precipitation and chapter 1.3.2 to liquid chromatography for proteins.
For the purification process developed in this thesis, an exploration of the transfer to
a continuous process has been examined. Therefore, chapter 1.3.3 presents the current
state of continuous manufacturing in the biopharmaceutical industry. Chapter 1.3.4, 1.3.5,
and 1.3.6 present the different development strategies currently used, i.e. knowledge-based
process development, high-throughput process development (HTPD) and mechanistic
chromatography modeling.
1.3.1. Fundamentals of Industrial Protein Precipitation and
Crystallization
Since Cohn developed the first industrial fractionation process in 1941 to recover albu-
min from blood plasma, precipitation has been used in biotechnological processes as a
downstream operation [80]. Precipitation, or related operations, such as flocculation, or
crystallization, can be used at any step of the downstream process. While flocculation
is mainly used for the clarification of cell debris, precipitation is used for capture, or
intermediate steps. Crystallization is mostly applied during polishing, or formulation.
For most unit operations, two different approaches are conceivable: Either precipitation of
the product itself, or the precipitation of the impurities while the product remains soluble.
The precipitation of the impurities has the advantage that a phase transition of the product
is avoided, and thus, the risk of damaging the product is also avoided. On the other hand,
native precipitation of the product makes it possible to combine, and integrate three unit
operations: Purification, stabilization, and concentration [81].
In any case, a phase transition is induced by changing the solvent conditions. This induces a
change in the product solubility, or in the solubility of the impurities [82]. Even if a change of
temperature, pH-value of the solution, or concentration of the product would be conceivable,
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the most common way to induce the phase transition is the addition of precipitants [83].
In the biopharmaceutical industry, ethanol is used to extract immunoglobulin G (IgG)
from human plasma, similar to the original approach of Cohn [84]. Besides organic
solvents, chaotropic agents such as inorganic salts, or non-ionic polymers, such as PEG, are
possible alternatives to ethanol. [68, 85]. As an industrial application viruses, or virus-like
particles (VLP) are precipitated, or concentrated, with the precipitants ammonium sulfate,
or PEG [86–88]. For mAbs, one of the most important classes of biopharmaceutical
drugs, there is currently no large-scale industrial process on the market. And this despite
the fact that many academic studies dealt with ethanol-, salt-, or PEG-induced mAb
precipitation [21, 27, 89]. In particular, the use of PEG showed promising potential as
it is inexpensive, commonly available, non-toxic, non-flammable, and has a low vapor
pressure [90]. In addition to the classical precipitation approaches, recent studies deal with
new methods, such as, affinity precipitation, or the use of salt-tolerant copolymers. These
studies aim to achieve higher selectivities, compared to classical approaches [91, 92].
In order to increase the acceptance of protein precipitation, and crystallization, simple and
fast process development needs to be ensured. Since the mechanism of protein precipitation
is not fully understood, the majority of process development is done empirically. High-
throughput methods, and Design of Experiment (DoE) can contribute to faster and
more material saving process development. These methods can also help to increase the
acceptance of phase separation techniques in the biopharmaceutical industry. In the case
of polishing steps, however, separations based on chromatographic modes is probably
irreplaceable, as these techniques are associated with very high selectivities.
1.3.2. Fundamentals of Liquid Protein Chromatography
Chromatographic purification of biopharmaceuticals is widely used and of great importance
because of its high resolution, leading to a high purity of the product. Hence, it is
common practice to perform protein separation using liquid chromatography (LC). Thereby,
the proteins, solved in the mobile phase, are separated by selective interaction with the
stationary phase [93]. Different modes are established for analytical as well as for preparative
chromatography. They differ by the interaction mode of the proteins with the ligands. A
schematic overview of the most commonly used chromatographic modes, size exclusion
chromatography (SEC), affinity chromatography (AC), ion exchange chromatography
(IEX), and hydrophobic interaction chromatography (HIC) is presented in Fig. 1.7. SEC
separates the molecules depending on their hydrodynamic radii. In an ideal case, no
interaction between the stationary phase and the mobile phase takes place. Separation is
possible, as particles of different size have different pathways through the porous stationary
phase and, therefore, a different residence time. Smaller particles can enter the pores more
easily and accordingly have a higher retention time compared to larger ones [95].
AC is potentially the most selective method for protein purification. During an AC step,
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Figure 1.7.: Schematic representation of the most commonly used chromatographic modes.
Shown from left to right: Size exclusion chromatography (SEC), affinity chromatography (AC),
ion exchange chromatography (IEX), and hydrophobic interaction chromatography (HIC).
Illustration adapted from [94].
specific interaction between the protein in the mobile phase and the ligand takes place. In
theory only the product should bind to the resin. As a matter of fact, also contaminants
are found in the pool after elution [96]. Hence, also for AC additional purification steps
are necessary. Nevertheless, AC can lead to high yields and simultaneously a high purity.
Unfortunately the drawbacks of affinity resins are the high price and the poor ligand
stability [97]. Protein A affinity chromatography for the purification of mAbs is among the
most prominent usage of AC. Other examples are the use of specific tags like histidin (HIS)
or glutathione S-transferase (GST)-fusion proteins to enable the affinity chromatography
for the purification of proteins [98, 99].
IEX uses the interaction of the proteins with the immobilized charged groups onto the porous
beads of the stationary phase. Depending on the charge of the ligands, it is distinguished
between cation exchange chromatography (CEX) with negatively charged ligands and
anion exchange chromatography (AEX) with positively charged ligands. Protein-ligand
interaction is not only influenced by the stationary phase, but also by the mobile phase.
Changes in the pH of the utilized buffer solution can affect the surface net charge of the
protein, and influence the binding (Chapter 1.2.2.). Far away from the pI of the proteins a
stronger binding occurs if the charges of protein and ligand are opposite. The conductivity
of the mobile phase can prevent the protein from binding to the ligand, by shielding the
charged groups of the protein and the ligand. This can be used for selective elution by
applying a salt gradient. On the other hand, the conductivity can be a significant issue
for protein loading. Binding is usually performed in a conductivity range of 1-4mS/cm
equivalent to an ionic strength of 10-100mM [100]. Because of high salt concentrations
during fermentation, it can be necessary to dilute the clarified feedstock prior loading onto
IEX column.
During HIC, or reversed phase chromatography (RP), hydrophobic interaction between
the hydrophobic patches on the protein surface and the hydrophobic ligands takes place.
The nature of protein-ligand interaction can be influenced by changes in the mobile phase.
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During HIC, inverse to IEX, the adsorption increases with higher salt concentrations and
decreases at lower ones. Thereby, the mechanism is not depending on the conductivity, but
related to specific salt effects which strengthen or weaken hydrophobic interactions [101].
Furthermore, changes in the adsorption characteristics of proteins towards the ligands
can be achieved by variations of the ligand type, ligand chain length, ligand density,
or the material of the matrix [102]. Through the utilization of ligands with a higher
hydrophobicity a stronger binding can be achieved. However this can also lead to a
reduction of the selectivity. The retention mechanism during HIC is widely studied but
none of those theories has reached general acceptance [102]. Melander and Horvath
proposed a mechanism based on the solvophobic theory, and the formation of cavity during
the solvation process [103]. Thereby, the specific salt effects contribute to the different
changes of the surface tension. Arakawa presented an hydration model based on preferential
interaction between the protein and salts [104]. According to this theory the free energy of
the protein is increased by the addition of salts, which is thermodynamic unfavorable. As
the surface area is reduced during binding to the HIC ligand, preferential binding of salt
would transfer the protein to a more stable state. Tanford explained the hydrophobic effect
with reorganization of the water structure on the hydrophobic surface of the ligand and the
protein prior adsorption [105]. The higher order of water molecules around hydrophobic
patches could be proven by Shiraga et al. which carried out terahertz spectroscopy of
biomolecules [106].
1.3.3. Continuous Manufacturing of Biopharmaceuticals
According to the U.S. Food and Drug Administration (FDA), the transfer of a process to
continuous production should bring a number of advantages. For the development of a
continuous process, the first step is always a process integration, which ideally leads to a
reduction of the required purification steps. This has the advantage of shorter process times,
higher efficiency, and increased safety through fewer manual manipulations. Continuous
production also leads to a reduction in equipment size and thus to a smaller production
facilities. Additionally, continuous manufacturing is associated with the need for on-line
monitoring strategies. By applying real-time process monitoring and control, product
quality can be improved [107].
The key operation in downstream processes is the capture step, often performed as
affinity chromatography. For capture steps performed in bind and elute mode, continuous
chromatography can be run in periodic counter-current chromatography (PCCC) mode.
Thereby, multiple columns are run in parallel and concurrently [108]. This allows an
overloading of the columns without the risk of losing product, as the flow-through is
collected by a second interconnected column. Due to this mode the whole column capacity
can be used, and the number of elution steps, related to the amount of loaded material
onto the column, is reduced. Therefore, continuous chromatography can solve the problem
of high resin costs and poor resin lifetimes. Beside the improvement of the resin utilization,
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increase in productivity and reduction of the buffer consumption can be achieved by
using PCCC [109]. Angarita and coworkers presented an approach were only two columns
were used to perform a continuous process [110]. Anyhow, to allow a continuous flow,
often additional columns are used. These columns are not interconnected, but eluted and
equilibrated during the other ones are used for loading.
During the polishing steps, product-related contaminants are removed. These contaminants
only have slightly different surface characteristics, compared to the product, resulting
in similar elution behavior. Hence, using chromatography separation often leads to an
overlapping of the contaminants with the product during the elution. Flatten the gradient
can sometimes solve this problem, but consequently leads to a reduction of the productivity.
Therefore, in most of the cases purification will lead to a yield-purity trade-off, depending
on the pooling decision, i.e. the fractionation of the eluted material. In a continuous mode
this problem can be solved by loading the overlapping regions of the chromatogram onto a
second column. This recycling strategy differs from that during capture chromatography.
During a continuous capture step recycling of the breakthrough occurs during loading,
while during a continuous polishing step recycling is performed during the elution [111].
Different approaches are possible to turn a precipitation or a crystallization process into a
continuous one. By using a mixed suspension mixed product removal reactor (MSMPR)
the growth of the particles can be controlled depending on the residence time. This is a
simple approach as a MSMPR works similar as a continuous stirred tank reactor (CSTR),
which is already established for continuous protein refolding [112]. As an alternative,
tubular reactors are used for continuous precipitation. Thereby, mixing is ensured by static
mixers. The size of the reactor, respectively the tube length is defined by the kinetic of the
precipitation in combination with the flow velocity. This design allows a simple integration
into a fully continuous process. The variation of the tube length allows a process integration
without the necessity of changing the flow rate, and therefore the possibility to forego to
hold tanks [113]. Beside the precipitation, resolubilisation of the precipitated product was
shown to be challenging for a continuous manufacturing. To achieve acceptable yields, the
precipitated product has to be separated from the liquid and resolubilisized completely.
The phase separation can be carried out by centrifugation or filtration using depth filter or
tangential flow filtration (TFF). Thereby, centrifugation is commonly used in lab-scale, but
has the huge disadvantage that the precipitate flocks are compacted during the separation,
which makes it more difficult to resolubilise them afterwards [114]. In continuous mode,
depth filtration can be realized through parallelisation and sequential backflush of the
filters. However, this comes with the disadvantage of high investment costs through the
fast blocking of the depth filters. Kuczewski and coworker presented an approach where
the precipitate was captured and resolved using TFF [115]. In a first step the precipitate
was concentrated and washed using an 0.22µm membrane, which is capable of retaining
the precipitated flocks. In a second step the precipitate was resolubilised using precipitant
free buffer. This method avoids a complete phase separation and consequently allows the
precipitate to stay in solution. Following, higher yields in combination with a concentration
of the product can be achieved.
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1.3.4. Platform Process for Monoclonal Antibodies - A Heuristic
Approach
MAbs are among the most important class of biopharmaceutical products. Each mAb is
composed out of two heavy and two light chains held together by intra-molecular disulfide
bonds. Each heavy and light chain can be divided into a constant and a variable domain.
While the variable part is acting as antigen binding region, the constant domain contains
the fragment crystallizable (Fc) region [116]. This high similarity among different mAb
species and in particularly the presence of the Fc-region in each mAb enables the use of a
platform process with a sequence of equal or similar process steps.
Expression of mAbs usually takes place in mammalian cell culture suspensions. The most
common and dominantly used cell lines are chinese hamster ovary (CHO) cells. The
upstream processing is usually performed in Batch/Fed-Batch cultivation. For Fed-Batch
processes essential nutritions are feeded after inoculation during the cultivation [117]. The
first purification step of a generic antibody process is the clarification of the cell culture
media using centrifugation and/or depth filtration. For the capture step the clarified cell
culture media (HCCF) is loaded onto a Protein A affinity chromatography column. After
loading, the elution is performed by applying a low pH step, following by an hold step at
low pH to ensure virus inactivation. Afterwards, polishing is carried out by two additional
chromatographic steps. Often a CEX in bind-and-elute mode is followed by an AEX
step in flow-through mode. Finally, the product is concentrated and transferred into the
formulation buffer using ultra- and diafiltration (UF/DF). Since the first introduction of a
mAb to the market in 1986 this sequence of unit operations was consequently developed
further, and became the basis for a platform process. Only minor changes and adjustments
have to be performed, resulting from the variations between the different mAb species [14].
The basis of this process is the Protein A affinity chromatography step, which combines high
selectivity with high yields in a generic process step [118]. Anyhow, the key disadvantages
of this step are the high resin costs in combination with the low stability of the resin.
Especially, the low pH elution can lead to leaching of the Protein A ligands, and hence
reduce the lifetime of the affinity resin [119]. Therefore, different approaches are currently
under investigation either to reduce the cost of an affinity based purification process or
to replace chromatography as unit operation for the capture step. Replacing Protein A
chromatography comes with the disadvantage of renouncing the platform process. Therefore,
alternative process development strategies are necessary.
1.3.5. High-Throughput Process Development
The biopharmaceutical industry is operating under constant pressure, to lower the cost for
process development and ensuring a fast and save process development. High-throughput
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process development (HTPD) can help to fulfill these needs. HTPD is thereby characterized
by three principles: miniaturization, automation, and parallelization [120]. The large
number of experiments, enabled through the low amount of material, requires the use of
robotic based high-throughput screenings (HTS). While HTPD was first implemented in
the analytical sector and for lead discovery in the 1990s, it is today widely applied for
downstream process development [121]. The applications include methods for membrane
processes, chromatography operations, solubility screenings, or protein folding studies [122–
124].
HTS is applied for the optimization of a varity of alternative purification methodologies.
Bensch and coworkers showed an approach using HTS for the development of aqueous
two-phase systems (ATPS) [125]. Kevelman and coworkers developed an HTS approach for
the screening of PEG based precipitation [26]. For precipitation processes the high amount
of influencing parameters, like pH value, conductivity, feed concentration, contaminant
profile, or different precipitation agents, leads to the necessity of HTS. The possibility to
scale by volume, makes this process step an ideal approach for HTS.
To reduce the number of single experiments it can be useful to combine HTS with DoE. A
DoE can help to investigate the influence of different parameters on a system. In a classical
one-factor-at-a-time (OFAT) experiment, one factor is varied while the other variables
are kept constant. This can be very time consuming and inefficient. However, sometimes
this is unavoidable, when the influence of each parameter towards the others can not be
described mathematically. In contrast, during a factorial experiment different factors a
varied together. Thereby, a well designed experiment can provide answers to the question
which parameter influences the investigated system and to which output the parameter
yields. Following, DoE can lead to an empirical model which characterizes the system
performance [126].
Especially in early development phases, HTS can provide useful information for chromato-
graphy process development. Traditionally, several dozen column experiments have to be
performed to optimize the conditions for one chromatography step [127]. HTS can help to
optimize different parameters and lower the time and material consumption significantly. It
allows to screen a huge variety of resins, which might differ in particle size, ligand type, or
the pressure flow characteristics. Resin screening can be performed in 96-well format using
so called PreDictor plates, or specially designed Robocolumns. Another process parameter
which can be optimized, using HTS, is the binding capacity of the target protein. This,
among others, changes strongly in relation to the buffer conditions [128, 129]. Further, HTS
can be used to determine parameters needed for mechanistic modeling of chromatography
processes. Therefore, the combination of HTS and mechanistic modeling has shown huge
potential for the future of chromatography process development [130].
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1.3.6. Mechanistic Modeling of Ion Exchange Chromatography
Mechanistic chromatography modeling and numerical simulation can help to reduce the
number of wet laboratory experiments during chromatography process development. This
can help to save time, material, and process development costs [131]. In this thesis, a
CEX chromatography step is optimized for aggregate removing using mechanistic modeling.
Therefore, in the present chapter the theoretical basis of chromatography modeling is
discussed exemplarily on the CEX.
Figure 1.8.: Schematic representation of column phenomena leading to peak broadening.
Axial dispersion is a result of (a) fluid dynamic adhersion between the particles, (b) Eddy-
diffusion, or (c) wall effects. (d) Mass transfer phenomena occur because of 1. convection and
diffusion transport, 2. film diffusion, 3. pore diffusion, 4. surface diffusion, and 5. adsorption
and desorption.
During chromatographic separation in an ideal case a rectangular signal would be the
answer of a pulse injection. In reality, non-idealties of fluid distribution occur, resulting in
peak broadening. A schematic representation is shown in Fig. 1.8.. Hydrodynamic effects
are summarized in the axial dispersion. The rest of the peak broadening is a result of mass
transfer phenomena.
Axial dispersion occurs due to extra column effects, owning the presence of pumps, tubing
or valves. To minimize these effects, especially for analytical chromatography systems,
death volumes and tubing lengths should be held at a minimum. For larger columns
the critical point for axial dispersion is the column head and the fluid collection at the
column outlet. In the column non-ideal fluid distribution can occur too (Fig 1.8. (a, c)).
Fluid dynamic adhesion between the macroscopic channels of the packed bed results in a
non-uniform flow profile (Fig. 1.8. (a)). Additionally, local inhomogeneity of the packed
bed can result in different microscopic fluid distribution of the molecules, the so called
Eddy-diffusion (Fig. 1.8 (b).). Finally, wall effects caused by interaction of the fluid with
the column wall, and the material lead to a broadening of the peak (Fig. 1.8. (c)) [93].
Mass transfer phenomena are the second aspect contributing to the peak broadening.
For enlarging the capacity of the utilized chromatography media, particles with a porous
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structure are used. Depending on the mode of chromatography, specific ligands are bound
to the porous particles. Resulting from this structure several mass transfer parameters
have to be considered (Fig. 1.8. (d)). These parameters describe convective and diffusive
transport towards the particles, film diffusion in the laminar boundary layer around the
particles, and pore and surface diffusion in the particles. The actual separation takes
place through interaction with the adsorbers, described with adsorption and desorption
kinetics [93].
To describe the behavior of proteins during a chromatographic process, a description of the
convection and diffusion in the chromatography column and a description of the adsorption
behavior is necessary. In this thesis, the general rate model (GRM) was employed to cover
the convection and diffusion in the column of the length L and the adsorber beads of the
radius rp [93]. In the GRM two mass balances, Eq. 1.5 and Eq. 1.6, describe the mass
transfer of the component i from the bulk phase towards the stationary phase during a
chromatographic separation.
∂ci(x,t)
∂t
= −u(t)∂ci(x,t)
∂x︸ ︷︷ ︸
convection
+Dax
∂2ci(x,t)
∂x2︸ ︷︷ ︸
axial dispersion
−1− b
b
kfilm,i
3
rp
(ci(x,t)− cp,i(x,rp,t))︸ ︷︷ ︸
mass transfer
(1.5)
∂cp,i(x,r,t)
∂t
=

1
r2
∂
∂r
(
r2Dp,i
∂cp,i(x,r,t)
∂r
)
− 1−pp
∂qi(x,r,t)
∂t for r ∈ (0, rp),
kfilm,i
pDp,i
(ci(x,t)− cp,i(x,rp,t)) for r = rp,
0 for r = 0.
(1.6)
Eq. 1.5 describes the transfer between the mobile phase with the concentration ci(x,t)
and the pore phase, depending on the position x in the column, and the time t. Thereby,
the first term of Eq. 1.5 describes the convection in the column depending on the flow
velocity of the mobile phase u. The second term describes the axial dispersion by the axial
dispersive coefficient Dax. The last term describes the transfer from the bulk phase towards
the pores with the concentration cp,i(x,r,t). This term is influenced by the film transfer
coefficient kfilm,i, and the voidage of the adsorber bed b. Eq 1.6 describes the mass
transfer from the pore volume with the concentration cp,i(x,r,t) to the stationary phase qi
and vice versa, depending on the adsorber particle voidage p, the component-specific pore
diffusion coefficient Dp,i, and the radial pore position r within the particle.
Adsorption and desorption processes of the particles on the adsorbers during a CEX step
can be described with the steric mass action (SMA) isotherm, developed by Brooks and
Cramer [132]. Velayudan and Horvath developed the theory, that during CEX salt ions
and proteins compete for available binding sites[133]. Nilsson and coworker assumed that
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this was a first order reaction and developed the kinetic formulation shown in Eq. 1.7 [134].
kkin,i
∂qi(x,t)
∂t
= keq,i(Λ−
k∑
j=1
(θi + σi)qj(x,t))θicp,i(x,t)︸ ︷︷ ︸
adsorption
(1.7)
−cp,salt(x,t)θiqi(x,t)︸ ︷︷ ︸
desorption
∀i 6= salt
The fist part of the kinetic SMA isotherm describes the adsorption of the protein in the
stationary phase with the concentration qi. It depends on the protein concentration itself,
the ionic binding capacity Λ , the pore phase concentration of the protein cp and the
characteristic charge of the directly involved binding sites θ. σ is a shielding factor, taking
into respective that not all binding sides are accessible for the protein, because of steric
effects. The second part of the kinetic SMA isotherm represents the desorption term
depending on the the pore phase salt concentration cp,salt and the stationary phase protein
concentration qi. For numerical stability and to separate the parameter effects on the
retention time and height of the chromatogram, respectively, the equilibrium coefficient
and the kinetic coefficient were used instead of kads and kdes [135]. The salt concentration
in the stationary phase qsalt is described with Eq 1.8.
qsalt(x,t) = Λ−
k∑
j=1
θjqj(x,t) (1.8)
The combination of GRM and SMA, together with numerical methods for parameter
estimation allows the modeling and in silico optimization of the CEX processes, developed
in this thesis.
1.4. Process Analytical Technology
Production processes for pharmaceutical and biopharmaceutical products are traditionally
monitored by oﬄine analytics after the batch has been produced. However, in 2002 the
FDA has introduced process analytical technologies (PAT) as a key element of good
manufacturing practice (GMP) [136]. In 2004 the FDA has introduced a guidance for the
implementation of PAT in biopharmaceutical industry with the goal to improve process
development, manufacturing, and quality assurance [137]. PAT describes a broad field
of tools and principles which allow real time analytic of process components, as well as
process understanding. This real time analytics can lead to a better process understanding,
enable real time process control, and help to make real time risk-based decisions [138].
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In the past the focus was set on on-line and at-line high-performance liquid chromatography
(HPLC). Recently, the implementation of spectroscopic methods has shown great potential.
As opposed to HPLC methods, spectroscopic methods are faster and can often be performed
in-line, without the necessity of removing samples out of the process steam. Furthermore,
they avoid the risk of harming the product. However, spectroscopic, or chemometric
methods come with the drawback of a limited selectivity for different components. To
overcome this drawback, not only selected wavelength are used, but the information
contained in the hole spectra is recorded. That in a turn leads to great amount of data.
To overcome this challenge, multivariate data analysis (MVDA) is applied to extract
information out of the complex spectra [34]. In this thesis in-line FTIR spectroscopy
is investigated as process analytical technology. Therefore, chapters 1.4.1 and 1.4.2
describe the fundamentals of the applied MVDAs and chapter 1.12 the fundamentals of
the investigated FTIR sensor.
1.4.1. Principle Component Analysis
Principle component analysis (PCA) is often the basis for data and noise reduction,
outlier detection, or classification during MVDA. During a PCA, a transformation of
possibly correlating variables into a smaller number of uncorrelated variables, the principle
components or factors, is performed. The original data are described as linear combination
of different weighted principle components. A graphic illustration of how PCA is calculated
can be seen in fig 1.9. TherebyX represents a matrix of the original data with the dimension
Figure 1.9.: Schematic representation of how PCA is calculated, adapted from [139].
NxM . To carry out a data reduction principle components have to be found. The most
common way is to use the mathematical nonlinear iterative partial least square (NIPALS)
algorithm. The first principle component is that one, which points in the direction of the
highest variance. The first principle component defines a new coordination system with
one dimension. The second principle component is orthogonal to the first one, and so on.
Finally, a data reduction is reached, if the dimension of the new generated system is lower
than the original one. All principle components build the matrix P T with the dimension
AxM . Each column of P T is represented by one principle component, and the number
of rows is defined by the number of variables in the original matrix X. After finding
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the principle components the transformation of the original data in the new coordination
system is performed. For each new factor a score or weighting is calculated. The scores
build the matrix V with the dimension NxA, which has as many rows as the original data
and the number of columns is equal to the number of applied principle components. Data
reduction is achieved by projecting the original data to a number of principal components
smaller than the original dimensions of the data. The variance in the data, that is not
explained by the projection, is described in the matrix E as residual or noise [139]. The
mathematical representation of Fig. 1.9 is shown in Eq.1.9
X = V P T + E (1.9)
1.4.2. Partial Least Square Regression
Partial least square regression (PLS) is a multivariate regression method that correlates a
set of Y -variables with a set of X-variables (Eq.1.10).
Y = XB + E (1.10)
By calibrating a PLS model with known Y and X data, it can be applied to estimate
unknown Y -data. In this thesis, PLS is employed to determine the concentration of
proteins and process contaminants in combination with Fourier-transform infrared (FTIR)
spectroscopy. Hence, the FITR spectra are utilized as X-data for PLS regression. Thereby,
the (N xM) X matrix is composed of N objects with M properties, in the present case
different spectral data. The corresponding protein or contaminant concentrations build the
matrix Y . The PLS model correlates Y -values to the X-data with the help of a regression
matrix B. The residues are summed up in the matrix E [139]. A schematic representation
of a PLS model is shown in Fig. 1.10.
Figure 1.10.: Schematic representation of a PLS regression model, adapted from [139].
To calibrate a PLS model, spectral data are generated and the corresponding response values
are determined with the help of oﬄine analytic. In a second step, the model is validated
with data not included in the model building, to prove the assurance and predictability
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of the model. In the last step the model can be used to estimate the concentrations in
samples associated with new spectral data.
The idea of a PLS is to perform a kind of PCA for the X-data (Eq. 1.11), as well as for
the Y -data (Eq. 1.12). The matrix X is separated in the score matrix V and the principle
components P T , while the Y -matrix is described by the score matrix W and the principle
components QT . The residues are described by the matrices E1, respectively E2 [139].
X = V P T + E1 (1.11)
Y = WQT + E2 (1.12)
In opposite to classical PCA a PLS does not aim to find the highest variance of X and Y ,
but rather to find the highest correlation between the scores of X and Y . Hence, a model
is developed in such a way that the different score values W have a maximum covariance
to the associated score values V . The linear correlation between both scores is described
in the regression matrix B. Finally, by describing W in dependency of V , it is possible to
determine the responses in matrix Y out of the initial detected spectral data matrix X. A
graphic illustration of the procedure of calibrating PLS is shown Fig. 1.9.
Figure 1.11.: Schematic representation of the procedure for performing PLS regression,
adapted from [139].
1.4.3. Fourier-Transform Infrared Spectroscopy
In this thesis FTIR was applied as in-line analytical tool, for the monitoring of downstream
process steps. FTIR is a non-invasive analytical technique, and can be used for a wide range
of sample types. In particular it allows to investigate proteins in their natural environment.
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Thereby, it is possible to determine concentrations, but also to get information about the
protein structure [140].
Figure 1.12.: Schematic representation of Michelson-Interferometer. Illustration adapted
from [141].
FTIR is a vibrational spectroscopy. Hence, molecular vibrations or rotations are measured
to detect and distinguish between different molecules. In general all atoms oscillate around
an equilibrium position. This also influences the bond length. As the resonance frequency
of these motions is in the infrared region, it can be excited by IR-light [141]. However, only
changes in the vibration mode which influence a dipole moment of a molecule show up
in an IR-spectrum. In other words, only asymmetric molecules can be detected. When a
mid-infrared spectroscopy is used, the functional groups of the molecules get excited, with
light in the region between 4000 cm−1 and 400 cm−1. For proteins, especially vibrations in
the amid I band between 1700 cm−1 and 1600 cm−1 and amid II band between 1580 cm−1
and 1510 cm−1 are of high importance. Vibrations of the amid I band mainly result from
C––O stretching while the amid II band can be correlated to N–H and C–H stretching.
Both bands are directly related to the backbone of the proteins. The region between
1400 cm−1 and 400 cm−1, is called the finger print region, and is highly specific for the
configuration and physical state of the protein [140].
Spectrometers equipped with an interferometer are often used to detect mid-infrared
spectra. In Fig. 1.12. a schematic representation of a Michelson-Interferometer is presented.
The polychromatic light is emitted by a thermal source such as a globar and divided into
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two parts by a beamsplitter. One part of the light hits a fixed mirror after the distance L,
is reflected, and meets the beamsplitter a second time after the distance 2L. The other part
of the light is reflected by a movable mirror of the distance x, and therefore the distance to
the beamsplitter 2(L+ x) correlates to the position of the mirror. The reunion of the two
beams after different path lengths causes interference, leading to different amplitudes of
the resulting beam. The modulated light passes the sample and hits the detector, were the
interferogram is recorded. In this interferogram the intensity is correlated to the position
x of the movable mirror. Fourier transformation is used as mathematical transformation
of the deflection amplitude domain into a frequency amplitude domain. The resulting
spectrum shows the intensity of each wavenumber [141].
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2.1. Research Proposal
The pharmaceutical market continues to grow and the group of biopharmaceuticals has the
highest growth rate by comparison. This opens up the opportunity for biopharmaceuticals
to become the core of the industry in the future. That not only requires new products,
but also higher production capacities and more efficient processes. Progress in upstream
process development (USP) has already, at least partially, met these challenges, and shifted
the bottleneck towards downstream process development (DSP). In DSP chromatographic
separation is still the workhorse. High resin, and operating costs, combined with a slow
volumetric throughput demand new approaches based on Anything but Chromatography
(ABC) methodologies. Preparative protein precipitation is one of the most promising
techniques among these unit operations. In particular, it is known as a cost-effective
alternative for small scale production. For monoclonal antibodies (mAb), polyethylene
glycol (PEG) induced precipitation has been presented as an easy-to-use alternative,
especially for continuous production. However, there is no large-scale mAb precipitation
process on the market yet. The focus of this thesis is to identify the main obstacles that
prevent preparative protein precipitation from being applied in industry and to overcome
them.
A major challenge in the development of a precipitation process is the high complexity of
the underlying processes. Understanding the different forces, acting between the different
particles involved, can help to overcome this complexity. Protein phase behavior is
influenced by a combination of molecular and process-related factors. Molecular factors
are mainly defined by the amino acid composition of the protein. The different residues, of
the amino acids lead to different protein structures and influence its charge distribution,
as well as the formation of hydrophobic patches on the protein surface. Process-related
factors such as ionic strength, pH value, buffer composition, or impurities can change these
surface attributes, depending on the process conditions. Understanding the acting forces
is a prerequisite for the understanding of protein phase behavior. In particular, the role
of hydrophobic interactions still requires the attention of academic research. Therefore,
the first part of this thesis will focus on the role and the mechanism of hydrophobic
interactions. In order to gain a deeper understanding of the acting forces and the underlying
mechanism, a first study will need to investigate similarities between hydrophobic interaction
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chromatography (HIC) and protein phase behavior [1]. Based on this data, it will be
evaluated whether these findings can be used to predict protein phase behavior and/or
serve as a basis for a mathematical description of the precipitation process [2]. The results
will provide the framework for an in silico process development of a precipitation-based
process. A study will be carried out to develop a mechanistic precipitation model and to
determine whether the model enables simpler and faster process development. In addition,
it will be evaluated whether the model can serve as a basis for further model extensions.
The study will also investigate how the model can contribute to a deeper understanding of
the process.
Often the process development of a precipitation step is still purely empirical and con-
centrates on the individual unit operation itself. In contrast, traditional mAb process
development is based on an integrated platform process, using Protein A affinity chromato-
graphy as capture step. The use of a generic capture step enables simple, and fast process
development. In order to establish a precipitation-based process as appropriate alternative,
two studies will be conducted. The first study will investigate the influence of the upstream
conditions on the subsequent precipitation step [3]. It will be analyzed whether the contam-
inant composition influences the purification outcome and, consequently, which parameters
have to be considered for successful process development. A further study will concentrate
on the optimization of the precipitation step itself and the integration of the subsequent
polishing steps [4]. Thereby, it is important to consider the mutual influences of precipi-
tation, resolubilisation, and further polishing steps. It will be investigated whether the
combination of high-throughput screening (HTS), empirical, and mechanistic modeling can
contribute to the establishment of a fast, simple, and material-saving development strategy.
In addition, it will be examined whether the resulting process meets the requirements of a
fast, flexible and robust purification strategy. In order to meet the current trends in the
biopharmaceutical industry, it will also be investigated whether the development platform
is suitable for the development of both, a classical batch process, and a continuous one.
In addition to the complexity of the process, and the mutual influences of different
parameters on the purification outcome, the monitoring of PEG-induced precipitation is a
limiting factor for an industrial application of a precipitation-based purification process.
Precipitation leads to a turbidity of the solution, which makes it impossible to monitor
the precipitation step itself. This makes it even more important to accurately monitor the
following polishing steps. Although PEG is an approved excipient, successful depletion
must be ensured during the subsequent purification steps. The challenge in detecting PEG
is that it is a component that cannot be detected by conductivity or UV/Vis measurements.
Both are currently the standard methods used as in-line process analytical technologies
(PAT). For these reasons, the last part of this thesis is dedicated to the development of
new technologies and measurement setups for monitoring the subsequent chromatographic
polishing step [5]. In particular, the potential of in-line Fourier-transform infrared (FTIR)
spectroscopy will be investigated. It will be examined whether the combination of FTIR
spectroscopic data with a partial least square regression (PLS) model allows differentiation
between different proteins. In addition, it will be tested whether the developed setup is
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capable of quantifying other process-relevant impurities including PEG.
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2.2. Outline and author statement
In several of the following chapters, first authorship was shared (contributed equally)
among colleagues and me. This was undertaken to elevate the quality of our common
publication. A detailed listing of author contributions signed by the respective authors is
given in AppendixD of the examination copy. In general, work connected to Preparative
Protein Precipitation as put forward in Abstract and Research Proposal has been performed
by myself. Fundamentals for techniques concerning hydrophobic interaction chromato-
graphy, mechanistic chromatography modeling as well as process analytical technology
used throughout the study, have been laid by the thesis of a) Baumgartner, K. (2015)
Development of a methodology linking protein phase behavior and Hydrophobic Interaction
Chromatography, b) Wang, G. (2018) Advancing Downstream Process Development
Mechanistic Modeling and Artificial Intelligence and c) Rüdt, M. (2018) Spectroscopy as
process analytical technology for preparative protein purification.
Chapter 3: Prediction of salt effects on protein phase behavior by HIC
retention and thermal stability
K. Baumgartner*, S. Großhans*, J. Schütz*, J. Hubbuch (*contributed equally)
Journal of Pharmaceutical and Biomedical Analysis (2016) Volume 128, Pages 216–225
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In chapter three, hy-
drophobic effects oc-
curring during aggre-
gation and influenc-
ing protein phase be-
havior were investi-
gated. Retention
times during hydrophobic interaction chromatography (HIC) in combination with
measurements of the thermal stability were used as estimation tools for protein
stability. In particular, HIC retention times, of the model protein glucose isomerase,
were correlated to crystal size and form at varying salt concentrations, salt types, pH
values, and protein concentrations. The focus in chapter three was the development
of the HIC and temperature stability analytics, the generation of the data, and the
comparison and evaluation of the received results. Using HIC a deeper understanding
of appearing hydrophobic effects during protein-protein interaction was generated.
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Chapter 4: Water on hydrobobic surfaces: Mechanistic modeling of
polyethylene glycol induced protein precipitation
S. Großhans*, G. Wang*, J. Hubbuch (*contributed equally)
Bioprocess and Biosystems Engineering (2018) Volume 42, Issue 4, pp 513–520.
In this chapter, similarities between HIC and
protein phase behavior were used to derive a
mechanistic model for polyethylene glycol (PEG)
induced protein precipitation. The presented
approach proposes an equilibrium between well-
ordered and bulk-like ordered water molecules
on the hydrophobic surfaces of the protein, as
driving force for the precipitation process. The
model predictability was proven with the help of high-throughput precipitation
experiments. Model parameters were estimated for the model proteins lysozyme,
myoglobin, bovine serum albumin (BSA), and a monoclonal antibody (mAb) at two
different pH values. The model is capable to predict the amount of precipitated
protein, depending on the initial protein and PEG concentration. Following, the
model was validated with a data set not included into the model building, and
beyond the calibration range. The main task in chapter four was the establishment
of the screening platform with the corresponding analytics, the generation of the
data, model calibration and validation, the transfer of the theoretical assumption to
a mathematical model, and the interpretation of the results and model parameters.
Chapter 5: Precipitation of complex antibody solutions - Influence of
contaminant composition and fermentation media on the precipitation
behavior
S. Großhans, S. Suhm, J. Hubbuch
Bioprocess and Biosystems Engineering (2019) Volume 42, Issue 6, pp 1039–1051.
In chapter five, the influence of upstream con-
ditions, and contaminant composition on the
PEG-induced precipitation behavior of a com-
plex mAb solution was investigated. A destabi-
lization of the mAb, induced through the addition
of contaminants, could be shown, compared to
a pure mAb solution. By re-buffering the con-
taminants solution, prior to the mixing step, the
observed destabilization could be correlated to
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mAb-macromolecular interactions. Furthermore, also a destabilization of the con-
taminants was observed. In contrast, for molecules with a size smaller than 10 kDa a
stabilizing effect could be shown. This effect could be related to molecules present in
the cell culture medium. Hence, the chapter points out the importance of integrating
up- and downstream process development. The key tasks in chapter five were the
design of the study, the selection of screening parameters, and the preparation of
protein and contaminant solutions, so that variations in the precipitation efficiency
could be attributed to individual factors.
Chapter 6: An integrated precipitation and ion-exchange chromatogra-
phy process for antibody manufacturing: Process development strat-
egy and continuous chromatography exploration
S. Großhans*, G. Wang*, C. Fischer, J. Hubbuch (*contributed equally)
Journal of Chromatography A (2018) Volume 1533, Pages 66–76.
This chapter presents a fast and material saving-process development platform, for
an integrated precipitation and ion-exchange chromatography mAb process. By
combining high-throughput screening, Design of Experiment (DoE), and mechanistic
chromatography modeling a promising strategy was presented, which has shown the
potential to replace Protein A as affinity chromatography step.
Process-related contami-
nants like host cell pro-
teins (HCP) and DNA
were successfully removed
during the precipitation
and resolubilisation steps.
Cation-exchange chroma-
tography (CEX) was used
to remove aggregates. Finally, the capability of a continuous chromatography process
was explored theoretically, with the help of in silico simulations. The main task in
chapter six was the development of the HTS platform with corresponding analytics,
the implementation of the DoE, the process integration of the various steps and the
execution of the case study, to enable an efficient purification process.
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Chapter 7: In-line Fourier-transform infrared spectroscopy as a ver-
satile process analytical technology for preparative protein chromato-
graphy
S. Großhans*, M. Rüdt*, A. Sanden*, N. Brestrich, J. Morgenstern, S. Heissler, J.
Hubbuch (*contributed equally)
Journal of Chromatography A A (2018) Volume 1547, Pages 37-44
In chapter seven FTIR spectroscopy was implemented as in-line
process analytical technology (PAT) tool for chromatographic
purification steps. With the help of FTIR spectroscopy, the
possibility to distinguish, and selectively quantify different pro-
teins, based on variations in their secondary structure, was
shown. Furthermore, it was demonstrated, that in-line FTIR
spectroscopy is a powerful tool to detect non UV/Vis active
molecules. In a case study the PEGylation degree of proteins
could be measured in-line, based on selective in-line quantifica-
tion. Additionally, selective mass balancing was performed for the process-related
contaminant Triton X-100. The main challenge in chapter seven was the transfer of
the knowledge gained from oﬄine analysis using FTIR spectroscopy to the require-
ments of an in-line sensor, the implementation of the sensor and the required oﬄine
analytical methods, as well as the interpretation of the data.
Overview of Selected Proteins and Model Systems
In order to investigate the process development, integration, and monitoring of
a preparative protein precipitation process, different systems were selected which
were adapted to the requirements of the five studies carried out. The preparative
protein precipitation process was optimized for a monoclonal antibody (mAb). The
antibody was provided by an industrial partner and used in chapter four, five, six,
and seven. In order to gain a deeper and more generalized knowledge of the effects of
hydrophobicity, appropriate model proteins were selected in chapters three and four.
In chapter three, glucose isomerase proved to be the most suitable model protein,
since precipitation, crystallization, and denaturation of the protein could be detected,
depending on the chosen parameters. In chapter four, the model proteins lysozyme,
myoglobin, bovine serum albumin (BSA), and one mAb, were selected as they show
a variety in properties such as size, charge, or hydrophobicity. In order to investigate
the influence of the feed solution on precipitation behavior, two different mAbs, one
IgG1 and one IgG2, were investigated in Chapter five. To demonstrate the ability
to monitor and distinguish different proteins using in-line FTIR, a system of mAb
and lysozyme was chosen in Chapter seven. In addition, PEGylated lysozyme was
chosen as the model protein to demonstrate the ability to differentiate between a
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protein and polyethylene glycol.
34
3. Prediction of Salt Effects on
Protein Phase Behavior by HIC
Retention and Thermal
Stability∗
Understanding and controlling protein phase behavior is of great importance in the
biopharmaceutical industry. A stable protein solution is crucial to avoid product
loss during processing and storage. Furthermore, understanding of the acting forces
between all involved particles, like proteins, salts, or contaminants, is mandatory to
achieve a better control of intentionally induced preparative precipitation. In the
last decades a lot of research has been conducted in this field [49, 75]. However,
the role of hydrophobic interactions in particular is not yet fully understood and
therefore, requires further academic investigation [45]. In this chapter, which can be
viewed as full manuscript in the appendix A, the correlation between protein phase
behavior, hydrophobic interaction chromatography (HIC), and thermal stability was
investigated. The goal of the study was to investigate new analytical technologies,
to reach a deeper knowledge of the role of hydrophobic interaction, and to develop a
method to predict the effect of salts on the protein phase behavior.
To do so, the model protein glucose isomerase was used, as it showed a large variation
in its morphologies at different pH values and different ionic strengths. In order
to detect these different morphologies, a high-throughput screening (HTS) was
developed. This HTS enables the visualization of the protein phase behavior at
constant protein concentration by simultaneous variation of pH and ionic strength. In
order to investigate the influence of different salt ions, the phase behavior of glucose
isomerase with addition of sodium chloride, sodium sulfate, ammonium chloride,
and ammonium sulfate was examined. For glucose isomerase, the metastable zone
showed the occurrence of protein crystallization or the formation of precipitate in
combination with skin formation, depending on the salt that was used as precipitant.
∗ A full version of this publication is given in Appendix A and [1]. In the following the major findings
relevant for this thesis are summarized.
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Both phenomena occurred over time. This was of particular interest as it allowed to
investigate the retention volume during the HIC and the thermal stability of these
conditions. The retention volume during HIC was investigated as it allows to detect
variations of the hydrophobic effect without considering charge induced attraction or
repulsion. The HIC analysis was supplemented by the measurement of the thermal
stability, in order to differentiate between conformational and colloidal stability of
the protein. The aggregation temperature is an indicator for the colloidal stability,
while the melting temperature gives information about the conformational stability
of the investigated protein. The information from all applied analytics was compared
to the phase state of the protein and the result was used to explain and predict the
effects of the different salt ions.
Comparing the different investigated salts a stronger influence of the anions compared
to that of the cations was seen. The formation of protein crystals could only be
observed in systems with sulfate ions. In comparison, the addition of salts with
chloride led to precipitation and skin formation of the protein. This indicates that the
addition of salts with sulfate, compared to those with chloride, led to a stabilization of
the native conformation of glucose isomerase. These assumptions could be confirmed
with measurements of the thermal stability. Systems with chloride showed lower
aggregation temperatures and a tendency to melt at lower temperatures, compared
to systems with sulfate ions. Measurements of the retention behavior of glucose
isomerase showed the importance to consider the hydrophobic effect in the process of
precipitation and aggregation. The retention volume during HIC depended strongly
on the used salts and the pH value of the solution. While HIC experiments with
salts containing chloride led to an isoelectric elution of the proteins, systems with
salts containing sulfate led to an immobilized of the proteins on the HIC column.
Subsequently, these samples could be eluted with a decreasing salt gradient. In the
presence of sulfate different retention volumes could be detected depending on the
composition of the solution (Fig. 3.1).
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Figure 3.1.: Hydrophobic interaction chromatography elution ionic strength (ISElution) of
glucose isomerase at 4.00M binding ionic strength (ISBinding) of sodium sulfate (green) and
ammonium sulfate (black) in dependence of the pH value.
The retention volume could be correlated with the pH value of the solution. Higher
retention volumes could be measured close to the pI of the protein. These results
indicate that the charge of the protein has an important influence on the hydrophobic
effect as well. In addition, the retention volumes were higher for systems with salts
containing sodium ions compared to salts containing ammonium ions. This in turn
could be correlated with the crystal shape. Strong hydrophobic interactions led
to small needle-shaped crystals, while moderate attraction led to large tetragonal
crystals (Fig. 3.2).
pH        5.22          5.47 5.73          5.98
(NH4)2SO4
Figure 3.2.: Determined crystal size and form of 10mg/mL glucose isomerase at an ionic
strength of 4.00M sodium sulfate and ammonium sulfate in the pH range from pH5.22 to
pH5.98.
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The results of this study show how important it is to consider different specific
salt effects, to understand the observed protein phase behaviour. The influence of
different salt ions and salt concentrations is of great importance, as the purification
processes always take place on the background of specific salts from buffers or earlier
production steps. In particular, the capture step, after the fermentation of the
product, often has to cope with a high salt load. Changing the salt type or ionic
strength during the fermentation can be a critical factor for a robust purification
strategy. This topic is further discussed in the chapter 5 of this thesis. The different
investigated analytical technologies in this study can help to estimate the influence of
different salt ions without having to perform long-term storage tests. In addition, this
study demonstrates the importance of considering hydrophobic interactions to explain
protein phase behavior. The correlation between HIC and protein phase behavior
gives the possibility to obtain a mechanistic understanding of the precipitation process.
In chapter 4 this correlation was used to derive a mechanistic precipitation isotherm,
based on an isotherm previous developed to describe the interaction between a
hydrophobic patch and a protein.
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Abstract
For the purification of biopharmaceutical proteins, liquid chromatography is still
the gold standard. Especially with increasing product titers, drawbacks like slow
volumetric throughput and high resin costs lead to an intensifying need for alternative
technologies. Selective preparative protein precipitation is one promising alternative
technique. Although the capability has been proven, there has been no precipitation
process realized for large-scale monoclonal antibody (mAb) production yet. One
reason might be that the mechanism behind protein phase behavior is not completely
understood and the precipitation process development is still empirical.
Mechanistic modeling can be a means for faster, material-saving process development
and a better process understanding at the same time. In preparative chromatography,
mechanistic modeling was successfully shown for a variety of applications. Lately, a
new isotherm for hydrophobic interaction chromatography (HIC) under consideration
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of water molecules as participants was proposed, enabling an accurate description of
HIC.
In this work, based on similarities between protein precipitation and HIC, a new pre-
cipitation model was derived. In the proposed model, the formation of protein-protein
interfaces is thought to be driven by hydrophobic effects, involving a reorganization
of the well-ordered water structure on the hydrophobic surfaces of the protein-protein
complex. To demonstrate model capability, high-throughput precipitation experi-
ments with pure or prior to the experiments purified proteins lysozyme, myoglobin,
bovine serum albumin, and one mAb were conducted at various pH values. Polyethy-
lene glycol (PEG) 6000 was used as precipitant. The precipitant concentration as well
as the initial protein concentration was varied systematically. For all investigated
proteins, the initial protein concentrations were varied between 1.5mg/mL and
12mg/mL. The calibrated models were successfully validated with experimental
data. This mechanistic description of protein precipitation process offers mathe-
matical explanation of the precipitation behavior of proteins at PEG concentration,
protein concentration, protein size, and pH.
4.1. Introduction
Biologics represent a growing share of the pharmaceutical market, reaching global
sales of USD 228 billion in 2016 [142]. Among them, monoclonal antibodies (mAb)
are the most important family of products [143]. The fact that many mAbs have a
relatively low potency requiring high doses makes mAbs among the most expensive
drugs [144]. In 2015, the patent of first-generation mAbs began to expire, resulting
in a number of biosimilars approved in the USA and Europe [145]. Together
with an increasing pressure on healthcare budgets, cost savings are desired [146].
Therefore, improvements in downstream processes such as alternative methods or
novel development strategies are necessary [147].
Selective protein precipitation has been known as a cost-efficient alternative pu-
rification step for a long time [113]. Phase separation is carried out by adding
precipitation agents, such as inorganic salts, organic solvents, or nonionic polymers
to the protein solution [57, 89, 148, 149]. Especially, the use of polyethylene glycol
(PEG) is favorable as it is not reported to harm the protein by, for example, causing
denaturation [68]. For some biopharmaceutical products, precipitation is already
well established. For example, ethanol, or PEG precipitation is the basis of the ex-
traction of immunoglobulin G from human plasma [84]. Viral vaccines and virus-like
particles (VLP) are purified or concentrated through PEG or salt precipitation [87,
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88]. Although there are a lot of studies on precipitation of recombinant mAbs as
well, it has not been implemented for large-scale mAb production yet [21, 150, 151].
For downstream process development (DSP), mechanistic understanding is needed
to meet the demands of the quality by design (QbD) approach suggested by the US
Food and Drug Administration (FDA) [152]. For precipitation, the understanding
of protein phase behavior is mandatory [153]. Although protein phase behavior
has been well investigated experimentally, the mechanism behind precipitation has
not been completely understood. This leads to many degrees of freedom in process
development and makes it challenging.
Modeling can reduce the number of experiments and lead to a more thorough
process understanding [20]. Cohn et al. derived an equation to describe protein
precipitation [154]. This equation is a useful empirical expression, but not much of
a mechanistic description [155]. Its parameters were specified for salt precipitation
and its application to precipitation using polymers was shown [69, 156]. Sim et
al. generalized the model on the basis of hydrodynamic radii [90]. Quantitative
structure-activity relationship (QSAR) modeling was used to estimate the parameters
of the Cohn equation [157]. Anyhow, all these models have difficulty dealing with
small molecular weight proteins and are not capable to cover variations in the initial
protein concentration.
PEG-induced precipitation can be described by the theory of excluded volume [158–
160]. According to this theory, adding a certain amount of PEG to a protein solution
results in a phase transition of the proteins. The polymers are reported to trap the
solvent and, atherefore, sterically exclude proteins from solvent regions occupied by
the polymers. In other words, the polymers and proteins compete for the solvent
which they are solved in. The theory of attractive depletion introduces osmotic
pressure as additional force in the process of PEG-induced protein precipitation [71,
72]. According to this theory, the polymer is sterically excluded from the surface
of the protein, the depletion zone. The overlapping of two depletion zones causes
a concentration gradient which leads to the described osmotic pressure. In both
theories, there is no interaction between PEG and the proteins described; hence, all
other forces between particles are still valid. Electrostatic interaction is known to have
mainly repulsive influence on protein-protein interaction, so that attractive forces can
be reduced to hydrophobic effects [161]. On the molecular level, water molecules next
to hydrophobic surfaces are thought to have a well-ordered structure, as opposed to
the bulk-like ordered water in free solution [106, 162, 163]. During precipitation, a
rearrangement of the protein occurs and the solvent-accessible hydrophobic surface
area is reduced. Simultaneously, the water structure has to be reorganized. A new
equilibrium between well-ordered and bulk-like water is reached, resulting in an
increased entropy [105, 164]. The hydrophobic effect described above is thought to
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occur between two proteins in precipitation, as well as between protein and ligand
in hydrophobic interaction chromatography (HIC). This means that the mechanism
which causes a protein to be retained on an HIC column is analogous to the mechanism
that causes proteins to stick together and precipitate. Similarities between HIC
and precipitation have been already shown. Melander and Horváth investigated the
salt influence on the hydrophobic effect in precipitation and HIC [101]; Nfor and
coworkers studied the interrelation between the number of released water molecules
in protein precipitation and HIC [165]; Baumgartner and coworkers investigated the
retention behavior during HIC and its correlation to protein-protein interaction [1].
The mechanistic effects of HIC are well-investigated [166–168].
In this study, a mechanistic protein precipitation isotherm model was derived, inspired
by recent results in HIC modeling [169]. Based on existing precipitation theories,
water was introduced as an additional component for the model building. With the
help of high-throughput precipitation experiments, data for lysozyme, myoglobin,
bovine serum albumin (BSA), and a mAb were generated. For each protein, 50
data points were used to calibrate the model. The three highest protein and the
two highest PEG concentrations were excluded and afterward used as validation
set (Fig. 4.1.). The model predictability for a wide range of properties such as size,
hydrophobicity, and the isoelectric point (pI) was shown.
Figure 4.1.: Mechanistic protein precipitation modeling. By varying the amount of buffer,
protein and precipitant stock solutions, the precipitant and protein concentration were varied in
high-throughput experiments. After phase separation, the protein concentration was detected
using UV 280 measurement. 50 Data points were used as calibration set. With this data, the
parameters of the model were estimated. The so generated model was validated with the other
46 data points of the experimental data.
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4.2. Theory
In 1925, Cohn and coworkers introduced an afterward widely accepted semi-logarithmic
equation for modeling protein precipitation:
log(C) = C0 −mα. (4.1)
The useful empirical equation describes the protein solubility C in mg/mL in the
presence of m PEG in %(w/w). Here, the phase behavior of a constant protein
concentration depends on the precipitation efficiency α and the protein solubility
in the absence of PEG C0. This equation represents a summary of a macroscopic
observation of the precipitation behavior.
In the present work, the focus is placed on a mechanistic level, especially on the
behavior of water molecules during protein precipitation. In the model assumption,
the precipitation mechanism of n protein molecules P by a PEG molecule PEG
forming the precipitate Pp is considered. The hydrophobic surfaces of proteins are
thought to be stabilized by well-ordered water molecules. The precipitate Pp is
assumed to be stabilized by β bulk-like ordered water molecules WB:
nP + PEG
 Pp + nβWB. (4.2)
Precipitation using PEG is known to be a fast process [114]. Investigations by Atha
and Ingham showed that longer incubation times did not have an influence on the
precipitation behavior [69]. Thus, the following equilibrium was considered:
∆µ = µPp + nβµWB − nµP − µPEG. (4.3)
The chemical potentials µ are deduced to apply this constraint. It was assumed that
the protein surface charges can be considered negligible in the present hydrophobically
driven mechanism.
Considering the equilibrium ∆µ = 0 at constant temperature and pressure, it is
RT ln xPpγPp + nβRT ln xWBγWB − nRT ln xPγP −RT ln xPEGγPEG (4.4)
= −µ0Pp − nβµ0WB + nµ0P + µ0PEG (4.5)
= −∆G0 = RT lnK. (4.6)
To simplify the model equation, the activity coefficients of protein, PEG, and
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precipitate are assumed to be a constant. The equilibrium constant K is derived
K =
xPpx
nβ
WB
xnPxPEG
⇒ K = qa
nβ
WB
cnP cPEG
(4.7)
with q and cP being the precipitated protein and protein in solution, respectively.
cPEG depicts the concentration of PEG in solution, and aWB the activity of the
bulk-like ordered water molecules. In the following step, parameterizations for aWB
and β have to be found. According to stoichiometric considerations, the number of
water molecules involved is linearly correlated to the precipitated protein q. Thus, a
linear correlation is proposed to substitute aWB :
anβWB
∼= νqnβ. (4.8)
The stoichiometric constant ν is assumed to be independent of the PEG concentration.
Inserting Eq. 4.8 into Eq. 4.7, and collecting all constants on the left-hand side, the
following isotherm equation is obtained:
K = νq
1+nβ
cnpcPEG
(4.9)
· 1
ν⇐⇒: keq = q
1+nβ
cnpcPEG
. (4.10)
Finally, the PEG and protein dependency of the bulk-like ordered water molecules β
is modeled. Since hydration of PEG, protein, and salt ions has high similarities, e.g.,
attracting water molecules to form a hydration shell, the model originally describing
the hydration number of the salt ions h is employed [170]:
h = h0 exp(−kcs) (4.11)
where h0 is the ionic hydration number at infinite dilution and k the constant that
accounts for the dependency of the hydration number on the ionic concentration
cs. β and h are assumed to be reciprocal, so that the model parameter β can be
approximated by the exponential term:
β = β0 exp(β1cPEG + β2cp0) (4.12)
where β0 is the hydration number at infinite dilution of PEG and protein, whereas β1
and β2 are the constants that account for the dependency of the hydration number
on PEG and initial protein concentration, respectively. This completes the derivation
of the equilibrium formulation of the precipitation isotherm model.
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4.3.1. Disposables
All precipitation experiments were carried out in 350µL polypropylene flat bottom
96-well micro plates (Greiner Bio-One, Kremsmünster, Austria). For spectroscopic
measurements, samples were diluted into Greiner UV-Star® micro plates (Greiner
Bio-One, Kremsmünster, Austria).
4.3.2. Chemicals and stock solutions
As buffer substances, sodium hydrogen carbonate and tris(hydroxymethyl)-
aminomethane (both Merck KGaA, Darmstadt, Germany) were used. Tris hy-
drochloride was obtained from PanReac AppliChem (Darmstadt, Germany). Sodium
carbonate was obtained from Sigma Aldrich (St. Louis, MO, USA). The PEG with
a median molecular mass of 6000 was obtained from Merck KGaA (Darmstadt,
Germany). All buffers were prepared with a concentration of 50mM . For this, the
appropriate amounts of associated buffer components were weighed and dissolved
in ddH2O. The desired pH was achieved by varying the amount of acid and basic
component for each buffer. For the 40% (w/w)PEG 6000 and 50% (w/w)PEG 6000
stock solution, the buffer components were first dissolved in ddH2O followed by
adding the appropriate amount of PEG 6000.
4.3.3. Preparation of protein stock solutions
Lysozyme from chicken egg white was purchased from Hampton Research (Aliso Viejo,
CA, USA). Myoglobin and BSA were purchased from Sigma Aldrich (St. Louis, MO,
USA). The mAb was provided as purified mAb from LEK d.d. (Ljubljana, Slovenia).
Lysozyme, myoglobin, and BSA were provided as lyophilized powder and, therefore,
first dissolved in the appropriate buffer. Afterward, all proteins including the
mAb were filtered using 0.2µm cellulose acetate syringe filters (Satorius, Göttingen,
Germany). Following the filtration, proteins were rebuffered and desalted into the
associated buffer using PD 10 desalting columns (GE Healthcare, Little Chalfont,
UK).
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4.3.4. Generation of precipitation curves
All precipitation experiments were carried out on a Tecan Freedom Evo 200 System
liquid handling station (Tecan, Männedorf, Switzerland). The liquid handling
station was equipped with an 8-tip liquid handling arm, a robotic manipulator
arm, a Te-Shake orbital shaker, an Infinite® 200 UV-Vis spectrophotometer (all
Tecan, Männedorf, Switzerland), and a Rotanta 46RSC centrifuge (Hettlich GmbH
& Co. KG, Tuttlingen, Germany). The system was controlled by Evoware 2.5
(Tecan, Männedorf, Switzerland). Excel 2016 (Microsoft, Redmond, WA, USA)
was used as data import format and for data storage. All calculations were done
using Matlab® R2016a (The Mathworks, Natick, MA, USA). All experiments were
carried out at 20◦C, controlled by air-conditioning. Systems with a total volume
of 250µL containing varying protein and PEG concentrations were prepared. The
PEG concentration was varied in 12 equidistant steps. The protein concentration
was varied from 1.5mg/mL to 12.0mg/mL in 12 steps. The position for each
system on the 96-well micro plate was randomized. After adding the protein stock
solution, the system was incubated for 15min on the orbital shaker at 1000 rpm,
and followed by 15min without shaking. To analyze the amount of precipitated
protein, the microplate was centrifuged for 30min at 3400 g. Then, the supernatant
was sampled and diluted at a ratio of 1:6 for lysozyme, 1:3 for BSA, and 1:4 for
myoglobin and the mAb. Subsequently, UV-Vis absorption at 280nm was measured.
The protein concentration was calculated based on a linear calibration curve. For
data pretreatment the percentage standard error for each triplicate was calculated.
In case of deviations larger than 5% possible outliers were eliminated.
4.3.5. Numerical procedures
The equilibrium precipitation isotherm model Eqs. 4.10 and 4.12 proposed in the
previous section contain unknown parameters, which cannot be determined directly.
Model calibration and simulation were carried out in Matlab® R2018a (The Math-
works, Natick, MA, USA). To solve the nonlinear equation, fsolve was used. The
heuristic algorithm simulated annealing simulannealbnd was employed to deliver the
parameter estimates for keq, n, β0, β1, and β2.
The data generated in high-throughput experimentation were split into calibration
data and validation data. For model calibration, the three highest protein and
the two highest PEG concentrations were excluded. The remaining 50 data points
were used to prove the descriptive capability and accuracy of the suggested model.
The other 46 data points, used as validation set, were compared with the model
prediction to back up the model’s accuracy. This data were out of calibration range
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and therefore also showed the potential of the model to expand the predictability of
the model.
4.4. Results and Discussion
4.4.1. Model calibration
All precipitation data from high-throughput experimentation were divided into two
data sets. The calibration data sets contained the five lowest protein and the ten
lowest PEG concentrations. With the selection of the calibration data sets the model
predictability out of the calibration range should be proved. For paramter estimation
simulated annealing with the calibration data sets was used. The equilibrium
coefficient keq, the number of proteins affected by one PEG molecule n, the hydration
number at infinite dilution β0, and the constants accounting for the dependency
of hydration number on PEG concentration β1 and protein concentration β2 for
lysozyme, myoglobin, BSA, and mAb at pH7.5 and pH8.5 are given in Table 4.1.
Here, the natural logarithm of the keq is presented for a better overview.
Table 4.1.: Parameters of the precipitation model estimated from the calibration high-
throughput experimental data. The natural logarithm of the equilibrium coefficient keq is
presented for a better overview.
parameter lysozyme myoglobin BSA mAb7.5 mAb8.5
ln keq [−] 34.71 15.41 9.78 22.53 19.83
n [−] 5.55 3.06 2.60 3.65 3.22
β0 [−] 6.92·10−3 4.30·10−4 2.74·10−3 1.46·10−2 3.77·10−2
β1 [L/mol] 9.29·101 1.18·102 1.40·102 2.37·102 2.50·102
β2 [L/mol] 2.06·103 1.51·103 1.58·103 1.05·104 6.61·103
Fig. 4.2. shows the model simulation as solid curves and the experimental data used
for model calibration as dots for lysozyme (Fig. 4.2. (a)), myoglobin (Fig. 4.2. (b)),
BSA (Fig. 4.2. (c)), mAb at pH7.5 (Fig. 4.2. (d)), and pH8.5 (Fig. 4.2. (e)). In
all cases, the results cover eight protein concentrations between 1.5mg/mL and
12mg/mL with equidistant steps of 1.5mg/mL. The investigated range of PEG
concentrations varies according to the precipitation behavior of each protein. For
lysozyme, myoglobin, and BSA, PEG concentrations of up to 0.056mol/L are shown.
The mAb precipitated at lower PEG concentration, so that PEG concentrations of
up to 0.02mol/L are presented.
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Despite the very different protein characteristics such as size, hydrophobicity, and
surface charge distribution, the calibration data sets are described by the precipitation
model accurately in all cases. Regardless of the differences in experimental conditions
such as PEG concentration and pH value, a good identifiability of precipitation model
parameters is observed. As the smallest protein investigated, lysozyme (14.6 kDa)
shows the highest number of proteins affected by one PEG molecule with n = 5.55.
The slightly larger protein myoglobin (17.0 kDa) shows lower n with 3.06. For all
other proteins, the n values were similar to those of myoglobin.
The hydration number constants β0, β1, and β2 of each protein influence the β
function in the same order of magnitude. β1 accounts for the hydration of PEG.
Consequently, the behavior can be reconciled with the theory of excluded volume.
By adding PEG, the accessible water for the protein is reduced. As this exclusion is
caused by a steric phenomenon, the influence can be attributed to protein size, when
the PEG species is kept the same. A linear correlation between β1 and the molecular
weight is observed in accordance with the linear correlation of precipitation behavior
and the hydrodynamic radius of the protein for PEG as precipitant reported by Sim
et al. [90]. The similarity of the β1 values determined for the mAb at pH7.5 and
pH8.5 supports this assumption. Furthermore, Hämmerling et al. confirmed this
assumption, but pointed out the influence of additional factors, such as protein shape
and other surface characteristics [157].
In the case of mAb, shifting the experimental conditions closer to their pI (pH8.3-
8.5) to pH8.5 from pH7.5 leads to decrease of n, and keq and an increase of β0,
resulting in precipitation of mAb at lower PEG concentrations. At the same time,
a decrease in β2 was observed. While β1 could be assigned to the protein size, the
nature of β0 and β2 appears to be more complex. The pH dependence of these
parameters suggests a correlation to the surface characteristics of protein. The pH
dependency of the hydration number β0 is consistent with the results delivered by
Xia and coworkers [171] suggesting that the water release increases as the buffer pH
approaches the protein’s pI in HIC. The hydration number parameter β2 is attributed
to the influence of the protein concentration. Closer to the pI, this influence appears
to be less important. In the absence of electrostatic interactions, the well-ordered
water conformation is reported to be less stable and, therefore, it is favored to set
free well-ordered water molecules [172].
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Figure 4.2.: Comparison of model prediction (solid lines) and high-throughput experimental
data used for model calibration (dots). Data points represent mean values of at least triplicates.
(a) represents lysozyme, (b) myoglobin, (c) BSA, (d) mAb at pH7.5, and (e) mAb at pH8.5.
4.4.2. Model validation
To assess the predictive power of the calibrated precipitation models, the validation
data sets were used. Precipitation processes using PEG as precipitation agent come
with the drawback of highly viscous PEG solution, especially if PEG has to be
added as liquid stock solution. In contast to labratory-scale process development or
production, the addition of solid PEG is no option for high-throughput screenings.
Furthermore, the availability of highly concentrated protein stock solutions is not
always given. Hence, using a calibration set containing of low protein and PEG
concentration and using the model for expanding the response in both directions can
simplify process development and give new options to the production process.
Fig. 4.3. shows the model prediction as solid curves and the experimental data
excluded from model calibration as crosses for lysozyme (Fig. 4.3. (a)), myoglobin
(Fig. 4.3. (b)), BSA (Fig. 4.3. (c)), mAb at pH 7.5 (Fig. 4.3. (d)), and pH8.5 (Fig. 4.3. (e)).
A very good prediction can be found especially for myoglobin, BSA, mAb at both
pH values, and for lysozyme at low protein and, respectively, or at high PEG concen-
tration. For lower PEG concentrations however, the models tend to overestimate the
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amount of precipitated protein for all tested proteins. For 12mg/mL lysozyme the
model overestimated the precipitation behavior over the examined PEG range. The
root mean square errors of prediction (RMSEP) were 3.22·10−5mol/L for lysozyme,
3.02·10−5mol/L for myoglobin, 7.51·10−6mol/L for BSA, 3.62·10−6mol/L for mAb
at pH7.5, and 2.71·10−6mol/L for mAb at pH8.5.
Although simplifications and assumptions were made during the precipitation model
derivation to balance accuracy with ease of use, predictability and validity are backed
up by high-throughput experimental data of very different proteins under diverse
operating conditions. The main difference between the widely used models, such as
Cohn equation and models related to it, and the proposed precipitation model is
its mechanistic nature and capability to describe the protein precipitation process
dependent on both PEG and protein concentration.
The validation data showed the predictability of the model even out of the calibration
range. This allows a easier and faster model calibration. Furthermore, it opens the
possibility using the model for prediction and control of processes with variations in
the protein feed concentration.
Figure 4.3.: Comparison of model prediction (solid lines) and high-throughput experimental
data used for model validation (crosses). Data points represent mean values of at least
triplicates. (a) represents lysozyme, (b) myoglobin, (c) BSA, (d) mAb at pH7.5, and (e) mAb
at pH8.5. The solid lines are identical with Fig. 4.2. and are shown here for comparability.
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4.5. Conclusion
In the presented work, a mechanistic model for protein precipitation behavior with
PEG was introduced by considering the insights into the water structure on a
hydrophobic surface. The present approach proposes the equilibrium between well-
ordered and bulk-like ordered water molecules on the hydrophobic surfaces of protein
as the driving force for the precipitation process. This equilibrium is described for a
constant buffer composition, in particular without change in pH and PEG type.
The model predictability could be proven for the proteins lysozyme, myoglobin, BSA,
and mAb at pH 7.5, and the same mAb at pH 8.5 using validation data. The validation
data were not included into the model building and beyond the calibration space.
The model predictability could be found to be reasonable for proteins investigated
despite of their differences in properties such as size, hydrophobicity or charge of
the proteins. Th estimated model parameters lead to insights into the precipitation
process itself, i.e., the mathematical explanation of proteins’ precipitation behavior
dependent on their size, pH, and hydration.
In further studies, the dependency of model parameters on changes in pH and
PEG type should be investigated to enhance the mechanistic understanding of
protein precipitation with PEG. The applicability of the suggested model to protein
precipitation with salt-induced precipitation could be tested in a systematic manner.
Multi-component systems such as harvested cell culture fluid should be described to
enable model-based optimization of selective precipitation processes.
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Abstract
Preparative protein precipitation is known as a cost-efficient and easy-to-use alter-
native to chromatographic purification steps. This said, at the moment, there is
no process for monoclonal antibodies (mAb) on the market, although especially
polyethylene glycol-induced precipitation has shown great potential. One reason
might be the highly complex behavior of each component of a crude feedstock during
the precipitation process. For different investigated mAbs, significant variations in
the host cell protein (HCP) reduction are observed. In contrast to the precipitation
behavior of single components, the interactions and interplay in a complex feedstock
are not fully understood yet.
This work discusses the influence of contaminants on the precipitation behavior
of two different mAbs, an IgG1, and an IgG2. By spiking the mAbs with mock
solution, a complex feedstock could successfully be mimicked. Spiking contaminants
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influenced the yield and purity of the mAbs after the precipitation step, compared to
the precipitation behavior of the single components. The mixture showed a decrease
in the contaminant and mAb solubility. By re-buffering the mock solution prior to
spiking, special salts, small molecules like amino acids, vitamins, or sugars could
be depleted while larger ones like HCP or DNA were still present. Therefore, it
was possible to distinguish the influence of small molecules and larger ones. Hence,
mAb-macromolecular interaction could be identified as a possible reason for the
observed higher precipitation propensity, while small molecules of the cell culture
medium were identified as solubilisation factors during the precipitation process.
5.1. Introduction
Since the development of the first recombinant biopharmaceuticals, like insulin or mon-
oclonal antibodies (mAb) in the 1980s, the industry has been growing rapidly [173].
The relative low potency of mAbs in combination with the treatment of chronic
diseases and cancer currently leads to a high amount for each dose and, consequently,
a considerable amount of total mAbs produced. Their success made mAbs one of the
most expensive drug classes on the market [144]. In the past, the focus was set on
bringing innovative products fast to the market and less on developing cost-efficient
processes. Additionally, there was hardly a link between manufacturing costs and
the cost of the final product [14]. Restricted healthcare budgets and the development
of bio-similars, the first monoclonal antibody having been approved in 2013 by the
European Medicines Agency (EMA), however, raised the need for a more economic
production [174, 175].
Currently, mAbs are mostly manufactured using platform processes, consisting of
batch/fed-batch or perfusion cell cultures, followed by the respective downstream
process. The downstream process is mainly a combination of chromatography steps.
For the capture step, Protein A affinity chromatography is still the most common
technique. High resin costs and slow volumetric throughput make this step an easy-
to-use, but expensive unit operation [176]. In upstream process development (USP),
higher cell densities and cell culture titers led to an increase in process efficiency [177].
With perfusion cell cultures, titers up to 25mg/mL were reported [147]. These efforts
lead to a demand for new and cost-efficient alternative techniques for downstream
process development (DSP). These methodologies need to be comparable to the
purification performance of the chromatography step.
Selective protein precipitation has shown promising results such as cost-efficient
alternatives. Particularly for small-scale production, PEG as precipitation agent has
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shown its potential as easily scalable and simple technique [23, 178]. At best, the mAb
is selectively precipitated while the contaminants stay in solution. New techniques
such as high-throughput process development (HTPD), design of experiment (DoE),
or model-based approaches can help to make precipitation process development
faster and with less brute force [2, 26, 90]. However, huge variations in the host cell
protein (HCP) reduction were seen for different investigated mAbs [21]. Especially
for the development of a generic mAb platform process, a better understanding
of the precipitation mechanism is mandatory. Most studies, hence, have aimed
more at efficient process development of one mAb feedstock and less at a detailed
understanding of the complex behavior of components among each other.
For single protein solutions, much effort was put into the understanding of the mech-
anism of PEG-induced protein precipitation [68, 179, 180]. In general, precipitation
using PEG can be described with two theories. According to the theory of excluded
volume, the polymers are reported to trap the solvent and sterically exclude proteins
from the solvent region occupied by the polymer [158, 159, 181]. Because this is a
steric effect, the selectivity of PEG-induced protein precipitation is given by the size
of the proteins. Proteins with a larger hydrodynamic radius tend to precipitate at
lower PEG concentrations compared to proteins with a smaller hydrodynamic radius.
The theory of attractive depletion further introduces osmotic pressure as additional
force to the precipitation process [71, 72]. This force is caused by the steric exclusion
of the PEG molecules from the ambiance of the proteins, the depletion zone. When
two depletion zones overlap, a PEG-free area is created, and a concentration gradient
towards the bulk is formed. This gradient leads to the described osmotic pressure.
In both theories, there is no direct interaction between the protein and the polymers
described. All other forces between particles, such as electrostatic or hydrophobic
interactions, are still valid. This fact makes PEG-induced protein precipitation a
function of changes in process conditions, such as pH or conductivity.
In opposite to single protein solutions, there is only little research on the precip-
itation behavior of protein mixtures. Mahadevan and Hall developed a theory
describing the precipitation of protein mixtures by nonionic polymers using sta-
tistical mechanics [182]. Coen and co-workers investigated the phase behavior of
aqueous binary protein mixtures containing either lysozyme-chymotrypsinogen or
lysozyme-ovalbumin [183]. Solms et al. developed a thermodynamic framework for
the description of a phase diagram of a lysozyme-ovalbumin system [184]. Sieberz et
al. investigated the influence of model proteins as contaminants on the precipitation
behavior of mAbs during an polyelectrolyte preciptiation process [185]. All these
findings suggest, on the one hand, that the protein-protein interaction influences the
protein phase behavior and, on the other, that this influence is not simply a linear
or otherwise geometric combination of pure species interaction terms [186].
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When developing a preparative precipitation process, not only a binary protein system
has to be looked at, but the challenge is rather to purify one protein out of a complex
multi-component system. Beside other proteins such as host cell proteins (HCP),
small molecules like endotoxins, vitamins, or small cell culture media additives are
present as contaminants as well and have to be removed [116]. The influence of small
molecules on single proteins, known as osmolytes or co-solutes, is reported in many
studies and can be explained by the preferential interaction theory [63, 187, 188].
According to the theory, originally developed by Timasheff et al., the co-solvents
either preferentially interact with the protein or with water [62]. A preferential
interaction of the co-solvent with the protein, also known as salting-in, leads to
an increase in the colloidal stability of the protein. On the contrary, a preferential
interaction with water leads to a destabilization of the system, known as salting-out.
Thus, the purification of a mAb out of a complex feed stock might be influenced by a
multitude of contaminants and interactions. Changes in USP can lead to variations in
pH, conductivity, contaminant profile, or product titer. These variations, in turn, can
possibly influence the precipitation efficiency in terms of yield or purity. Especially
with a focus on a platform-based approach to processes using precipitation, the focus
should not be limited to the optimizing of one unit operation alone. An integrated
process development of up- and downstream is necessary [189].
The aim of this study is to investigate the influence of contaminants and their
composition on the precipitation behavior on a preparative mAb precipitation. A
workflow of the presented study is illustrated in Fig. 5.1.. Precipitation curves of
two purified mAbs at varying concentrations were generated using high-throughput
experiments. These results were compared with the precipitation behavior of the
same mAbs spiked with mock solution from a Chinese hamster ovary (CHO) cell line.
Through this experimental setup, a complex feedstock was imitated. This allows to
investigate the influence of a complex feedstock on different mAbs as well as different
mAb concentrations. To explain the observed differences in the precipitation behavior,
the mAbs were also spiked with purified re-buffered mock solution. Thereby, it was
possible to exclude the variations caused by different pH values or conductivities and
focus on the influence of protein-contaminant interactions. Finally, the re-buffered
mock solution was spiked with fresh cell culture media prior to the precipitation to
investigate the influence of the small molecules solved in the cell culture media on
the observed interactions.
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Figure 5.1.: Schematic overview of the workflow for the precipitation experiments carried
out in this study. For high-throughput experiments, mAb, mock, precipitant, and buffer
stock solutions were mixed on a liquid handling station with varying concentrations. Two
different mock solutions were investigated. One was used without pretreatment, the other
one was re-buffered prior to use. After phase separation, the supernatant of each system was
investigated for mAb and contaminant concentration.
5.2. Materials and Methods
All precipitation experiments were carried out in 350µL polypropylene flat-bottom
96-well micro plates (Greiner Bio-One, Kremsmünster, Austria). For spectroscopic
measurements, samples were diluted into Greiner UV-Star® micro plates (Greiner
Bio-One, Kremsmünster, Austria).
5.2.1. Chemicals and stock solutions
All buffer solutions were prepared using water purified by a PURELAB Ultra water
purification system (ELGA Labwater, High Wycombe, UK). As buffer substances,
tris(hydroxymethyl)-aminomethane (Merck KGaA, Darmstadt, Germany) and tris
hydrochloride (PanReac AppliChem, Darmstadt, Germany) were used. The polyethy-
lene glycol (PEG) with a median molecular mass of 6000 g/mol was obtained from
Merck KGaA (Darmstadt, Germany). All buffers were prepared with a buffer ca-
pacity of 50mM . The desired pH was achieved by varying the amount of acid and
basic component for each buffer. For the 40% (w/w)PEG stock solution, the buffer
components were first dissolved in ddH2O. Then, the appropriate amount of PEG
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was added. RPMI Medium 1640 (1x) + GlutaMAX™ (Thermo Fisher Scientific,
Waltham, MA, USA) was used for spiking the samples with cell culture media.
5.2.2. Preparation of protein stock solutions
Two mAbs, A and B, were provided as purified solutions from Novartis (Basel,
Switzerland). Additionally, mAbA was provided as harvested cell culture fluid
(HCCF). The characteristics of the mAbs are listed in Tab 5.1. Further more,
Novartis supplied a mock solution originating from the same cell line used for the
mAb fermentation. When mimicking a complex mAb solution, the mock solution
was spiked with varying concentrations of purified mAbs. All protein solutions
were filtered using 0.2µm cellulose acetate syringe filters (Sartorius AG, Göttingen,
Germany) before usage or further pretreatment. All provided protein and feed
solutions were stored at −80 ◦C for long-term and at −30 ◦C for short-term storage,
after aliquotation.
Table 5.1.: Characteristics of the utilized protein and contaminant stock solution
Molecule mAbA
purified
mAbA
HCCF
mAbB
purified
Mock
untreated
Mock
re-buffered
Type IgG2 IgG2 IgG1 - -
Molecular mass [kDA] 144.7 144.7 144.2 - -
pI 8.3-8.5 8.3-8.5 8.3 - -
mAb [mg/mL] 27.3 3.3 22.3 - -
HCP [mg/mL] <0.01 1.26 <0.01 1.04 3.18
5.2.3. Pretreatment of the protein stock solution
After filtration, the purified mAb was re-buffered and desalted into the 50mM tris
buffer pH7.5 using PD 10 desalting columns (GE Healthcare, Little Chalfont, UK).
The mock solution was divided into two parts. One part was spiked later to the
mAb without further pretreatment. The other part was re-buffered to 50mM tris
buffer pH7.5 using a KrosFlow Resarch IIi tangential flow filtration (TFF) system
(Spectrum Labs, Breda, Netherlands). To restrain larger contaminants like HCP
or DNA and deplete small molecules present in the HCCF, the TFF system was
equipped with a 10 kDa modified polyethersulfone (mPES) MicroKros® hollow fiber
filter module (Part number: C04-E010-05-S) and an automated back-pressure valve
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(both Spectrum Labs, Breda, Netherlands). The process was performed with a flow
rate of 27mL/min, a transmembrane pressure (TMP) of 0.6 bar, and a shear rate of
5800 1/s. First, the mock solution was concentrated fivefold in ultrafiltration mode
(UF). Subsequently, the mock solution was re-buffered into 50mM tris buffer over 5
diafiltration volumes (DV). The concentration of both mock stock solutions is listed
in Tab. 5.1.
5.2.4. Analytical methods
To determine the component content and size distribution, the UHPLC system
ultimate 3000RSLC, controlled with Chromeleon 6.8 (both Thermo Fisher Scientific,
Waltham, MA, USA) was used. For mAb concentration and contaminant content,
the ultra-high performance chromatography (UHPLC) system was equipped with a
Poros analytical Protein A column (Thermo Fisher Scientific, Waltham, MA, USA).
The mAb concentrations were calculated by integration of the elution peak area,
using calibration curves. The corresponding contaminant content was measured
by integration of the flow-through peak. Analytical size exclusion chromatography
(SEC) was performed using a TSKgel SuperSW mAb HTP column (TOSOH, Tokio,
Japan). For conductivity measurements, a CDM 230 conductivity meter (Radiometer
Analytical SAS, Lyon, France) was used. HCP concentration of the mock solutions
was determined using a microfluidic CD-based ELISA-like assay on the Gyrolab
XPlore station controlled by Gyrolab (Gyros AB, Uppsala, Sweden).
5.2.5. High-throughput method for precipitation screening
Precipitation experiments were carried out on a Tecan Freedom Evo 200 System
liquid handling station (Tecan, Männedorf, Switzerland). The liquid handling station
was equipped with an 8-tip liquid handling arm, a 96-MultiChannelArm® (MCA),
a robotic manipulator arm, a Te-Shake orbital shaker, an Infinite® 200 UV-VIS
spectrophotometer (all Tecan, Männedorf, Switzerland), and a Rotanta 46RSC
centrifuge (Hettich GmbH & Co. KG, Tuttlingen, Germany). The system was
controlled by Evoware 2.5 (Tecan, Männedorf, Switzerland). Excel 2016 (Microsoft,
Redmond, WA, USA) was used as data import format and for data storage. All
calculations were done using Matlab® R2018a (The Mathworks, Natick, MA, USA).
All experiments were carried out at 22 ◦C, controlled by air conditioning. To avoid
evaporation of the systems, the microplates were capped prior to each incubation or
centrifugation step. Systems with a total volume of 200µL containing varying mAb,
mock, and PEG concentrations were prepared. The PEG concentration was varied in
12 equidistant steps. For mAbA, the PEG concentration was varied from 0% (w/w)
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to 10% (w/w), for mAbB from 0% (w/w) to 14% (w/w). The mAb concentration was
varied from 1mg/mL to 8mg/mL in 8 equidistant steps in the case of mAbA, and
from 1mg/mL to 5mg/mL in 5 equidistant steps for mAbB. For systems containing
mock solution, the mock concentration was adjusted referring to a HCP concentration
of 0.5mg/mL, in each system. When cell culture medium was added to the samples,
the added volume was kept equal to that of the mock solution. To avoid systematic
errors due to automated pipetting, the position for each system on the 96-well micro
plate was randomized. After adding the protein stock solution, the system was
incubated for 15min on the orbital shaker at 1000 rpm to ensure complete mixing
of the system. Following the system was incubated for additional 15min incubation
time without shaking. To analyze the amount of precipitated protein, the microplate
was centrifuged for 30min at 3400 times g. Then, the supernatant was sampled
and diluted at a ratio of 1:2 or 1:3, depending on the initial mAb concentration to
avoid detector saturation. Subsequently, analytics of the generated samples were
performed using either UV-VIS spectroscopy for systems containing only mAb, or
UHPLC for complex mAb solutions.
5.3. Results
In this study, the precipitation behaviors of two mAb species using PEG as pre-
cipitation agent were investigated. Particularly, the focus was set on the influence
of contaminants on the phase behavior of the mAbs and vice versa, as well as on
the influence of the mAb on the co-precipitation of the contaminants. In a process
based on preparative precipitation, the yield of the precipitation step is defined
by the precipitation behaviour of the mAb, while the purity is influenced by the
precipitation behavior of the contaminants.
To identify variations in the precipitation behavior through the presence of contam-
inants in mAb solutions and to determine critical process parameters, three sets
of experiments were conducted. Precipitation curves of pure mAb solutions were
compared to precipitation curves of mAb spiked with untreated and re-buffed mock
solution. To imitate a complex mAb feed and, therefore, to investigate the influence
of all present contaminants in a cell culture fluid, the mAb was spiked with untreated
mock solution. To distinguish between small molecules and molecules larger than
10 kDa, like HCP or DNA, the mAb was spiked with re-buffered mock solution. At
the same time, a defined environment could be created, and influencing factors like
pH, or buffer components were excluded.
To identify critical process conditions, the influence of conductivity and the cell
culture media on the precipitation behavior was investigated in further experiments.
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5.3.1. Solubility of the mAbs
To investigate the precipitation behavior of mAbs, the concentrations of two pure
mAb species in supernatant after phase separation were measured. Therefore, the
initial mAb and the PEG concentration were varied. The results were compared
to the solubility of the same initial mAb concentrations spiked with two different
mock solutions (Fig. 5.2.). Solubility data of the two pure mAb species in the
supernatant after precipitation at varying initial mAb and PEG concentrations is
shown in Fig. 5.2. (a), (b). For all investigated mAbA concentrations (Fig. 5.2. (a)),
the mAb was completely soluble at PEG concentrations below 4.5%(w/w). Above
this concentration, the solubility was depending on the initial mAb concentrations.
Anyhow, all investigated mAbA concentrations approach to the same solubility
line. At 10%(w/w) PEG, mAbA was completely precipitated for all examined mAb
concentrations. Compared to these results, mAbB showed a higher solubility and
was completely soluble at PEG concentrations below 7.64%(w/w) (Fig. 5.2. (b)).
Independent of the initial mAb concentration, mAbB was completely precipitated at
14%(w/w) PEG.
To investigate the influence of contaminants on the precipitation behavior, the mAb
solutions were spiked with two different mock stock solutions. The added mock
solution volume was normalized to a HCP concentration of 0.5mg/mL. To study
the influence of all contaminants present in the cell culture fluid, small ones like
sugars, amino acids but also larger ones like HCP or DNA, the mAb solutions were
spiked with untreated mock solution. The results are shown in Fig. 5.2. (c), (d). To
distinguish between the influence of an entire cell culture fluid and components with
a size larger than 10 kDa, like HCP, or DNA, the mock solution was re-buffered
prior to spiking. The results are shown in Fig. 5.2. (e), (f). Adding contaminants to
the mAbs lowered the solubility at each PEG concentration for both investigated
mAbs. Thus, the PEG concentration needed for causing precipitation, was lower
comparing pure mAb systems with both spiked ones. For systems with re-buffered
mock solution, the solubility decrease was even more pronounced. For a concentration
of 8mg/mL mAbA, the initial PEG concentration needed to precipitate the mAb
dropped from 4.5%(w/w) PEG for the pure mAb solution to 2.7%(w/w) PEG
for the mAb solution spiked with untreated mock solution. For mAbA spiked with
re-buffered mock solution, precipitation started at 0.9%(w/w) PEG. For 5mg/ml
mAbB, initial precipitation was observed at 5.09%(w/w) PEG when the solution was
spiked with untreated mock solution. Spiking mAbB with re-buffered mock solution
led to precipitation at 1.29%(w/w) PEG. Furthermore, there was no approach to
the same solubility line detectable for the spiked samples, comparing different initial
mAb concentrations. Comparing the precipitation behavior of the same initial mAb
concentrations, the spiked samples showed a higher precipitation propensity overall
and a flattened solubility line.
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Figure 5.2.: Solubility data of mAbA (a, c, e) and mAbB (b, d, f) in the supernatant after
phase separation at varying mAb and PEG concentrations. Data points represent the mean
value of triplicates. All experiments were conducted using 50mM tris buffer at pH7.5. (a)
and (b) Purified mAb was precipitated. (c) and (d) The mAb was spiked with untreated mock
solution containing 0.5mg/mL HCP each. (e) and (f) The mAb was spiked with re-buffered
mock solution containing 0.5mg/mL HCP each. The mock solution was re-buffered to 50mM
tris pH 7.5.
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Developing a preparative precipitation process, the precipitation propensity of the
mAb can be linked directly to the yield of the purification step. For all investi-
gated conditions mAb yield after the precipitation did depend on the initial mAb
concentration, as well as on the contaminant composition. For an initial mAbA
concentration of 1mg/mL the highest yield for samples containing pure mAb solution
was reached at 10%(w/w) PEG with a value of 86%. However, previous studies
have shown that a yield of up to 98% can be achieved after precipitation [4]. In
this work, this value was reached for 1mg/mL mAb concentrations at 10%(w/w)
PEG when untreated mock solution was spiked before. For solutions containing
re-buffered mock solution 98% yield were reached at 6.36%(w/w) PEG. At an
initial mAbA concentration of 8mg/mL the maximum yield for the pure mAb solu-
tion was 97.6%. For solutions containing untreated mock solution the 98% yield
was reached at 10%(w/w) PEG. For samples containing re-buffered mock solution
9.08%(w/w) PEG were therefore necessary. For mAbB trends were comparable to
that of mAbA. At 1mg/mL initial concentration of mAbB a maximum yield of 92%,
and for 5mg/mL mAbB a maximum yield of 98% could be observed at 14%(w/w)
PEG. For mAbB spiked with untreated mock solution 98% yield were reached at
12.73%(w/w) PEG for all investigated initial mAbB concentrations. For an initial
mAbB concentration of 1mg/mL, spiked with re-buffered mock solution 98% yield
were reached at 11.45%(w/w) PEG. At 5mg/mL initital concentration of mAbB,
12.73%(w/w) PEG were necessary to reach the target yield.
While the precipitation propensity of the mAbs determines the yield, the precipitation
behavior of the contaminants affects the purity of the process. Therefore, the solubility
of the contaminants was measured as well.
5.3.2. Solubility of contaminants
The amount of the contaminants in the supernatant after phase separation is
shown in Fig. 5.3.. Prior to the addition of PEG, each system was spiked with
one of the two utilized mock solutions, normalized to a HCP concentration of
0.5mg/mL. With increasing PEG concentration, the solubility of the contaminants
decreased. This decrease was less pronounced comparing samples spiked with un-
treated mock solution (Fig. 5.3. (c), (d)) to samples spiked with re-bufferd mock
solution (Fig. 5.3. (e), (f)). For systems containing 8mg/mL mAbA and untreated
mock solution, the solubility dropped to 87% of the initial amount at 10%(w/w)
PEG. For the same mAbA and PEG concentrations, the amount dropped to 25%
when re-buffered mock solution was utilized. For mAbB, a higher contaminant
solubility and therefore less precipitation was observed in the same PEG range. Like
for mAbA, using re-buffered mock solutions led to a higher amount of precipitated
contaminants compared to untreated mock solution.
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(c) (d)
(f)
(a/b)
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Figure 5.3.: Solubility data of mAbA (a, c, e) and mAbB (b, d, f) in the supernatant after
phase separation at varying mAb and PEG concentrations. Data points represent the mean
value of triplicates. All experiments were conducted using 50mM tris buffer at pH7.5. (a)
and (b) Purified mAb was precipitated. (c) and (d) The mAb was spiked with untreated mock
solution containing 0.5mg/mL HCP each. (e) and (f) The mAb was spiked with re-buffered
mock solution containing 0.5mg/mL HCP each. The mock solution was re-buffered to 50mM
tris pH 7.5.
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For samples spiked with untreated mock solution, the solubility showed no dependence
on the initial mAb concentration. In contrast, the solubility of the re-buffered
contaminants could be connected to the initial mAb concentration in each system.
With higher mAb concentrations, lower solubility of the contaminants was detected.
This behavior was shown for both investigated mAbs.
In Fig. 5.3. (a/b), systems with 2mg/mL mAbA and mAbB spiked with mock
solution are compared to systems containing pure mock solution without addition of
mAb. Comparing the samples with mAb and untreated mock solution to pure-mock
solution samples, the solubility of the contaminants was lowered by the addition of
mAbA. For the pure mock solution samples, a contaminant solubility of 94.6% of the
initial amount was detected at 10%(w/w) PEG. For the samples of mAbA spiked
with untreated mock solution, the residual solubility was 88.9%, and for samples
containing mAbB, the amount was 94.7%. By comparison, spiking the mAb with
re-buffered mock solution lowered the solubility of the contaminants significantly. At
10%(w/w) PEG, 54.0% of the initial contaminant amount was detected for samples
containing mAbA, and 49.7% for samples containing mAbB.
Purities after the precipitation step were calculated from the solubility measure-
ments of the impurities and the mAbs. The purity was dependent on the initial
mAb concentration, but also on the kind of added mock solution. For the highest
investigated PEG concentration and an initial mAbA concentration of 1mg/mL, a
purity of 95% was determined when untreated mock solution was added. At the
same initial mAbA concentration, this value dropped to 86%, when re-buffered mock
solution was spiked. For an initial concentration of 8mg/mL mAbA, the purity
was 99% for samples containing untreated mock solution compared to 94% for
samples containing re-buffered mock solution. Similar trends could also be observed
for mAbB. The calculated purities at the highest investigated PEG concentration
for samples containing untreated mock solutions were 93% and 99% for an initial
mAbB concentration of 1mg/mL, respectively 5mg/mL. For samples containing
re-buffered mock solution, the purities were 82%, respectively 96%, for 1mg/mL,
respectively 5mg/mL mAbB.
The observed differences between untreated and re-buffered mock solution suggest
that the differences are caused by small molecules depleted through the UF/DF
step. To exclude possible influences of the UF/DF step itself or mixing on the liquid
handling station, additional experiments were conducted. Subsequently, the influence
of conductivity and fresh cell culture media was examined.
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5.3.3. Comparison of the utilized mock solutions
UF/DF of protein solutions can lead to a higher aggregation level, and the protein
size is known to be a significant parameter for PEG precipitation [190]. To prove
the integrity of the re-buffered mock solution, the size distributions of both mock
solution samples were compared using analytical size exclusion chromatography
(SEC), displayed in Fig. 5.4.. Until 6.5min retention time, both chromatograms show
a similar peak profile. After this, the UV signal differs, and for the untreated mock
solution, an additional peak was detected. Based on the size standard, molecules
eluting after this time have a molecular weight smaller than 14 kDa.
Figure 5.4.: SEC chromatogram of untreated (solid line) and re-buffered (dotted line) mock
solution samples. (a) Referred to the size standard (dashed line), molecules above 6.6min are
smaller than 14 kDa. (b) Displays the magnified details of the size distribution of both utilized
mAbs.
Beside the UF/DF, mixing the solutions on the liquid handling station is an additional
factor in the used experimental setup, which might cause the observed deviations.
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Spiking mock solution to the mAb solutions comes along with an additional mixing
step of mAb and mock solution, comparing the imitated crude feed stock to the
actual HCCF. Hence, the phase behavior of spiked mAbA samples was compared to
that of mAbA provided as HCCF (Fig. 5.5.). Comparing the precipitation behavior
of the HCCF to that of purified mAbA spiked with untreated mock solution, only
minor changes could be detected. Compared to these, the systems with purified
mAbA and re-buffered mock solution showed a lower solubility for each investigated
PEG concentration.
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Figure 5.5.: Solubility data of mAbA in the supernatant after phase separation at varying
PEG concentrations. Data points represent the mean value of triplicates. Comparison of
mAbA provided as HCCF, purified mAbA spiked with untreated mock solution, and purified
mAbA spiked with re-buffered mock solution. All experiments were conducted using 50mM
tris buffer at pH7.5 and a mAbA concentration of 2mg/mL.
As no influence of the experimental setup could be shown, the different phase
behaviors of the mAb and contaminants had to be caused by differences in the
composition of untreated and re-buffered mock solution. Due to re-buffering the
mock solution, small molecules were depleted. Consequently, the conductivity of the
re-buffered solution decreased from 9.91mS/cm to 3.5mS/cm. To study this effect
on the precipitation behavior, the conductivity of the re-buffered mock solution was
adjusted to 9.91mS/cm again, using a 1M NaCl solution. Afterwards, the solubility
of mAbA and the contaminants was measured at a mAbA concentration of 3mg/mL.
The results were compared to the precipitation behavior of the mAb spiked with
unadjusted mock solution (Fig. 5.6.). For the mAb solubility (Fig. 5.6. (a)) as well as
for the solubility of the contaminants (Fig. 5.6. (b)), no significant influence of the
conductivity was detected.
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Figure 5.6.: Solubility data of mAbA (a) and contaminants (b) in the supernatant after
phase separation at varying PEG concentrations. Data points represent the mean value of
triplicates. All experiments were conducted using 50mM tris buffer at pH7.5 and mAbA
concentration of 3mg/mL. The mAbA was spiked with untreated mock solution, re-buffered,
and conductivity-adjusted re-buffered mock solution. All samples were adjusted to a HCP
concentration of 0.5mg/mL.
By the UF/DF step, not only salts were depleted, but other small molecules like
amino acids and vitamins probably as well. Thus, the influence of these small
molecules was tested. Therefore, samples containing 3mg/mL mAb and re-buffered
mock solution were spiked with cell culture medium, and afterwards precipitated
using PEG (Fig. 5.7.). The used cell culture medium was not identical with the
original one used for the fermentation. However, it is composed out of the same
group of components: amino acids, vitamins, inorganic salts, and sugars. For mAbA
(Fig. 5.7. (a)), as well as for mAbB (Fig. 5.7. (b)), adding cell culture medium led
to a comparable precipitation behavior of the samples containing re-buffered mock
solution and mAb and the samples containing mAb and untreated mock solution.
Figure 5.7.: Solubility data of (a) mAbA and (b) mAbB in the supernatant after phase
separation at varying PEG concentrations. Data points represent the mean value of triplicates.
3mg/mL mAb was spiked with untreated mock solution, re-buffered mock solution, or re-
buffered mock solution and cell culture medium.
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5.4. Discussion
The effect of contaminants on the precipitation behavior of two different mAbs,
an IgG1, here named mAbB, and an IgG2, here named mAbA, was investigated.
Therefore, the precipitation curves of the mAbs at varying PEG concentrations were
determined. Although mAbA and mAbB are similar in size and pI, a different phase
behavior was observed. In comparison, higher PEG concentrations were needed to
precipitate mAbB. This indicates that the molecular weight, or the overall surface
charge of proteins is not the only factor influencing PEG-induced precipitation. This
is consistent with the investigation of Haemmerling et al. [157]. They showed, with
the help of quantitative structure activity relationship models (QSAR), that surface
characteristics, such as charge distribution, amount of hydrophobic patches, and
their distribution on the surface, might play an important role for the precipitation
behavior of proteins as well.
The precipitation behavior of the pure mAb solutions was compared to systems
which were spiked with one of two different mock solutions as contaminants. To
investigate the influence of the complete cell culture medium, the mAbs were spiked
with untreated mock solution. The cell culture fluid includes a variety of small
molecular weight contaminants which can briefly be divided into four groups: amino
acids, vitamins, inorganic salts, and other components, mainly sugars. Side products
like fermentation metabolites, or added antifoam, may be included in the cell culture
fluid as well. Furthermore, one finds larger contaminants like HCPs or DNA. To
investigate the influence of contaminants with a size larger than 10 kDa, the mAbs
were spiked with re-buffered mock solution. During the UF/DF step, components
with a molecular weight smaller than 10 kDa were removed. The successful removal
could be shown with the help of SEC analytic. Additionally, the integrity of the
re-buffered mock solution, after the UF/DF step, could be proven. Thereby, changes
in the size distribution of the mock solution could be excluded.
To further prove the usability of the developed screening system, the precipitation
behavior of mAbA provided as HCCF was compared to systems containing purified
mAbA and mock solution. The precipitation behavior of mAbA and the contaminants
present in the HCCF could successfully be imitated by mixing purified mAbA with
untreated mock solution in a similar proportion. Thus, mixing effects on the liquid
handling station could most likely be excluded.
Focusing on the influence of the contaminants on the precipitation behavior of the
mAbs, mAbA, and mAbB showed a similar behavior. In both cases, the addition of
contaminants led to a decrease in the solubility of the mAbs. When contaminants
were added, precipitation started at lower PEG concentrations. Additionally, the
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amount of PEG needed for complete precipitation of the antibodies was reduced
for both of the mock solutions used. The destabilizing effect could be shown for
all investigated mAb concentrations. The higher precipitation propensity was even
more pronounced when the mock solution had been re-buffered before. This suggests
that, in general, the addition of contaminants destabilizes the antibody, but small
molecular contaminants removed through re-buffering the mock solution stabilize
the mAb during precipitation. The influence of small molecular contaminants known
as osmolytes or co-solutes can be explained with the preferential interaction theory.
According to this theory, a preferential binding of co-solutes to the proteins would
lead to a stabilization of the system, also known as salting-in [191]. This would
mean that the presence of co-solutes either stabilized the mAbs or avoids interaction
with larger contaminants present in the re-buffered mock solution. For preparative
PEG precipitation, lowering the solubility of the mAb is required. Especially when
PEG precipitation is intended to be used as capture step, the amount of required
PEG is directly linked to the process costs, as there is no recycling strategy for PEG
yet. Therefore, a reduction of the PEG amount is desirable. On the other hand,
product loss through incomplete precipitation should be avoided. Changes induced
through contaminants are a critical factor for process development, in particular
when considering a robust process.
While the amount of precipitated mAb can be linked to the yield, the amount of co-
precipitated contaminants influences the purity of the product after the precipitation
step. In previous studies it was shown, that the purity can be further increased
through selective resolubilisation of the product [4]. However, a lower co-precipitation
of the contaminants is advantageous, as it reduces the effort for the next step and the
risk that the undissolved impurities lead to filter clogging. In this study, investigation
of the contaminant solubility showed a slight decrease, comparing mAb spiked with
untreated mock solution to pure mock solution systems. For systems with re-buffered
mock solution, the hiring of the precipitation propensity was more pronounced.
This is similar to the precipitation behavior of the mAbs. The increase of the
precipitation propensity can hence be correlated to the different investigated initial
mAb concentrations when re-buffered mock solution was added. An increase in the
mAb concentration led to an increase in the precipitated contaminants. This in turn
implies a direct or indirect protein-contaminant interaction between the mAbs and
the contaminants prior or during the precipitation process.
This leads to a complex problem for process development. Since PEG-induced
precipitation of mAbs is mainly used as a capture step, a high yield is of primary
significance. For example, for an initial product concentration of 8mg/mL mAbA,
10%(w/w) PEG were necessary to achieve a yield of 98%. This resulted in a
purity of 99% after the precipitation, when untreated mock solution was spiked as
contaminant. If re-buffered mock solution was utilized as contaminant 9% less PEG
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was required to achieve the same yield. However, this also led to a decrease in the
purity of 9.5%. For an initial product concentration of 1mg/mL mAbA, the effect
was different. When re-buffered mock solutions was added as contaminant, 36.4%
less PEG was required, compared to experiments were untreated mock solution was
used, to reach 98% yield. At the same time, the purity was 2% higher. For an
initial mAB concentration of 1mg/mL, 11% more PEG was required to achieve
98% yield when comparing untreated mock to re-buffered mock solution. At the
same time, the purity was 21% higher. The examples illustrate how changes in
process conditions, such as different product concentrations, changes in the cell
culture medium composition, or a change of the product, can affect the purification
outcome.
An indication, that protein-contaminant interaction is the reason for the observed
differences in yield and purity, is also provided by other studies investigating variations
in the HCP level after Protein A chromatography. Sisodiya et al. found that the
variation of the HCP level varies between different mAb species and is caused by
electrostatic and hydrophobic interactions between the mAb and the HCPs [96].
This confirms the assumption that the presence of large molecular contaminants
destabilizes the mAb as well as the contaminant by mAb-contaminant interaction. For
systems with untreated mock solution, the correlation between mAb concentration
and contaminant precipitation behavior was not possible. Subsequently, modifications
during the UF/DF step had to cause the different observed precipitation behaviors.
Two possible explanations for this behavior were investigated. During the UF/DF
step, the conductivity was reduced. Beside PEG concentration and pH, the conductiv-
ity of the precipitation samples is known to influence the precipitation process [192].
Electrostatic interactions are a conceivable reason for the observed destabilizing effect
of added re-buffered mock solution. At the investigated pH of 7.5, both mAbs have
a positive net charge while contaminants like HCP, with an average pI of around
pH5.0, are mostly charged negative [52]. Hence, electrostatic attraction might take
place and lead to mAb-contaminant interaction and therefore to co-precipitation.
However, adjustment of the conductivity did neither show an effect on the phase
behavior of mAbA nor on that of the contaminants. This implies either that no
electrostatic interaction took place or, more likely, that the higher ionic strength was
not the only stabilizing factor.
As changes in the conductivity have not explained the behavior satisfactorily, the
other small molecules present in the cell culture fluid, and probably their interplay
had to cause the observed variations. By mixing mAb, re-buffered mock solution,
and fresh cell culture medium prior to the precipitation, the stabilizing effect of
the cell culture media components could be shown. For process development, this
is a significant issue, as USP is mostly driven by the needs of higher cell culture,
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respectively product titers, and less with respect of the needs for DSP [177]. As side
product of USP development, the co-solute composition might change. Furthermore,
variations in the HCP profile are reported as a function of the cultivation condition
and may be induced during primary clarification [193, 194]. This implies that changes
during early production phases are critical for a precipitation process. They can
change the precipitation behavior of mAb or contaminants and can, therefore, lead to
a variation in yield and purity. Hence, especially for the development of a platform
process containing PEG-induced precipitation as the capture step, an integration of
up- and downstream steps is of great importance.
5.5. Conclusion
In the present work, the influence of contaminants on the precipitation behavior of
mAb and the contaminants during a preparative PEG-induced precipitation step
was shown. Higher precipitation propensity could be correlated to the protein-
contaminant interaction of the mAb with contaminants larger than 10 kDA. Ad-
ditionally, a stabilizing effect of the mAb as well as of the contaminants could be
linked to small molecules contained in the cell culture media. Other factors like
size distribution or conductivity were successfully excluded. It was pointed out that
variations in the cell culture media during USP may influence the precipitation
performance. This study shows that the amount of PEG, required for a successful
precipitation step, can vary by up to 36.2%, depending on the contaminant com-
position. This theoretically opens up the possibility of reducing the required PEG
quantity and thus developing a more economical process. At the same time it helps
to estimate the robustness of the process. Also the influence on the purity, after
the precipitation step, was found to be a critical factor. Variations of up to 21%
were seen for the various process conditions. Therefore, the knowledge gained in this
study can probably be used to increase the product purity. It provides the possibility
to use co-solutes for manipulation of the precipitation behavior and increase product
purity or yield.
The results demonstrate the importance of integrated up- and downstream process de-
velopment. Deeper knowledge of the phase behavior of complex protein solutions can
simplify empirical precipitation process development. Furthermore, understanding
the protein precipitation of complex solutions can help to derive new in silico-based
models and therefore, make process development faster and less material consuming.
During the whole purification process, protein-contaminant interactions play a critical
role for the product quality. The results obtained in this study may therefore also
be important for other unit operations, like chromatographic separations. Hence,
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Abstract
In the past decades, research was carried out to find cost-efficient alternatives
to Protein A chromatography as a capture step in monoclonal antibody (mAb)
purification processes. In this work, polyethylene glycol (PEG) precipitation has
shown promising results in the case of mAb yield and purity. Especially with respect
to continuous processing, PEG precipitation has many advantages, like low cost of
goods, simple setup, easy scalability, and the option to handle perfusion reactors.
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Nevertheless, replacing Protein A has the disadvantage of renouncing a platform
unit operation as well. Furthermore, PEG precipitation is not capable of reducing
high molecular weight impurities (HMW) like aggregates or DNA. To overcome
these challenges, an integrated process strategy combining PEG precipitation with
cation-exchange chromatography (CEX) for purification of a mAb is presented.
This work discusses the process strategy as well as the associated fast, easy, and
material-saving process development platform. These were implemented through the
combination of high-throughput methods with empirical and mechanistic modeling.
The strategy allows the development of a common batch process. Additionally, it is
feasible to develop a continuous process. In the presented case study, a mAb provided
from cell culture fluid (HCCF) was purified. The precipitation and resolubilisation
conditions as well as the chromatography method were optimized, and the mutual
influence of all steps was investigated. A mAb yield of over 95.0% and a host cell
protein (HCP) reduction of over 99.0% could be shown. At the same time, the
aggregate level was reduced from 3.12% to 1.20% and the DNA level was reduced
by five orders of magnitude. Furthermore, the mAb was concentrated three times to
a final concentration of 11.9mg/mL.
6.1. Introduction
From 1992 to 2015, 47 monoclonal antibodies (mAbs) have been approved either by
the US Food and Drug Administration (FDA), or the European Medicines Agency
(EMA) [195]; until January 11, 2017, the number of approved therapeutic mAbs by
FDA has increased to 68 [196]. Currently, 230 and 52 mAbs have been reported to
undergo the phase 2 and phase 3 clinical studies, respectively. Compared to early
2010 (26 mAbs in late-stage studies), a 100% increase has been achieved, delivering
the evidence for a continuing strong growth of the mAb market [197]. The global
mAb market was currently expected to reach almost $ 125 billion by 2020 [198].
Based on recent advances in upstream processing, a titer increase at commercial
scale up to approximately 20% from 2014 to 2019 has been predicted, whereas
improvements in downstream processing have been adopted more slowly [199]. In
2016, FDA has approved the first mAb biosimilar infliximab-dyyb for the US market,
which will be sold with an estimated discount at 20-30% to its originator. The game-
changing biosimilars, along with the increasing demand for mAbs, and achievements
in upstream processing have placed downward pressure on downstream processing.
As Protein A chromatography provides highly specific binding to the Fc-region of a
variety of mAb types, resulting in high product yield and purity in a single step, it
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has become the golden standard for the capture step in the platform process [176, 200,
201]. However, its disadvantages such as slow volumetric throughput and high resin
costs have become even more pronounced under the circumstances mentioned above.
As a result, a growing interest in the development of non-chromatographic mAb
purification processes could be observed [92, 150, 202–206]. Especially precipitation
methods based on polyethylene glycol (PEG) showed promising results as alternative
capture step [26, 114]. Hammerschmidt et al. [207] investigated the economics of
precipitation in comparison to the actual platform process. The results showed cost
reduction for the precipitation process during clinical as well as in the commercial
phase. Especially in the clinical phases and in small scale production replacing
Protein A resins showed economical benefit.
Additionally, a trend from conventional single column batch chromatography towards
multi-column chromatography has been reported [110, 208–213]. While operating in
semi-continuous fashion, the overall operating time can be reduced. Furthermore,
higher resin utilization per cycle leads to columns with reduced volume. Thus, an
increased productivity may be achieved.
On the process side, Protein A chromatography has been established as an expensive
but easy-to-use technique for mAb capturing, which does not require high development
effort. In comparison, the process development for both precipitation and multi-
column chromatography, however, is much more complicated, which contradicts the
desire for shorter development timelines in the biopharmaceutical industry. Thus,
the necessity of simplification of process development while maintaining product
quality is a major challenge.
In this work, a case study on industrial mAb purification from a harvested cell culture
fluid (HCCF) by integrating PEG precipitation and cation-exchange chromatography
(CEX) is presented. The occurring difficulties by renouncing Protein A chromato-
graphy are addressed. A combined process development strategy minimizing the
amount of feedstock needed and experimental effort is suggested. In particular,
high-throughput experimentation, design of experiments (DoE), and mechanistic
chromatography modeling were employed to develop the precipitation, resolubilisa-
tion, and CEX chromatography step. The developed toolbox and the process scheme
of the case study are illustrated in Fig 6.1.. Additionally, based on mechanistic mod-
eling, the optimized single-column batch chromatography process was transferred to
a three-column CEX periodic counter-current chromatography (3C-PCCC) mode
to investigate the advantages and potential of multi-column chromatography in the
considered case.
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Figure 6.1.: Flowchart of the development toolbox and the integrated process which combines
precipitation, resolubilisation and cation-exchange chromatography.
6.2. Theory
6.2.1. Fundamentals of precipitation
Protein precipitation has been known for a long time as a separation method for
the purification of complex protein solutions [56]. Phase separation is carried out
by adding precipitation agents, like inorganic salts, organic solvents, or nonionic
polymers to the protein solution [57, 89, 148, 149]. For the precipitation of a
complex mAb solution, in particular the use of polyethylene glycol (PEG) with an
average molecular weight of 6000DA as precipitation agent has shown promising
results [68]. Although this phenomenon is well investigated and there are several
models describing the behavior of proteins in PEG solution, the mechanism is
not completely understood [90, 154, 157]. The two theories which describe the
mechanism of PEG-induced precipitation are, on the one hand, the theory of excluded
volume [158–160] and on the other hand the theory of attractive depletion [71, 72].
The theory of excluded volume is based on the assumption that PEG traps the solvent
in the coiled structure and the folded filament of the solved molecules. This results
in the steric exclusion of proteins from the solvent regions occupied by the polymers.
Molecules with a larger hydrodynamic radius are more strongly excluded compared to
molecules with a smaller one. According to this view, the sterically excluded proteins
are concentrated until their solubility is exceeded and precipitation occurs [69]. In
contrast to this assumption, the theory of attractive depletion describes a force of the
order of osmotic pressure which leads to protein precipitation. This force is caused
by mainly steric exclusion of the PEG molecules from the ambience of the proteins,
described as depletion zone. If two depletion zones are overlapping, a PEG-free
area is created and, therefore, a concentration gradient is formed. This gradient
leads to an osmotic pressure which further leads to precipitation of the proteins.
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Both theories describe the mechanism of PEG-induced precipitation but additionally
other factors which influence the colloidal stability of protein solutions like protein
concentration, pH or ionic strength, have to be considered [26].
6.2.2. Ion exchange chromatography modeling
The following theoretical background was used to carry out mechanistic chroma-
tography modeling for the subsequent CEX step. The general rate model (GRM)
is employedf to cover the convection and diffusion in a chromatography column of
length L and adsorber beads of radius rp [214]:
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Within the mobile phase ci(x,t), the mass transfer between the pore volume cp,i(x,r,t)
and the interstitial volume is described by Eq. (6.1). The voidage of the adsorber
bed b, the axial dipersive coefficient Dax, and the film transfer coefficient kfilm,i
describe the peak-broadening effects in the interstitial volume. The mass transfer is
from the pore volume concentration cp,i to the stationary phase qi and vise versa.
p is the adsorber particle voidage and Dp,i the component-specific pore diffusion
coefficient. Eqs. (6.3) and (6.4) are the Danckwerts boundary conditions.
The widely accepted steric mass action (SMA) isotherm model introduced by Brooks
and Cramer describes adsorption and desorption processes on adsorber surfaces [132].
The kinetic formulation suggested by Nilsson et al. is shown in Eq. 6.5 [134]. Here,
the stationary phase protein concentration q depends on q itself, pore phase protein
concentration cp, and pore phase salt concentration cp,salt. ν is the characteristic
charge representing the binding sites number involved in binding directly. σ is the
number of binding sites on the adsorber surface sterically hindered by protein binding.
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Λ is the ionic binding capacity of the column related to adsorber skeleton.
kkin,i
∂qi(x,t)
∂t
= keq,i(Λ−
k∑
j=1
(νi + σi)qj(x,t))νicp,i(x,t) (6.5)
−cp,salt(x,t)νiqi(x,t) ∀i 6= salt
The salt concentration in the stationary phase is described in Eq. 6.6.
qsalt(x,t) = Λ−
k∑
j=1
νjqj(x,t) (6.6)
The adsorption rate coefficient kads and the desorption rate coefficient kdes were
replaced by the equilibrium coefficient keq=kads/kdes and the kinetic coefficient
kkin = 1/kdes to simplify parameter estimation, as keq and kkin correlate mainly with
the retention time and peak height, respectively [135]. Out of several reasons, the
kinetic formulation has been chosen. Because of limitations in the binding kinetics,
protein adsorption is often slow as reported by Carta and Jungbauer. Additionally,
true adsorption equilibrium may not be established in column chromatography. The
hydroxylated methacrylic polymer-based and polymer-grafted adsorber (Toyopearl
GigaCap S-650M) provides high ligand density, resulting in limited access to bind-
ing sites with increasing protein binding due to steric crowding and electrostatic
repulsion [215, 216].
Combining both GRM and SMA, the presented CEX chromatography process can
be modeled using numerical methods.
6.2.3. 3C-PCCC
Periodic counter-current chromatography is a simulated moving-bed process patented
by GE Healthcare as a semi-continuous purification process [217]. Usually, it is
operated in three- or four-column configurations.
Since PCCC allows the loading of columns much closer to their static binding
capacity, it has the potential to reduce resin volume, buffer consumption, and
process time in comparison to conventional batch chromatography [208–210, 218].
Economical simulation of a Protein A capture step in 3C-PCCC and 4C-PCCC mode
has demonstrated that PCCC can reduce manufacturing costs particularly in early
clinical phases [218]. Compared to traditional batch single-column chromatography,
where the process steps of a chromatography cycle are conducted consecutively, in
PCCC, multiple steps are performed simultaneously but distributed along several
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columns. In 3C-PCCC, the process consists of two interconnected columns and one
short-circuited column. The columns are shifted only periodically after two out of
four process steps. In the first stage, column 3 is interconnected with column 2. In
steady-state, column 3 was fed with feed material in the previous steps and is now
fully saturated. Wash buffer is passed through this column to remove unbound and
weakly bound proteins. The wash eﬄuent is directed to the equilibrated column 2 to
recover leached product. In the meantime, feed material is loaded onto column 1.
The flow-through is discarded until the first product breaks through. As soon as the
first product breaks through, column 1 is switched into the interconnected lane and
the outflow is loaded directly onto column 2. Since the load step is now performed
with two columns in series, resin capacity utilization can be increased by loading
column 1 beyond 1% product breakthrough [217].
While column loading is continued in the interconnected lane, column 3 is short-
circuited and the product is eluted. The short circuit allows the application of
arbitrary elution gradients and center-cut separation. After product elution, column 3
is regenerated and equilibrated. Column 1 and column 2 remain in the interconnected
lane and continue to receive feed material without product breaking through column 2.
The procedure is repeated several times, so that each column is loaded, washed, eluted,
and regenerated several times in the process. In addition to column regeneration, it
might also be necessary to integrate a CIP step. This step can be carried out after
a certain number of process cycles, or, alternatively, as a part of each regeneration
step [217].
6.3. Materials and Methods
6.3.1. Feed stock
The mAb used in this work was provided as HCCF from LEK d.d. (Ljubljana,
Slovenia). The HCCF was stored at -80◦C for long-term and at -30◦C for short-term
storage. All samples were filtered through 0.2µm syringe filters (Satorius, Göttingen,
Germany) directly before use.
6.3.2. Disposables
All precipitation experiments were carried out in 350µL polypropylene flat bottom 96-
well micro plates (Grainer Bio-One, Kremsmünster Austria). For all resolubilisation
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studies, 350µL AcroPrep filter plates with a 0.2µm GH polypro membrane (Pall
Corporation, Port Washington, NY, USA) were used. For DNA quantification, black
96-well polystyrene microplates (Thermo Fisher Scientific, Waltham, MA, USA) were
used. Before loading onto the CEX column, pH of the mAb samples was adjusted
using pD 10 desalting columns (GE Healthcare, Little Chalfont, UK).
6.3.3. Chemicals and stock solutions
As buffer substance, acetic acid, sodium acetate trihydrate, sodium chloride, sodium
hydrogen carbonate, and tris(hydroxymethyl)-aminomethane (all Merck KGaA,
Darmstadt, Germany) were used. Tris hydrodochloride was obtained from PanReac
AppliChem (Darmstadt, Germany). Sodium carbonate was obtained from Sigma
Aldrich (St. Louis, MO, USA). The PEG with an average molecular mass of 6000
was obtained from Merck KGaA (Darmstadt, Germany). All buffers were prepared
with a concentration of 100mM . For this, the appropriate amounts of associated
buffer components were weighted and dissolved in ddH2O. The desired pH was
reached by varying the amount of acid and basic component for each buffer. For the
40% (w/w)PEG 6000 stock solution, the buffer components were first dissolved in
ddH2O followed by adding the appropriate amount of PEG 6000.
6.3.4. Liquid handling station
All precipitation experiments were carried out on a Tecan Freedom Evo 200 System
liquid handling station (Tecan, Männedorf, Switzerland). The liquid handling station
was equipped with an 8-tips liquid handling arm, a Te-VacS vacuum separation
module, a Te-Shake orbital shaker (all Männedorf, Switzerland), and a Rotanta
46RSC centrifuge (Hettlich GmbH & Co. KG, Tuttlingen, Germany). The system was
controlled by Evoware 2.5 (Tecan, Männedorf, Switzerland). Excel 2013 (Microsoft,
Redmond, WA, USA) was used as data import format and for data storage. All
calculations were done using Matlab R2015a (The Mathworks, Natick, MA, USA).
For reproducible HTS, the 8-tips liquid handling arm was calibrated. A separate
liquid class for each buffer, precipitant, and protein solution was created. The
calibration procedure was described earlier by Oelmeier et al. [219] in detail. By
variation of air gaps and the adjustment of the aspiration, dispensing and beakeoff
speed accuracy pipetting, even for viscous solutions, could be ensured.
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6.3.5. Liquid chromatography system
The chromatographic experiments for mechanistic model calibration were performed
using an Ettan liquid chromatography (LC) system equipped with a pump module
P-905, a dynamic single chamber mixer M-925 (90µL mixer volume), an autosampler
A-905, and a fraction collector Frac-950. The LC system was additionally equipped
with an UV monitor UV-900 (3mm optical path length) and a pH and conductivity
monitor pH/C-900 (all GE Healthcare, Little Chalfont, Buckinghamshire, UK). The
LC system was controlled with UNICORN™ 5.31.
As chromatography resin, the strong cation exchanger TOYOPEARL™ GigaCap
S-650M (TOSOH, Stuttgart, Germany) was applied. The resin beads are comprised
of a polymethacrylate backbone with a mean particle size of 75 µm. The resin
was prepacked by TOSOH in three 1mL ToyoScreen™ columns with dimensions of
6.4mmx 3 cm.
6.3.6. Analytical methods
To determine mAb concentration and aggregate content, the UltraHPLC system
Ultimate 3000RSLC, controlled with Chromeleon 6.8 (both Thermo Fisher Scientific,
Waltham, MA, USA) was used. For mAb concentration, a POROS analytical Protein
A column (Thermo Fisher Scientific, Waltham, MA, USA) was connected to a
UHPLC system. Analytical size exclusion chromatography (SEC) was performed
using a TSKgel SuperSW mAb HTP column (TOSOH, Stuttgart, Germany). Host
cell protein (HCP) concentrations of all samples were determined using a microfluidic
CD-based ELISA-like assay on the Gyrolab XPlore station controlled by Gyrolab
(Gyros AB, Uppsala, Sweden). DNA was quantified using a Quant-iT dsDNA assay
kit (Thermo Fisher Scientific, Waltham, MA, USA). The fluorescence intensity
was measured using a Tecan Infinity 200 UV-Vis spectrometer (Tecan, Männedorf,
Switzerland).
6.3.7. High-throughput method for precipitation screening
The precipitation procedure on the automated liquid handling station was described
in detail by Oelmeier et al. [23]. All experiments were carried out at 20◦C, controlled
by air conditioning. Systems with a total volume of 250µl containing an mAb concen-
tration of 1.5mg/mL were prepared. For finding the optimal precipitation conditions,
the PEG concentration was varied in 24 steps from 0% (w/w) to 13.8% (w/w)PEG
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6000. Additionally, the pH was varied in four steps from pH7.5 to pH10.5. After
adding the complex protein stock solution, the system was incubated for 15min on
the orbital shaker at 1000 rpm, and afterwards 15min without shaking. To analyze
the amount of precipitated protein, the microplate was centrifuged for 30min at
4000 rpm. Then, 100µl of the supernatant was sampled and diluted at a ratio of 1:2.
Subsequently, mAb and HCP concentration of the samples were analyzed.
6.3.8. Optimization of the resolubilisation using empirical modeling
To find optimal resolubilisation process parameters, a DoE was established using the
software Modde 10.1.1 (Umetrics, Umeå, Sweden). As design space, a full factorial
design with three factors was chosen. In preliminary experiments, the mAb showed
instabilities below pH4.0 during resolublisation (data not shown). Therefore, the
pH value of the resolubilisation buffer was varied between pH4.0 and pH6.0. The
filtration time after precipitation and resolubilisation was varied between 150 s and
600 s, and the incubation time of the resolubilisation was varied between 75min
and 150min. As response, mAb yield and the mAb purity were investigated. The
experiments for resolubilisation were carried out on the liquid-handling station with
a method similar to the one described before. Instead of mixing the systems in
96-well microplates, 96-well filterplates were used. After incubation, phase separation
was carried out applying three times 700mbar pressure difference for various times.
Subsequently, 240µl of resolubilisation buffer were added to each system. Afterwards,
the filterplates were incubated on the orbital shaker for various times. After the
incubation, a second filtration step was carried out using the vacuum separation
module three times at 700mbar pressure difference for various times.
6.3.9. Chromatography system characterization
The ÄKTA™ system and chromatography column were characterized using tracer
pulse injections at constant flow rates of 0.33mL/min. 25µL of 10 g/L non-
interacting, non-pore-penetrating tracer blue dextran 2000 kDa (Sigma-Aldrich,
St. Louis, MO, USA) and 25µL of 1%(v/v) pore-penetrating, non-interacting tracer
acetone (Merck, Darmstadt, Germany) in ultra-pure water were used to determine
the system voidage, interstitial volume and total voidage of the column. Here, the
UV signals at 260 nm were used and corrected due to system dead volumes. The
ionic capacity Λ of GigaCap S-650M was determined by applying acid-base titration
suggested by Huuk et al. [130].
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6.3.10. Bind-and-elute experiments
After the precipitation and resolubilisation steps, linear gradient elution (LGE)
experiments were carried out by means of model calibration. To determine the model
parameters in the linear region of the adsorption isotherm, a 0.5mL loop was used.
Post-loading wash steps of 1CV binding buffer were carried out, followed by an
elution step by increasing the salt gradient from 0Mto 1.0M NaCl with gradient
lengths of 10CV , 15CV , and 20CV . For the nonlinear region, 23.16mL protein
solution was injected via 50mL superloop before a wash step of 5CV binding buffer.
Subsequently, the elution was carried out by increasing the salt gradient from 0M to
1.0M NaCl with a gradient length of 25CV . After elution, the column was stripped
over 3CV at an NaCl concentration of 1.0M and re-equilibrated for 5CV binding
buffer. All experiments were conducted at 0.33mL/min.
6.3.11. Model calibration
The chromatograms from LGE in both linear and nonlinear region of the adsorption
isotherm were used to carry out the parameter estimation via the inverse method [220].
The first guess was delivered using adaptive simulated annealing (ASA) [221]. For fine
adjustment, the Levenberg-Marquardt (LM) algorithm [222] was used. Discretization
in space on a grid with equidistant nodes was carried out using the finite element
method. The θ-scheme discretization in time was conducted using the fractional
step [223]. The solution of the non-linear equation system was approximated via the
Picard iteration [224].
6.3.12. In silico optimization and model validation
Pareto optimization of the batch single-column chromatography was performed using
ChromX. As objective functions, monomer yield, purity, and production rate were
chosen. Optimization parameters are the injection volume and sodium chloride
concentration in elution step. The salt concentrations of the binding buffer and strip
buffer were kept constant to ensure maximal binding and a complete regeneration
of the columns. The OpenBeagleMultiObjective algorithm was employed for the
in silico optimization. One of the Pareto optima that provided monomer yield and
purity above 90% and 99%, respectively, and the maximal production rate were
chosen to be validated in the laboratory. In silico screening was carried out to
approximate the Pareto optima of the 3C-PCCC process. Here, 1000 simulations of
the 3C-PCCC process were generated by varying the protein injection volume and
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the optimal salt elution concentration. The fractionation was chosen to start and
end at 300mAU .
6.4. Results
6.4.1. Investigation of precipitation conditions
In this work, PEG precipitation of the mAb was performed as alternative capture
step for an mAb purification process. In specific, the goal was to find optimal process
conditions for selective precipitation of the mAb. On the one hand, the precipitant
concentration and, on the other hand, the pH value of the buffer used was varied.
As target parameters, mAb yield and HCP reduction were considered.
The mAb as well as the HCP concentration in the supernatant, after phase separation
through centrifugation, are shown in Fig 6.2.. All values shown are mean values of
at least triple determinations and refer to conditions at 0% PEG. 98.5% yield was
chosen as target parameter for the precipitation, as this was the maximum reached
yield in this study.
Figure 6.2.: Selected results of the precipitation screening. Data points represent the mean
values of at least triplicates. As feedstock HCCF was used. Precipitation was carried out using
PEG 6000, varied from 0% (w/w) to 13.8% (w/w)PEG, as precipitant. Additionally the pH of
the utilized buffer was varied. The relative amount refereed to conditions with 0% (w/w)PEG
of (a) mAb and (b) HCP in the supernatant after centrifugation are displayed.
With increasing PEG concentration, a decrease in the mAb concentration in the
supernatant could be observed (Fig. 6.2. (a)). This correlates to an increase in mAb
precipitation. For all pH values, the mAb stayed stable in solution for PEG concen-
trations below 4.2% (w/w)PEG. With the exception of pH 10.5, all other conditions
led to yields above 98.5%. Therefor, no further investigations were carried out at
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pH10.5. The shape of all curves of the different pH values differed in the initial PEG
concentration where the precipitation of the mAb began. For conditions with pH 7.5,
pH 8.5, and for pH 9.5, PEG concentrations of 12.6% (w/w)PEG, 13.2% (w/w)PEG,
respectively 13.8% (w/w)PEG were required to reach the predetermined yield.
All examined systems with pH values except for pH10.5 were investigated on HCP
concentration in the supernatant after phase separation (Fig. 6.2. (b)). For all
conditions, a decrease in HCP concentration in the supernatant could be observed
with increasing PEG concentration. This correlates to a decrease in the theoretical
purity of the precipitated mAb referred to HCP. Precipitation of HCP was not
detectable for conditions with PEG concentrations less than 7.2% (w/w)PEG. For
all conditions with pH8.5, a stronger reduction in the HCP concentration could
be observed compared to pH7.5 and pH9.5. Furthermore, for PEG concentrations
above 11.8% (w/w)PEG, less HCP reduction could be observed for systems with
pH9.5 compared to pH7.5. For conditions with the predetermined yield being greater
than 98.5% and pH8.5, HCP reduction over 60% could be reached. For systems
with pH7.5, 70%, and for systems with pH9.5, over 79% HCP reduction could be
detected.
6.4.2. Investigation of resolubilisation conditions
For precipitation, with the exception of pH10.5, all other investigated pH values
achieved satisfying results in the case of mAb yield. One precipitation condition
for each investigated pH value with an mAb yield over 98.5% and with the least
amount of PEG was chosen for further process optimization. For these conditions,
the resolubilisation was investigated. In detail, for pH 7.5 at least 13.2% (w/w)PEG,
for pH 8.5 12.6% (w/w)PEG, and for pH 9.5 13.8% (w/w)PEG were needed to reach
the predetermined yield. To optimize the resolubilisation, three factors were taken
into account. The pH of the resolubilisation buffer, the filtration time of the phase
separation through vacuum filtration, and the incubation time of the resolubilisation.
The screenings were carried out as DoE. From the results, a multiple linear regression
model (MLR) was built.
For all three precipitation conditions, a similar behavior of the responses, mAb yield
and purity, could be observed. No significant influence of the filtration time could
be measured and, therefore, this factor was not considered for the model (Fig. 6.3.).
This results allow the reduction of the parameter set for further investigations. By
reducing the filtration time an overall time saving for the HTS could be reached.
No influence of the pH of the resolubilisation could be observed in the case of mAb
yield. The only factor which had a significant influence on the mAb yield was the
resolubilisation time (Fig. 6.3. (a)). With longer resolubilisation times, higher yields
87
Integrated Precipitation and CEX Process Development
were detected. At 150min incubation, yields from up to 100% could be measured
(Fig. 6.4. (a)). For the mAb purity, the only factor which had a significant influence
was the pH of the resolubilisation buffer (Fig. 6.3. (b)). With lower pH values, a
higher mAb purity could be observed for all precipitation conditions. Purity of mAb
up to 97% could be detected under conditions with pH4.0 (Fig. 6.4 .(b)).
Figure 6.3.: Factors of the MLR model of mAb yield and mAb purity after resolubilisation.
HCCF was precipitated at pH7.5 and 13.2% (w/w)PEG, pH8.5 and 12.6% (w/w)PEG
and pH9.5 and 13.8% (w/w)PEG. Afterward the precipitated mAb was resolubilisation for
incubation times varying from 75min to 150min. Additionally the pH of the resolubilisation
buffer was varied from pH4.0 to pH 6.0. Furthermore the filtration time of the phase separation
by vacuum filtration was varied from 150 s to 600 s. For further investigation only the
resolubilisation time in case of yield and the pH of the resolubilisation buffer in case of the
mAb purity were taken into account for the MLR.
Figure 6.4.: MLR model of mAb yield (a) and mAb purity (b) after resolubilisation. HCCF
was precipitated at pH7.5 and 13.2% (w/w)PEG, pH8.5 and 12.6% (w/w)PEG, and pH9.5
and 13.8% (w/w)PEG. Afterwards the precipitated mAb was resolubilised. For the MLR
model of the mAb yield the influence of the incubation time was considered. For the MLR
model of the purity the pH influence of the resolubilisation buffer was considered.
88
6.4. Results
6.4.3. CEX system characterization
By conducting tracer experiments without a column attached, the LC system dead
volume of 280µl was determined, which was subtracted from all other data from the
LC. Based on the results of the tracer injections with a column attached, bed and
particle voidage, and axial dispersion were calculated. The acid-basic titration was
conducted to determine the ionic capacity. The results are listed in Tab. 6.1.
Table 6.1.: The voidages and axial dispersion are calculated based on tracer experiments.
The ionic capacity is determined via acid-base titration.
GigaCap S-650M
Bed voidage b 0.414
Particle voidage p 0.779
Total voidage t 0.870
Axial dispersion [mm2 · s−1] Dax 0.067
Ionic capacity [M ] Λ 1.383
6.4.4. In silico CEX process development
Three linear gradient experiments with gradient lengths of 10CV , 15CV , 20CV , and
25CV in linear and one with 25CV in nonlinear region of the adsorption isotherm
were used to estimate the chromatography model parameters kfilm, Dpore, keq, ν, and
σ via inverse method by employing ASA and LM algorithm. Non-binding impurities
were lumped to one component. The estimated parameter for monomer, aggregate,
and lumped impurity are given in Tab. 6.2. kkin was found to be not necessary for
the description of the system, since the equilibria of the components considered were
reached immediately.
Table 6.2.: The mass transfer model and adsorption isotherm parameters are estimated using
the inverse method.
Parameter mAb Aggregate Lumped impurity
kfilm [mm · s−1] 0.086 0.049 0.100
Dpore [mm2 · s−1] 3.508 ·10−5 2.788·10−5 1.648·10−5
keq [-] 2.724 ·10−7 6.832 ·10−9 3.995·10−12
ν [-] 8.899 11.340 -
σ [-] 101.380 98.262 -
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Figs. 6.5. (a)-(d) shows the simulated and experimental chromatograms used for the
model calibration. The lumped impurity broke through during the wash step. The
mAb and aggregate show similar behavior and peak overlapping during gradient
elution, whereas the latter shows a slightly stronger binding. Fig. 6.5. (e) shows the
magnified simulated and measured signals of the same process as in Fig. 6.5. (d).
Figure 6.5.: Plots of UV signals over process run time for the bind-and-elute chromatography
experiments. Dashed lines display the UV signal measured at column outlet. Black solid lines
represent the adjusted salt gradients with elution gradient lengths of 10CV (a), 15CV (b),
20CV (c), and 25CV (d). Blue solid lines and bars represent the simulation of monomer and
oﬄine analytical result, respectively. Red and green are the aggregate and lumped impurity.
(e) displays the magnified details of the breakthrough of lumped impurity and the elution of
aggregate in the same process as shown in (d).
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Knowledge of mass transfer and SMA parameters eventually enabled identification
of the optimal step-wise gradient process for the considered separation problem. To
find the optimal protein loading volume and elution salt concentration with respect
to maximizing monomer yield, purity, and production rate, a multi-objective in silico
process optimization was performed. The resulting Pareto-optimal points can be
seen in Fig. 6.6..
Figure 6.6.: Pareto-optimal operating points for the batch single column chromatography
process represent the maximal monomer yield, purity, and production rate by varying protein
loading volume and elution salt concentration.
Constraints for monomer yield and purity were set to be above 90% and 99%,
respectively, whilst the maximal production rate was chosen. The optimal protein
injection volume and elution NaCl concentration were predicted to be 35.98mL and
0.161M. The validation experiment conducted in the laboratory is compared to the
model prediction in Figs. 6.7. (a)-(c). It can be seen that the behavior of lumped
impurity, mAb monomer, and aggregate are predicted accurately. As magnified
details of Fig. 6.7 (a), Fig. 6.7. (b) and (c) show the simulated and measured signal
of lumped impurities and the aggregate, respectively. Small deviations, such as the
slight underestimation of the aggregate level in the main peak and the tailing of
mAb monomer, are shown. The in silico predicted and experimentally determined
monomer purity, yield, and concentration in the product fraction are compared in
Tab. 6.3. The monomer purity has a deviation of 0.3%, yields a prediction error of
8.4%, and the monomer concentration in pooled fraction is underestimated by 8.5%.
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Figure 6.7.: Plot of UV signal over process run time for the validation experiment. Dashed
lines display the UV signal measured at column outlet. Black solid lines represent the adjusted
step-wise salt gradient. Blue solid lines and bars represent the simulation of monomer and
oﬄine analytical result, respectively. Red and green are the aggregate and lumped impurity.
(b) and (c) display the magnified details of the breakthrough of lumped impurity and the
elution of aggregate in the same process as shown in (a), respectively.
Table 6.3.: Comparison between the in silico predicted and experimentally determined
objectives.
Objective Model Experiment Deviation
Monomer purity [%] 99.00 98.70 0.30
Monomer yield [%] 91.10 98.75 8.40
c(monomer) pooled [mg/mL] 10.94 11.87 8.50
To investigate the potential of a 3C-PCCC process in the considered case, an in silico
screening was carried out to approximate the Pareto optimal points with respect to
maximizing monomer purity and yield simultaneously. Overall, the optimal protein
injection volumes were found to be greater and the optimal salt elution concentrations
were lower than the ones in the batch single-column process. Improvements of both
monomer purity and yield were found as shown in Fig. 6.8..
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Figure 6.8.: Comparison of the Pareto-optimal operating proteins for the batch (blue triangles)
and 3C-PCCC process (orange circles).
6.4.5. Batch process validation
After optimization of each process step, a validation run with the optimal process
parameters was performed. The precipitation was performed at pH 8.50 with a PEG
concentration of 12.6% (w/w)PEG. Afterwards, the samples were resolubilised at
pH4.00 for 150min with a filtration time of 150 s. Before the CEX step, the pH of
the sample was adjusted to pH5.00. The subsequent CEX step was conducted at a
loading volume of 35.98mL, and elution NaCl concentration of 0.161M, as predicted
by the mechanistic chromatography model. At the beginning and after each step, the
mAb, HCP and DNA concentration as well as the aggregate content were measured.
In Tab. 6.4, these results are compared to a common purification run. The values
for Protein A are provided from Lek d.d. and were measured directly after Protein
A elution. During the integrated process, HCP and DNA reduction were mainly
reached during the precpitation and resolubilisation step. Aggregate reduction and
concentration of the product were reached during CEX. Compared to Protein A,
mAb yield, HCP reduction, and aggregate content reached similar values. The mAb
concentration of the integrated process was 63% lower in comparison to Protein A
chromatography, the DNA reduction was four magnitudes higher.
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Table 6.4.: Case study validation run after optimisation of the integrated process. Monomer
concentration, yield, and purity were detected after each step and compared to a common
Protein A process.
Objectives HCCF Precipitation CEX Protein A
c(monomer) [mg/ml] 3.30 1.69 11.87 32.20
Monomer yield [%] - 96.47 95.41 > 95.00
HCP reduction [%] - 98.23 99.28 99.99
Aggregate content [%] 3.12 3.96 1.30 1.20
DNA [ng/ml] 8.09e+07 2.3 e+03 2.48e+02 1.90e+06
6.5. Discussion
A process strategy for mAb processes was successfully developed. The integration of
PEG precipitation and CEX showed the potential of replacing Protein A as capture
step in an mAb process.
Through the replacement of Protein A, the necessity of establishing an alternative
development platform was given. Furthermore, in comparison to Protein A chro-
matography, PEG precipitation alone is not capable of reducing high molecular
weight impurities (HMW) like aggregates or DNA. The integrated process and the
development platform presented in this work can solve both problems. The PEG
precipitation showed promising results based on mAb yield and HCP reduction.
Resolubilisation at low pH values led to high mAb yields and a high amount of HCP
reduction. The results were comparable to common Protein A steps [116]. Further-
more, it allowed a direct loading onto CEX column. Resolubilisation in combination
with concentration is reported as being time-consuming and might end up with low
yields though incomplete resolubilisation [114]. Using CEX in bind-and-elude mode
combined a reduction of HMW with a volume reduction at the same time.
For this integrated process, a process development platform was designed. It com-
bines high-throughput methods with empirical and mechanistic modeling. For the
precipitation, a high-throughput method on a liquid handling station was successfully
generated. The PEG concentration and the pH of the surrounding buffer showed
significant influence on the precipitation behavior. Although PEG is a cheap raw
material, recycling is currently not an issue. Therefore, the amount of PEG is one
of the driving costs of the process and consequently at least possible PEG should
be used. Studies by Hammerschmidt et al. have shown that precipitation results,
like yield or purity, are independent of the operation mode [225]. This indicates that
development strategy presented here could be used for batch and continuous process
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development. After the precipitation, the resolubilisation was optimized using a DoE
and a MLR model, avoiding brute-force methodology. Afterwards, critical process pa-
rameters could be detected and optimized in a goal-driven manner. The mechanistic
chromatography modeling reduced the number of experiments needed to be carried
out in the laboratory. Thus, the material and time required for the development
of precipitation, resolubilisation, and chromatography processes could be reduced.
Furthermore, based on the mechanistic understanding gained, the potential of a
3C-PCCC process could be explored.
The development strategy was used to purify an mAb, provided as HCCF. The
highest observed mAb yield after precipitation was 98.5%. Comparing different pH
values, under conditions with pH8.5, the least amount of PEG was needed to attend
this objective. Conditions with pH 7.5 and pH9.5 reached this yield at slightly higher
PEG concentrations as well. Altogether, the lowest colloidal phase stability of the
mAb was observed near its isoelectric point (pI). This is equal to least electrostatic
repulsion. However, for these conditions, no more than 79.0% HCP reduction were
detected. Co-precipitation of HCP following the mAb could be a reason for this
partial reduction. Higher purities were detected under conditions with minor colloidal
phase stability of the mAb.
As the precipitation alone was not sufficient enough, the resolubilisation was optimized
as second purification step. The DoE showed the pH value to be a critical process
parameter for the reduction of HCP. The resolubilisation was carried out at pH values
near the pI of most of the HCP. This is reported to be around pH5.0 [52]. A selective
resolubilisation was observed, and HCP reductions of over 98.0% were detected. This
suggests that most of the HCP were not resolubilised and remained on the filter.
Simultaneously, the investigated pH values were at least 2.5 pH steps below the pI
of the mAb. This was probably the reason for a complete resolubilisation of the
mAb. Shifting the pH to even lower values could be a possibility to combine virus
inactivation with the resolublisation step. The resolubilisation time was detected
as the second significant process parameter. Higher yields were detected at longer
resolubilisation times. This implies a slow resolubilisation kinetics. The formation
of a filter cake is reported as reason for this phenomenon [225]. No reduction of
molecules with a hydrodynamic radius bigger than that of the mAb was expected.
The aggregate level stayed constant. However, a DNA reduction of over 5 magnitudes
could be seen. This might be due to the incubation conditions, as DNA is reported
to be sensitive towards low pH values [226].
Because the mAb showed instabilities at high salt concentrations (data not shown),
the pH was adjusted from pH4.0 to pH5.0 before the CEX step. For the CEX
step, the predicted Pareto-optimal process could be validated successfully. Here, the
chromatogram predicted showed good agreement with the validation experiment
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carried out in the laboratory. The elution of aggregate in the first step was slightly
underestimated, leading to a monomer purity overestimated by 0.3%. The tailing of
monomer was predicted to be more pronounced by the model, resulting in a yield
deviation of 8.4%. The reason of these deviations might be the simplification of the
protein system by neglecting different binding orientations and charge variants. In
the case of the 3C-PCCC process, an in silico screening predicted higher monomer
purity and yield, whereas the optimal protein injection volumes were found to be
greater and the optimal salt elution concentrations were lower than the ones in
the batch single-column process. This observation can be explained by the nature
of the 3C-PCCC mode i.e., by the fact, that a column can be loaded with more
protein. For for the monomers, a more nonlinear region of the adsorption isotherm
could be reached. This resulted in a lower elution salt concentration required. The
aggregates, however, bind in the linear region of the adsorption isotherm due to their
low concentration and tend to retain in the column during the elution step. Hence,
3C-PCCC shows a great potential to be combined with a continuous precipitation
capture process.
6.6. Conclusion
This work has shown a fast and material saving-process development method for an
mAb process. By integrating a PEG precipitation and CEX chromatography, a feasi-
ble alternative to Protein A chromatography as capture step was demonstrated. For
process development, a strategy combining high-throughput methods with empirical
and mechanistic modeling has shown promising results which might overcome the
drawback of replacing an affinity step.
Precipitating under conditions with pH 8.5 and 12.6% (w/w) PEG and resolubilisation
at pH 4.0 led to a significant reduction in HCP level in combination with a yield of over
96.4%. Additionally, loading onto a CEX column with only minor pH adjustments
was enabled. Using a step gradient, an aggregate reduction in combination with
product concentration to 11.9mg/mL was demonstrated. All in all, a flexible
time-and material-saving method was demonstrated which allows screening of even
more parameters than shown in this case study. Furthermore, the capability of a
continuous chromatography process was explored theoretically based on the calibrated
mechanistic chromatography model.
In further studies, the upscale of these results should be demonstrated. The execution
of a fully continuous process including continuous PEG precipitation in combination
with CEX-PCCC at a larger scale would be desirable.
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7. In-line Fourier-Transform
Infrared Spectroscopy as a
Versatile Process Analytical
Technology for Preparative
Protein Chromatography∗
Developing new biopharmaceutical purification technologies and process strategies
leads consequently also to an increased demand for advanced analytical technologies,
that can meet the requirements of such processes. On the one hand the change from
well established and proven platform processes to alternative purification strategies
raises the need for enhanced monitoring of the process. On the other hand, the
monitoring strategy faces the challenge of identifying different molecules. Usually,
biopharmaceutical processes are monitored with the help of univariate signals such as
pH, conductivity, pressure, and UV/Vis absorption at a single wavelength [214, 227].
Especially single wavelength UV/Vis adsorption measurements are most commonly
used for in-line process monitoring and control. However, this technology is limited
in some respects. For example, it is possible to detect multiple proteins in solution,
but it is not possible to destingiuish between them. The similarity of the signal
prevents the identification of these molecules. Additionally there are many molecules
that may be encountered in a purification process that are not UV active at all. For
example, PEG-induced protein precipitation involves the addition of a non UV/Vis
active precipitant, whose subsequent depletion must be ensured and monitored. The
overall objective of the seventh chapter of this work, added as full manuscript in
the appendix B, was to develop an in-line sensor capable of distinguishing between
different proteins while at the same time being sensitive to a wide range of commonly
used molecules in a downstream biopharmaceutical process.
Fourier-Transform Infrared Spectroscopy (FTIR) is a promising technology to fulfill
∗ A full version of this publication is given in Appendix B and [5]. In the following the major findings
relevant for this thesis are summarized.
99
In-line FTIR for Process Monitoring of Chromatography
this demand. This spectroscopy method is non-invasive, quantitative, fast, and has
the potential to be performed in-line [228–230]. FTIR spectroscopy measures the
vibrational modes of samples and provides a spectroscopic fingerprint of the different
measured organic molecules [140, 231, 232]. By measuring the backbone vibrations
of proteins, FTIR can be used to detect, quantify and identify proteins. Therefore,
FTIR is a widely used method for detecting and distinguishing the integrity of
proteins [140]. In this work, in-line FTIR was implemented as process analytical
technology (PAT) for preparative protein purification. For this purpose, the FTIR
spectrometer was coupled to a preparative chromatography system on laboratory
scale. The implementation of the sensor included enabling communication between
the devices and thus enabling automated FTIR measurements in the context of
chromatography runs. After the implementation, three case studies were conducted,
to demonstrate the versatility of the PAT sensor.
To demonstrate the ability to distinguish between different protein species, a mixture
composed of lysozyme and a monoclonal antibody (mAb) was purified using cation
exchange chromatography (CEX). The eﬄuent of four runs, with a variation in the
gradient elution length, were monitored in-line using FTIR spectroscopy. Three of
the runs were used to calibrate a partial least squares regression model (PLS), the
forth run was used as validation run. Both proteins show a significant difference
in their secondary structure. Therefore, the PLS model was able to successfully
distinguish between both proteins, although their elution profiles were overlapping
(Fig. 7.1).
In the second case study lysozyme molecules with different PEGylation degrees
were purified using CEX. Because PEG shows a prominent band at 1090 cm−1
with multiple shoulders, FTIR spectroscopy is able to detect and quantify PEG.
However, since proteins are also in the solution and have their fingerprint region
at this wavenumbers, it is not possible to quantify the PEG by simply applying an
adsorption coefficient. In order to distinguish between PEG and protein, a PLS
model was calibrated and applied. Hence, it was possible to quantify the amount of
PEG, the protein concentration, and finally calculate the PEGylation degree of the
lysozyme during elution (Fig. 7.2).
In a third case study the potential to monitor further process related impurities
was demonstrated by the detection and quantification of Triton X-100 in the flow
through of a CEX chromatography run. Triton X-100 is used as viral inactivation
agent and needs to be below a minimal level after the purification. With the help of
a linear regression it was possible to detect and quantify Triton X-100 in the flow
through and during the elution.
The results of the case studies show the potential of FTIR spectroscopy as an in-
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Figure 7.1.: Four chromatographic runs are shown for in-line FTIR measurements and
selective quantification of mAb and lysozyme. The red bars and lines refer to the mAb
off-line measurement and mAb PLS prediction, respectively. The blue bars and lines refer to
the lysozyme off-line measurement and lysozyme PLS prediction, respectively. The different
subplots show different gradient lengths: A 1CV , B 2CV , C 3CV , D 4CV .
line sensor for preparative protein purification. The applied monitoring and signal
processing strategies allow the monitoring of the process, but also has the potential
of active process control. This would, for example, allow active real-time decision
making during peak cutting. It was shown that FTIR spectroscopy has the great
advantage of being able to detect proteins as well as other small organic components.
For the integrated precipitation and IEX process, presented in chapter 6, this sensor is
an ideal solution for monitoring the CEX step. Thereby, two applications are feasible.
Either monitoring the resolubilized protein solution and thus, the loading onto the
CEX column or monitoring the elution of the protein during the CEX. In both cases,
in addition to the detection of the mAb concentration, the complete depletion of
the PEG, which was added during the precipitation step, can be verified. For the
precipitation process itself, the implementation of an in-line FITR sensor probably
opens up the possibility to monitor the precipitation and resolubilisation process
itself. FTIR spectroscopy has the option of using an attenuated total reflection (ATR)
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cell instead of measuring in transmission mode. As ATR has a very low penetration
depth into the sample, it might be possible to distinguish between precipitated
and soluble protein. Therefore, with ATR FITR only the soluble protein might be
detected. Further investigations have to show whether ATR FTIR can be a promising
technique for monitoring processes with turbid solutions.
Figure 7.2.: Four chromatographic runs are shown for in-line FTIR measurements and
selective quantification of PEG and lysozyme. The red bars and lines refer to the PEG
off-line measurement and PEG PLS prediction, respectively. The blue bars and lines refer
to the lysozyme off-line measurement and lysozyme PLS prediction, respectively. Grey bars
correspond to measured protein concentrations on partially precipitated samples. Black dots
show the molar ratio between PEG and lysozyme, i.e. the current mean PEGylation degree.
The different subplots show different gradient lengths: A 2CV , B 3CV , C 4CV , D 5CV .
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The present PhD thesis addresses issues, currently preventing preparative protein
precipitation to be implemented into a biopharmaceutical production process for
proteins. In academia, such precipitation processes have already proven applicability.
Compared to chromatographic based processes, they have shown the potential to
make process development easier, more flexible, and more cost-efficient. However,
for an industrial utilization there are still several challenges present. This includes
a deeper process understanding, a faster and easier process development, and an
enhanced monitoring of all included molecules. In these three fields challenges
of particular interest were defined. Among the acting forces between proteins,
hydrophobic interactions are of great importance, but the underlying mechanism
is not fully understood. The gained knowledge of the precipitation mechanism
can be used for better process understanding and was further applied to derive
a mechanistic precipitation model, for PEG-induced precipitation. The model
showed the possibility to make process development easier and less time consuming.
Additionally, a new process development strategy was presented, with the focus
on integrated up- and downstream process development. The influence of previous
production steps was considered, as well as following polishing steps. In addition,
new monitoring strategies, incorporating in-line FTIR spectroscopy as PAT tool,
were investigated. The applicability for chromatography was shown in three different
case studies.
In the first part of this thesis, measurements of the protein hydrophobicity and
thermal stability were applied, to explain and estimate the protein phase state. In
combination, both techniques could successfully be used to describe the crystallization
behavior of glucose isomerase, at varying salt types, salt concentrations, and pH
values. The different observed crystal structures could be described and explained
with differences in the protein surface hydrophobicity, and following estimated by
HIC. With the help of HIC, a deeper understanding of the influence of hydrophobic
interactions during protein-protein interaction was generated.
Consequently, the similarities between HIC and protein-protein interaction could
be dedicated to the same hydrophobic driven mechanism. By introducing water
as additional component into the precipitation process, it was possible to derive
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an isotherm, which is capable to describe the precipitation behavior of proteins at
varying initial protein and PEG concentrations. Thereby, an equilibrium between a
well-ordered, and a bulk-like ordered water structure was assumed. The developed
mechanistic precipitation model allowed to predict the precipitation behavior over
the entire precipitation curve. Together with the capability to describe accurately the
precipitation behavior of small proteins the model is superior to other commonly ap-
plied models. With the help of high-throughput experiments the model predictability
was validated with data beyond the calibration range.
The second part of this thesis focused on the process development of a purification step
for a complex mAb feedstock. The influence of upstream conditions on a PEG-induced
precipitation step was investigated. Thereby, a destabilizing effect of the contaminants
was detected, compared to pure mAb solutions. The destabilization could be assigned
to the occurrence of interactions between the mAb and macromolecules like HCP, or
DNA. On the other hand, a stabilizing effect of components present in the cell culture
medium could be shown. These molecules most likely prevent mAb-macromolecule
interactions, and therefore, lead to higher purities after the precipitation step. The
presented study pointed out the importance of considering the needs of a precipitation
step already during the development of the USP.
Considering the following purification strategies a development platform was evolved.
The platform combines HTS for the precipitation step, empiric modeling for the
resolubilisation step, and mechanistic modeling for the optimization of the following
CEX step. The developed process showed the potential to replace Protein A affinity
chromatography as capture step during a mAb process. Thereby, process-related
contaminants were purified mainly during the precipitation and resolubilisation
step. Product-related contaminants were depleted using CEX. By performing the
resolubilisation at low pH values, a direct binding of the product onto the CEX
column was enabled. Process integration was further considered as during CEX,
purification, and concentration of the product were performed simultaneously. The
development platform can be used to optimize a classical batch process, but is also
capable for the development of a continuous one.
The last part of the thesis was contributed to the development of in-line monitoring
strategies for chromatography, taking into account the requirements of a polishing
step after precipitation. A sensor setup was developed, combining in-line FTIR
spectroscopy with PLS regression modeling, for the monitoring of a chromatographic
separation step. Based on differences in their secondary structure, it was possible
to distinguish between different proteins. The strength of FTIR spectroscopy lies
in the ability to detect also non UV/Vis active molecules, for example PEG. This
was successfully shown in a case study, where different PEGylated lysozyme species
were detected during CEX elution. In another case study, the variety of FTIR
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spectroscopy was shown by performing selective mass balancing with the process-
related contaminant Triton X-100.
In summary, this thesis contributes to a better understanding of the acting forces
between proteins, and the mechanism of preparative protein precipitation. The
developed mechanistic precipitation model can build the basis for further model
extensions. An additional description of the behavior of multi-component solutions,
would enable in silico process development. The knowledge, obtained through the
study of the precipitation behavior of complex protein solutions, can build a good
basis for that. Model based optimization of the precipitation step would fit perfectly
in the presented development strategy. With the extension of the development
toolbox, a further reduction of necessary wet laboratory experiments, and material
consumption could be achieved. At the same time, meta modeling would be enabled,
to describe the influence of each purification step towards the whole production
process. This can lead to a reduction of uncertainties, a more robust process, and
probably help protein precipitation to be used as alternative purification step. While
for classical blockbuster mAb products the currently used platform based strategy
might be more comfortable, new drug, or biosimilar products will raise the necessity
for cheaper, and more flexible processes, including the corresponding development
strategies. Especially, with the transfer to continuous manufacturing, the necessity of
simple and easy adaptable processes could make protein precipitation more attractive
to the biopharmaceutical industry. The developed in-line monitoring strategy can
help to ensure constant product quality over long term productions. Especially, the
lack of an in-line sensor for monitoring the precipitation step itself, shows the need for
further research. The developed methods of this work could potentially be transferred
to different sensors and help to meet these requirements. Additionally, combination
with other in-line sensors would probably help to detect more, at the moment hidden,
information about the product, the contaminants, or the composition. As a result, in-
line process monitoring in combination with process modeling could help to perform
route cause investigations, and consequently active process control.
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Abstract
In the biopharmaceutical industry it is mandatory to know and ensure the correct
protein phase state as a critical quality attribute in every process step. Unwanted
protein precipitation or crystallization can lead to column, pipe or filter blocking. In
formulation, the formation of aggregates can even be lethal when injected into the
patient. The typical methodology to illustrate protein phase states is the generation
of protein phase diagrams. Commonly, protein phase behavior is shown in dependence
of protein and precipitant concentration. Despite using high-throughput methods
for the generation of phase diagrams, the time necessary to reach equilibrium is the
bottleneck. Faster methods to predict protein phase behavior are desirable. In this
study, hydrophobic interaction chromatography retention times were correlated to
crystal size and form. High-throughput thermal stability measurements (melting and
aggregation temperatures), using an Optim®2 system, were successfully correlated
to glucose isomerase stability. By using hydrophobic interaction chromatography
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and thermal stability determinations, glucose isomerase conformational and colloidal
stability were successfully predicted for different salts in a specific pH range.
A.1. Introduction
In biopharmaceutical processes knowledge and control of protein phase behavior is
of high importance. Controlling protein phase states - being in most processes a
critical quality attribute - is on the one hand essential to avoid protein loss during
upstream, downstream, and formulation of biopharmaceutical drugs, on the other
hand the application of phase transitions such as precipitation or crystallization can
be used as downstream unit operation. The influence of changing protein-solvent and
protein-protein interactions due to a change in process parameters - defining these
parameters as critical process parameters - on macroscopic protein phase behavior
can be displayed in protein phase diagrams as a function of protein concentration
and precipitant concentration [49, 75].
On a molecular level, the acting forces include long-range and short-range interactions.
In this context, electrostatic interactions are generally defined as long-range forces
whereas hydrogen bridges, van-der-Waals forces or hydrophobic interactions are
examples for short-range forces [53]. Changing these interactions can influence
protein phase behavior and therefore lead to phase transitions. Intermolecular
electrostatic repulsive interactions between equally charged protein molecules have a
stabilizing effect on protein solutions. Short-range attractive forces are superimposed
by these long-range interactions. By increasing the ionic strength of a solution,
these electrostatic repulsive effects are shielded and short-range attractive forces are
predominant [233, 234].
During purification, biomolecules are often exposed to high-salt conditions. In high-
salt conditions additional salt ion effects are induced and are not entirely understood.
The preferential interaction theory, first postulated by Arakawa et al. [235, 236], is
the most promising approach for explaining these effects. They distinguish between
preferential binding of co-solutes to protein and preferential exclusion from protein
surface. The former type is provoked by chaotropic agents which are found to
enhance protein solubility (salting-in) but destabilize the native protein conformation.
These agents are nonpolar and therefore weakly hydrated. The latter is induced by
polar kosmotropic agents that increase protein stability or lead to salting-out effects
due to their strongly hydrated character. Arakawa et al. [237] postulated that the
hydration of a protein in a concentrated solution of co-solute is at a constant level
independently whether this solute shows a preferential interaction or not.
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Protein stability comprises conformational and colloidal stability. Conformational
stability is important to assess as an indicator for protein unfolding. Exposed hy-
drophobic surface patches can enhance aggregate formation. Colloidal instability
describes the aggregate formation due to clustering of protein molecules. Increased
conformational and colloidal stability are believed to enhance overall protein stability
[238]. Long-term stability tests under stressed conditions [239–241] are generally
used to assess protein stability in pharmaceutical industry. In recent years, high-
throughput techniques to evaluate protein stability were established to determine
melting temperatures and aggregation temperatures. Differential scanning fluo-
rescence measures protein conformational stability by using extrinsic dyes, such
as SYPRO Orange, that bind to hydrophobic protein patches [242]. Differential
static light scattering monitors light scattering of protein solutions due to aggregate
formation [239, 243]. The combination of both parameters, melting temperature and
aggregation temperature, is important to evaluate protein stability [239]. These two
parameters have not been investigated in literature in dependence of the kosmotropic
and chaotropic character of the salts, their ionic strengths, and pH values in respect
to the protein’s isoelectric point (pI) so far.
In this study, the impact of pH value and ionic strength of different salts on protein
phase behavior was investigated using glucose isomerase as model protein. Sodium
sulfate, ammonium sulfate, sodium chloride, and ammonium chloride were used as
precipitants to investigate the influence of the two cations - sodium and ammonium
- and of the anions - chloride and sodium - on the protein phase behavior. The
high-throughput method to obtain protein phase diagrams was established earlier by
Baumgartner et al. [51]. In the present work, this method was adapted to obtain
information about protein phase behavior at varying pH values and different salt
ionic strengths at a constant protein concentration. A multi-component buffer system
[244] was used to ensure a constant buffer capacity over a defined pH range. By using
the same buffer for the whole investigated pH range, buffer effects were excluded.
The protein phase states are examined after 40 days of incubation.
Hydrophobic interaction chromatography (HIC) was used to investigate changes in
hydrophobicity of glucose isomerase caused by changing salt type and pH values.
Applying HIC bind-elute experiments, the diversity of short-range forces is reduced to
hydrophobic interactions.Furthermore, correlation of thermal stability measurements
to protein phase behavior was investigated measuring the melting and aggregation
temperature in the respective solutions. The present work demonstrates the use of
HIC bind-elute experiments and thermal stability measurements to predict protein
conformational and colloidal stability in fast time and at low sample consumption.
A schematic drawing of the used methodologies is shown in Fig. A.1..
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Figure A.1.: Schematic illustration of the experimental setup: Melting temperatures (Tm)
and aggregation temperatures (Tagg) and retention volumes in hydrophobic interaction chro-
matography were used to predict protein phase behavior.
A.2. Materials and Methods
A.2.1. Materials
The multicomponent buffer with a linear buffering range from pH3.5 to pH 11.5 con-
sisted of the organic acids CABS (4-(cyclohexylamino)butane-1-sulfonic acid) (Santa
Cruz Biotechnology, USA), AMPSO (2-hydroxy-3-[(1-hydroxy-2-methylpropan-2-
yl)amino]propane-1-sulfonic acid) (Sigma-Aldrich, USA), TAPSO (3-[[1,3-dihydroxy-
2-(hydroxymethyl)propan-2-yl]amino]-2-hydroxypropane-1-sulfonic acid) (Sigma-
Aldrich, USA), MES (2-morpholin-4-ylethanesulfonic acid) (AppliChem, Germany),
acetic acid (Merck Millipore, Germany), and formic acid (Merck Millipore, Ger-
many). The investigated salts sodium chloride, sodium sulfate and ammonium
chloride were obtained from Merck Millipore (Germany). Ammonium sulfate was
purchased from AppliChem (Germany). Sodium hydroxide for pH adjustment was
obtained from Merck Millipore (Germany). pH adjustment was performed using a
five-point calibrated pH meter (HI-3220, Hanna Instruments, USA) equipped with
a SenTix®62 pH electrode (Xylem Inc., USA) or an InLab® Semi-Micro pH elec-
trode (Mettler Toledo, Switzerland) dependent on the application. All buffers were
filtered through 0.2µm, and precipitant solutions through 0.45µm cellulose acetate
filters (Sartorius, Germany). Glucose isomerase (HR7-100) produced in Streptomyces
rubiginosus (PDB: 3KBS, pI: 4.78 [51]) was supplied by Hampton Research (USA).
Protein solutions were filtered through 0.2µm syringe filters with PTFE membranes
(VWR, USA). Size exclusion chromatography was conducted using HiTrap Desalting
Columns (GE Healthcare, Sweden) on an AEKTA prime plus system (GE Healthcare,
Sweden). A subsequent protein concentration step was performed using Vivaspin
centrifugal concentrators (Sartorius, Germany) with PES membranes and molecular
weight cutoff of 30 kDa.
Protein phase diagrams were prepared on MRC Under Oil 96-Well Crystallization
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Plates (Swissci, Switzerland) in microbatch experiments using a Freedom EVO®100
(Tecan, Switzerland) automated liquid handling station controlled by Evoware 2.5
(Tecan, Switzerland). Calibration of pipetting for liquid handling of buffers, precipi-
tant solutions, and protein solutions were generated using a WXTS205DU analytical
balance (Mettler-Toledo, Switzerland). The microbatch plates were covered with
HDclear ™sealing tape (ShurTech Brands, USA) to prevent evaporation. A Rock
Imager 182/54 (Formulatrix, USA) was used as an automated imaging system for de-
termining protein phase states. Protein concentration measurements were conducted
using a NanoDrop2000c UV-Vis spectrophotometer (Thermo Fisher Scientific, USA).
For hydrophobic interaction chromatography runs a 0.5mL Toyopearl Butyl-650M
column (Atoll, Germany) on an AEKTA™purifier (GE Healthcare, Sweden) was
applied. The AEKTA™purifier is equipped with an autosampler, UV detector, and
a conductivity cell. The operating software package for system control and data
analysis was Unicorn 5.1 (GE Healthcare, USA).
For determining protein melting temperatures and aggregation temperatures using
Optim®2 (Avacta Analytical, UK), operated with the Optim Client, protein samples
were analyzed in multi-cuvette arrays (Avacta Analytical, UK). Static light scattering
and intrinsic fluorescence data analysis was performed with the integrated Optim
Analysis software to evaluate protein thermal stability.
Data processing and creation of figures was performed in Matlab®R2014b (MathWorks,
USA) and CorelDRAW® Graphics SuiteX5 (Corel Corporation, Canada).
A.2.2. Methods
Preparation of Stock Solutions
Buffers were prepared by weighing and dissolving all buffer components in ultrapure
water to 90% of the final buffer volume. This volume was splitted into three
identical batches and pH value was adjusted using 4M sodium hydroxide solution
as titrant. The pH value was adjusted to both ends of the desired pH gradient
and an intermediate pH value. After filling up to the final buffer volume all buffers
were filtered through 0.2µm cellulose acetate filters. Precipitant stock solutions
were filtered through 0.45µm cellulose acetate filters. Buffers and precipitant stock
solutions were used at the earliest one day after preparation and after repeated pH
verification. The pH value was again adjusted at the day of use with an accuracy of
± 0.05 pH units. The global buffer capacity of 20mM was chosen over the buffering
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range of pH 3.5 to pH 11.5 . The buffer composition (Tab. A.1) was calculated using
a Matlab tool developed by Kröner et al. [244].
Table A.1.: Multi-component buffer composition with 20mM buffer capacitiy in a pH range
of pH 3.5 to pH11.5 based on Kröner et al. [244]
Substance Concentration [mM ] pKa
CABS 32.96 10.70
AMPSO 30.58 9.14
TAPSO 27.93 7.64
MES 29.52 6.10
Acetic acid 25.18 4.76
Formic acid 24.06 3.75
Sodium sulfate, ammonium sulfate, sodium chloride, and ammonium chloride were
used as precipitants. Precipitant stock solutions contained an additional ionic strength
of 2.5M and 5.0M , respectively. The intermediate salt concentration ensured pH
stability while mixing (data not shown). Otherwise, by mixing low-salt buffer (buffer
without additional salt) with 5.0M buffer at the same pH value, the pH value
would shift [51, 244]. To set up the protein stock solutions the crystal suspension of
glucose isomerase was diluted with low-salt buffer at pH 7.0 to redissolve the protein.
Centrifugal concentrators were used to reduce the volume. The protein solution then
was filtered through 0.2µm syringe filters to remove particulates and desalted using
size exclusion chromatography. Protein concentration was adjusted via centrifugal
concentrators to 50mg/mL.
Generation of Protein Phase Diagrams
Protein phase diagrams were prepared in high-throughput mode using the method
described by Baumgartner et al [51]. The protein phase diagrams were established on
96-well crystallization plates in microbatch experiments using an automated liquid
handling station. For buffer and precipitant solutions a maximum pipetting deviation
of below 2% could be realized [51]. For protein solutions the maximal deviation was
below 3%. The protein phase behavior at constant glucose isomerase concentration
of 10mg/mL was investigated with varying precipitant concentration and pH value
(Fig. A.1. center).
The pH value of the precipitant stock solutions of identical ionic strength (0.0M ,
2.5M , and 5.0M) was varied in twelve steps from pH3.5 to pH7.0 on one sample
plate. To ensure a linear pH performance while mixing, an intermediate pH step at
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pH5.5 was included. This has shown to smoothen pH deviations occurring due to
high salt contents to an experimentally satisfying extend (data not shown). Further,
for each pH step 0.0M , 2.5M , and 5.0M ionic strength were mixed to create eight
uniform salt dilution steps on a second sample plate.
The protein phase diagrams were then generated by adding 6µL of 50mg/mL protein
solution (low-salt buffer at pH7.0) to 24µL of the previously mentioned diluted
precipitant solution on the crystallization plate. The precipitant concentration was
varied per row and pH value was varied per column.
The final phase diagram was investigated at a resulting glucose isomerase concen-
tration of 10mg/mL in the pH range from pH4.2 to pH7.0 and an ionic strength
between 0.0M and 4.0M for sodium sulfate, ammonium sulfate, sodium chloride,
and ammonium chloride. Crystallization plates were then centrifuged for 1min at
1000 rpm to remove air bubbles and afterwards covered using optically clear and
UV compatible sealing film. The sealed plates were stored in the Rock Imager for
automated imaging for 40 days at 20◦C. The automated imaging was performed as
described earlier by Baumgartner et al. [51] to visually identify phase states such
as clear solution, crystallization, precipitation, and skin formation. With polarized
light at 90◦ crystals can be identified. Exposure to UV light was used to distinguish
between protein and salt crystals due to fluorescence of aromatic amino acids.
Hydrophobic Interaction Chromatography Bind-Elute Experiments
Bind-elute experiments in hydrophobic interaction mode were conducted on a 0.5mL
Toyopearl Butyl-650M column. Protein retention was evaluated at different pH values
(pH 5.47 - pH 7.00) and salt ionic strengths of 2.86M , 3.43M , and 4.00M . The high
salt conditions at protein injection were chosen to match the conditions at the protein
phase diagrams. Equilibration was performed with 10 column volumes (CV ) desalted
water and subsequently 4CV of low-salt buffer at a flowrate of 1mL/min. This was
followed by high-salt equilibration for 6CV at 1mL/min and 4CV at 0.2mL/min.
After equilibration, 100µL protein solution with 10mg/mL, in the respective high-
salt buffer, were injected using an autosampler. Elution was conducted in a linear
salt gradient of 20CV at 0.2mL/min from high-salt to low-salt. Subsequently, a
column wash with low-salt buffer was performed for 10CV . A constant pH value for
the entire experiment was ensured. The 280 nm UV signal was used to determine the
protein retention time. By using predetermined calibration curves, the conductivity
signal was converted into the ionic strength value of the applied salt. These 3rd
degree calibration curves were obtained due to reduction of high-salt (5.0M) to
low-salt (0.0M) condition in 5% steps.
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Determination of Melting and Aggregation Temperature
Melting and aggregation temperatures were determined using an Optim®2 system,
which combines intrinsic fluorescence and static light scattering measurements. This
device allows simultaneous analysis of the same low-volume sample in high-throughput
mode. Intrinsic tryptophan fluorescence is exploited to obtain information about
protein folding. The fluorescence spectra shift to red wavelengths due to a change in
the vicinity of the tryptophan residues from hydrophobic to hydrophilic environment
while protein unfolding. This label-free technique eliminates the possible influence of
extrinsic dyes on protein-protein interactions. The simultaneously measured static
light scattering evaluates the aggregation formation within the applied thermal shift.
Thermal stability was investigated using a temperature gradient from 20◦C to 90◦C
with a linear slope of 0.25K/min in the Optim®2 system. Measurements of 9µL
protein samples, pipetted into multi-cuvette arrays, were investigated in triplicates
using static light scattering at 473nm to determine aggregation temperatures. Fur-
ther, melting temperatures were determined by simultaneous measuring of intrinsic
fluorescence.
A.3. Results
A.3.1. Protein Phase Diagrams
Protein phase diagrams were established in microbatch format to obtain information
about protein phase behavior in dependence of pH value and precipitant ionic strength
at a constant protein concentration. This high-throughput approach provided a
versatile tool to screen protein phase behavior at low protein consumption.
Glucose isomerase phase behavior was investigated in a pH range of pH4.20 to
pH7.00 with the precipitants sodium sulfate, ammonium sulfate, sodium chloride,
and ammonium chloride in microbatch format.
10mg/mL glucose isomerase was soluble at low-salt (buffer without additional salt)
conditions with a pH value higher than pH4.45. At pH4.45 and below precipitation
occurred. For the investigated precipitants, phase transitions like precipitation,
crystallization, and skin formation were observed. The determined phase diagrams
are illustrated in Fig. A.2..
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Figure A.2.: Phase diagrams of 10mg/mL glucose isomerase for an ionic strength range of
0.00M to 4.00M of sodium sulfate (A), ammonium sulfate (B), sodium chloride (C), and
ammonium chloride (D) in the pH range of pH 4.20 to pH7.00. Four phase states for glucose
isomerase were observed: soluble, precipitate, crystal, skin. The dashed lines in the sodium
and ammonium chloride phase diagrams separates immediate and evolving precipitation zones.
Sodium Sulfate as Precipitant
For glucose isomerase with sodium sulfate as precipitant, phase transitions to precipi-
tation and crystallization occurred over the entire investigate pH range (Fig. A.2. (A)).
For and below pH4.96 precipitation occurred independent of ionic strength and addi-
tionally for pH 5.22 at the two highest ionic strength conditions (3.43M and 4.00M).
Crystallization occurred at 4.00M ionic strength for conditions above pH5.22 with an
exception at pH6.49. Crystallization was additionally observed for three conditions
(pH4.96 with 2.29M ; pH 5.22 with 2.86M or 3.43M) in the transition phase to
precipitation. These crystals partially co-existed with precipitation.
All ionic strength conditions below the mentioned crystallizing conditions, from and
above pH5.22, were soluble. Regarding the crystal structure at 4.00M ionic strength
it has to be noted that at higher pH values three-dimensional tetragonal crystal
formes were observed. Towards lower pH values (for example pH5.47) the crystals
were more elongated needles (Fig. A.3.).
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pH        5.22          5.47 5.73          5.98
(NH4)2SO4
Figure A.3.: Determined crystal size and form of 10mg/mL glucose isomerase at an ionic
strength of 4.00M sodium sulfate and ammonium sulfate in the pH range from pH5.22 to
pH5.98.
Ammonium Sulfate as Precipitant
For glucose isomerase with ammonium sulfate as precipitant phase transitions to
precipitation and crystallization occurred (Fig. A.2. (B)). Precipitation occurred at all
conditions at and below pH4.96 independent of ionic strength with two exceptions at
3.43M and 4.00M ionic strength for pH 4.96. For pH 5.22 and 2.86M ionic strength
an additional precipitated condition was observed. Crystallization was observed for
4.00M ionic strength in the pH range from pH4.96 to pH6.75 and for 3.43M ionic
strength up to pH6.24. In the transition phase from precipitation to crystallization,
co-existent precipitate and crystals were observed (pH4.71 at 4.00M ionic strength;
pH4.96 at 2.29M - 2.86M ionic strength; pH5.22 at 2.86M ionic strength). All
observed crystals were needle shaped. At lower pH value and higher ionic strengths
the extent of crystallization increased (Fig. A.3.).
Sodium Chloride as Precipitant
For glucose isomerase with sodium chloride as precipitant phase transitions to
precipitation and skin formation occurred at conditions with a pH value lower than
pH5.73 (Fig. A.2. (C)). At higher pH values all conditions were soluble. Precipitation
occurred for all conditions below pH5.47. The precipitation can be divided into two
zones of different kinetics. At precipitated conditions below pH4.96, precipitation
occurred immediately whereas the precipitation at higher pH values evolved over
time. Additional skin formation, which evolved over time, was observed for all
precipitated conditions with exception of the condition at pH5.22 and 0.57M ionic
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strength. Additionally, skin formation was observed for conditions at pH5.47 and
ionic strength higher than 0.57M although no precipitation was detected.
Ammonium Chloride as Precipitant
For glucose isomerase with ammonium chloride precipitation and skin formation
occurred over the entire investigated pH range (Fig A.2. (D)). A soluble region
occurred at low precipitant concentrations and high pH values. This region starts at
0.57M ionic strength for pH values above pH5.22 up to conditions below 2.86M
ionic strength for pH6.49 to pH7.00. The precipitation region at higher precipitant
concentrations and lower pH values can be divided in two zones of different kinetics.
At conditions below pH5.47 and 4.00M ionic strength immediate precipitation
occurred. At lower pH values lower ionic strength sufficed for immediate precipitate
formation. Between the immediately precipitated and soluble region, slowly evolving
precipitation occurred during the 40 days of incubation. At higher pH values and
lower ionic strengths precipitation kinetics decelerated. Skin formation evolved over
time at and above 0.57M ionic strength for precipitation conditions excluding the
conditions for each ionic strength at the respective highest pH value for 0.57M to
2.86M ionic strength.
A.3.2. Hydrophobic Interaction Chromatography Bind-Elute
Experiments
Hydrophobic interaction chromatography (HIC) bind-elute experiments of glucose
isomerase on a Toyopearl Butyl-650M adsorber were performed on an AEKTA™pu-
rifier system. The retention behavior was used as a degree of protein hydrophobicity.
In Fig. A.4. the corresponding ionic strengths to the retention volumes of the bind-
elute experiments are exemplarily shown at a binding ionic strength of 4.00M for
ammonium sulfate (black) and sodium sulfate (green) in dependence of the respective
pH value. For both salts, the retention volumes in dependence of pH value show the
same logarithmic progression, seeming to slowly converge to a threshold at higher
pH values. With increasing pH value the ionic strength of the retention volumes
increased, implying an earlier elution from the HIC column. For ammonium sulfate,
the elution ionic strengths were between 2.21M at pH5.47 and 2.66M at pH7.00.
The elution ionic strengths for experiments with sodium sulfate were generally lower
with the minimum of 2.20M at pH5.73 and the maximum of 2.49M at pH7.00.
Using sodium sulfate at pH5.47, glucose isomerase precipitated immediately in this
scale and thus no HIC experiment was possible. The bind-elute experiments at
varied binding ionic strengths (2.86M and 3.43M) showed the same progressions.
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For sodium chloride and ammonium chloride no binding of glucose isomerase to the
HIC column was feasible at the same ionic strengths.
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Figure A.4.: Hydrophobic interaction chromatography elution ionic strength (ISElution) of
glucose isomerase at 4.00M binding ionic strength (ISBinding) of sodium sulfate (green) and
ammonium sulfate (black) in dependence of the pH value.
A.3.3. Thermal Stability
For determining thermal stability of glucose isomerase, melting temperatures and
aggregation temperatures were measured using the Optim ®2 system.
Melting Temperature
Melting temperatures of glucose isomerase in dependence of salt type, salt ionic
strength and pH value are shown in Fig. A.5. The melting temperatures of 10mg/mL
glucose isomerase at low-salt conditions increased from 71.4◦C at pH5.47 to 84.9◦C
at pH 7.00. The melting temperatures with precipitant were generally lower regarding
the same pH value.
For sodium sulfate as precipitant, melting temperatures varied between 67.0◦C at
pH 5.47 and 78.9◦C at pH7.00 with an ionic strength of 2.29M (Fig. A.5. (A)). With
an increasing amount of sodium sulfate the melting temperatures are in a similar
range.
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Figure A.5.: Melting temperatures of 10mg/mL glucose isomerase in dependence of pH
value and ionic strength of sodium sulfate (A), ammonium sulfate (B), sodium chloride (C),
and ammonium chloride (D).
Using ammonium sulfate as precipitant (Fig. A.5. (B)), melting temperatures were
generally lower compared to results determined with precipitant sodium sulfate. At
an ammonium sulfate ionic strength of 2.29M the temperatures varied between
63.4◦C at pH5.47 and 74.6◦C at pH7.00. For 2.86M to 4.00M ionic strength of
ammonium sulfate, the temperatures stayed constant between ≈ 64.0◦C at pH5.47
and ≈ 70.0◦C at pH7.00.
For sodium chloride as precipitant (Fig. A.5. (C)), melting temperatures decrease
with increasing ionic strength. At pH7.00 the melting temperature decreased from
73.7◦C at an ionic strength of 2.29M to 65.5◦C at an ionic strength of 4.00M . The
same trend was observed at the other investigated pH values.
Using ammonium chloride as precipitant (Fig. A.5. (D)), the determined melting
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temperatures were lowest in comparison to the other applied precipitants with the
overall minimum of 51.7◦C at pH 5.47 and 3.43M ionic strength. As already noticed
for sodium chloride, the melting temperatures of glucose isomerase decreased with an
increasing ionic strength of ammonium chloride. At pH 7.00 the melting temperature
decreased from 68.5◦C at an ionic strength of 2.29M to 63.0◦C at 4.00M . The same
trend was observed at the other investigated pH values.
When comparing the melting temperatures at a constant ionic strength and different
pH values, the temperatures generally decreased with decreasing pH value. For
sodium sulfate and ammonium sulfate the differences in melting temperatures at
constant ionic strengths and varying pH values were much lower (≈∆ 10K) compared
to sodium chloride and ammonium chloride (≈∆ 20K).
Aggregation Temperature
In Fig. A.6. the aggregation temperatures of 10mg/mL glucose isomerase are shown
in dependence of ionic strength of the applied precipitants at varying pH values. At
low-salt conditions the aggregation temperatures were between 60.0◦C at pH7.00
and 39.2◦C at pH5.47. Adding salt to the protein solution generally decreased the
determined aggregation temperatures.
At an ionic strength of 2.29M sodium sulfate aggregation temperatures were between
45.3◦C at the highest pH values and 36.2◦C at pH5.47 (Fig. A.6. (A)). With an
increasing ionic strength aggregation temperatures increased approximately +3◦C.
Using ammonium sulfate as precipitant (Fig. A.6. (B)), aggregation temperatures
were lower compared to sodium sulfate as precipitant. At an ionic strength of 2.29M
ammonium sulfate the determined aggregation temperatures were around 38.0◦C at
all investigated pH values. With increasing ionic strength aggregation temperatures
increased up to 45.8◦C at pH7.00 at an ionic strength of 4.00M .
Aggregation temperatures of glucose isomerase with sodium chloride as precipitant
(Fig. A.6. (C)) were in a similar region as determined for the precipitants sodium and
ammonium sulfate. However, the progression of aggregation temperatures is different.
Starting at aggregation temperatures of 50.0◦C at an ionic strength of 2.29M at
pH7.00 the aggregation temperatures decreased to 44.1◦C at an ionic strength of
4.00M sodium chloride. The aggregation temperatures at lower pH values decreased
towards 35.7◦C at an ionic strength of 4.00M .
For ammonium chloride as precipitant large errorbars were observed (data not shown).
When comparing aggregation temperatures at different pH values and constant ionic
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strengths, aggregation temperatures decreased with decreasing pH value. The
observed difference was largest at low-salt conditions. By adding precipitant this
distinction reduced.
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Figure A.6.: Aggregation temperatures of 10mg/mL glucose isomerase in dependence of pH
value and ionic strength of sodium sulfate (A), ammonium sulfate (B), sodium chloride (C),
and ammonium chloride (D).
A.4. Discussion
A.4.1. Protein Phase Diagrams
In this paper a method to create protein phase diagrams with variation in pH value
and ionic strength at a constant protein concentration is presented. These microbatch
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experiments were realized in high-throughput as described earlier by Baumgartner
et al. [51]. The utilization of a multi-component buffer system, developed by Kröner
et al. [244], provides the possibility to manipulate pH linearly due to a constant
buffer capacity over the whole pH range. The desired pH value was maintained by
mixing different starting pH values in microbatch format. One protein phase diagram
consists of 96 different conditions with eight equidistant steps of ionic strength and
twelve equidistant pH steps at a constant protein concentration.
Phase Behavior of Glucose Isomerase
Glucose isomerase phase behavior at a concentration of 10mg/mL was investigated
in dependence of pH value and ionic strength. The pH value was varied between
pH4.20 and pH7.00. Precipitant ionic strengths of sodium sulfate, ammonium
sulfate, sodium chloride, and ammonium chloride were altered in an range of 0.00M
to 4.00M .
An influence of ionic strength on protein phase transitions was found for all in-
vestigated precipitants. For sodium sulfate and ammonium sulfate, precipitation
and crystallization zones were observed. Precipitation was observed at lower pH
values close to the isoelectric point (pI) and crystallization at higher pH values and
high ionic strengths. The crystallization zones were found for sodium sulfate and
ammonium sulfate at pH values from and above pH 4.96 and pH4.71, respectively. In
the transition zone from precipitation to crystallization both phase states co-existed.
Although the crystallization zone for ammonium sulfate was larger compared to
sodium sulfate, the crystal yield was higher for sodium sulfate. Here, at 4.00M ionic
strength three-dimensionally shaped crystals developed whereas for ammonium sul-
fate needle-shaped crystals were found. The formation of three-dimensional crystals
requires a larger number of specific binding sites on the protein surface compared
to two-dimensional needle-shaped crystals [245]. Due to shielding of long-range
electrostatic forces at high-salt conditions it is assumed that short-range forces on
protein surface provoke protein-protein attractive interactions, possibly resulting in
crystallization. These short-range interactions like van-der-Waals or hydrophobic
interactions contribute to protein crystal stability and formation [245–247]. These
short-range interactions have to be higher for sodium sulfate compared to ammonium
sulfate. Additionally, the nucleation onset of glucose isomerase was observed much
earlier for conditions with sodium sulfate compared to ammonium sulfate.
Further, the pH value had an additional influence on crystal form and size. For
sodium sulfate, needle-shaped crystals were found close to the precipitation zone
at pH5.47, whereas three-dimensional crystals were observed at higher pH values.
Altering the pH value, salt bridges and hydrogen bonds as well as hydration of
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protein are influenced [248]. At lower pH values, close to the pI, glucose isomerase
has a lower number of surface charges. This was verified using PDB structure 3kbs
using the molecular dynamics simulation tool Yasara (YASARA Biosciences) (data
not shown). Resulting, glucose isomerase is less hydrated and attractive hydrophobic
forces are higher. Due to this fact faster crystal nucleation and growth leads to
many small needle-shaped crystals. In the precipitation zone attractive forces are too
high for protein molecules to form structured crystal lattices [249]. For ammonium
sulfate as precipitant the extent of crystallization is higher, whereas crystal size is
smaller at lower pH values. This can be attributed to higher attractive forces close
to the pI. In summary, sodium sulfate had a stronger tendency to induce short-range
protein-protein interactions for glucose isomerase, enhancing crystallization, at the
investigated pH range from pH4.20 to pH7.00, when compared to ammonium sulfate.
This is consistent with findings for lysozyme from Lin et al. [250].
The phase behavior of glucose isomerase with sodium chloride or ammonium chloride
as precipitant, phase transition to precipitation and skin formation occurred. For
sodium chloride, no significant influence of ionic strength on precipitation and skin
formation was noted. For ammonium chloride, higher ionic strengths led to a broader
precipitated area at higher pH values. It can be concluded that ammonium chloride
had a more destabilizing effect on glucose isomerase phase behavior compared to
sodium chloride.
The impact of pH on phase behavior was clearly distinguishable for sodium chloride
and ammonium chloride as precipitants. At low pH values close to the isoelectric
point of glucose isomerase precipitation and skin formation was observed for both
precipitants. Skin formation is believed to be attributed to protein denaturation [73,
75] and therefore lower conformational stability. For glucose isomerase, higher pH
values, implying more charges on the protein surface, resulted in more stable solutions.
Ammonium chloride destabilized glucose isomerase more strongly compared to sodium
chloride.
The impact on glucose isomerase phase behavior was found to be mainly dependent on
the anion [67, 251]. Larger precipitation zones were found for salts containing chloride
than for sulfate. Additionally, skin formation and thereby protein denaturation can
be attributed to chloride. Sulfate led to crystallization for both investigated salts.
The impact of the cations sodium and ammonium was not as distinctively as of the
anions. The ammonium cation was found to obtain a more chaotropic character
compared to sodium.
155
Prediction of Salt Effects on Protein Phase Behavior
A.4.2. Hydrophobic Interaction Chromatography
In this study, retention volumes in hydrophobic interaction chromatography (HIC)
were examined to describe protein hydrophobic properties [235] as a component of
the short-range interactions mentioned in A.4.1. Due to high ionic strengths used
at binding to the adsorber, it can be assumed that electrostatic interactions are
shielded and predominantly hydrophobic interactions are decisive. Generally, in
HIC lower ionic strengths at elution imply stronger binding to the HIC adsorber.
Therefore, lower elution ionic strengths, as determined for sodium sulfate compared to
ammonium sulfate, imply stronger hydrophobic interactions of glucose isomerase with
the adsorber using sodium sulfate. This observation is compliant with findings made
by Lin et al. [250], who found sodium sulfate to enhance hydrophobic interactions
of lysozyme stronger compared to ammonium sulfate. For sodium chloride and
ammonium chloride, no HIC retention experiments were possible under the given
conditions. The applied ionic strengths at binding were too low to achieve binding of
glucose isomerase to the adsorber. Hence, it was observed that sulfate ions increased
hydrophobicity of glucose isomerase more strongly in comparison to chloride ions.
This is in accordance with literature [67], where it has been recorded that anions
have the main influence on binding in HIC.
The elution ionic strengths of glucose isomerase were lower at lower pH values. This
observation can be explained by the proximity to the isoelectric point of glucose
isomerase (pI: 4.78). At the isoelectric point protein surface net charge is zero. But
also the total amount of surface charges is smaller compared to conditions at higher
pH values for glucose isomerase (A.4.1). This weakens the hydration shell and
thus, hydrophobic interactions are strengthened. Therefore, elution ionic strengths
decrease rapidly with the proximity to the pI. At pH values towards pH 7.00 retention
volumes only change slightly. This behavior can be explained by the titration curve.
Above the pI, total amount of surface charges decreases rapidly close to the pI,
whereas further away the total amount of surface charges approaches a threshold.
Concluding, the pH value has a big influence on protein hydrophobicity. The degree
of hydrophobic interactions increase with decreasing distance to the isoelectric point.
This observation also correlates with the observations made by Baumann et al. [252].
Baumann et al. found that binding at pH values close to the proteins’ pI increased the
binding behavior in HIC.The progression of elution ionic strengths of sodium sulfate
and ammonium sulfate are similar in dependence of pH value. The small vertical shift
of the two curves can be attributed to the different cations sodium and ammonium.
Retention times in HIC were used to describe protein hydrophobic properties. These
relative hydrophobicities directly correlate with crystal size and form, determined
by the phase diagrams. The yield of protein crystallization was higher for sodium
sulfate compared to ammonium sulfate. Additionally, three-dimensional crystals
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were found for sodium sulfate implying more specific binding sites. When comparing
these two salts at the same pH value, enhanced hydrophobic interactions led to three-
dimensionally shaped crystals whereas reduced hydrophobic interactions resulted
in two-dimensional crystals. Regarding the pH value, crystal size decreased with
decreasing distance to the pI. Here, hydrophobicity is significantly higher, leading to
faster crystallization kinetics. The fast kinetics hinders the formation of complex
large crystals [245]. The HIC results indicate that hydrophobic interactions can
directly be correlated to crystal complexity.
A.4.3. Melting Temperature
In this study, melting temperatures were examined to correlate protein thermal
stability to protein phase behavior and bind-elute experiments on hydrophobic
interaction chromatography. Glucose isomerase was investigated at low-salt (buffer
without additional salt) and high-salt (2.29 - 4.00M ionic strength) conditions of
sodium sulfate, ammonium sulfate, sodium chloride and ammonium chloride. The
higher melting temperatures at low-salt conditions for all tested pH values compared
to high-salt conditions indicate a higher stability of glucose isomerase. Salt ions
influence the protein hydration, which was earlier described as preferential interaction
theory [63, 236]. Preferential interaction of ions with the protein weakens protein
hydration whereas preferential exclusion sustains hydration and is believed to stabilize
the protein in solution [237]. The observed decrease in melting temperature for glucose
isomerase indicates a weakening of the protein hydration in the investigated ionic
strength range for the analyzed salt types. This observation is in accordance to the
preferential interaction theory that all investigated salts should exhibit preferential
interaction with the protein, thus destabilizing the native protein conformation and
decreasing protein thermal stability [253–256]. The above-mentioned observations
are in concert with the observed phase behavior of glucose isomerase. The solubility
of glucose isomerase decreased with increasing salt ionic strength. This behavior was
mainly noticeable at pH values close to the isoelectric point where the precipitation
zone enlarged with addition of salt. Different salt type specific influences on melting
temperatures were observed. When comparing the melting temperatures an order
of ammonium chloride < sodium chloride < ammonium sulfate < sodium sulfate
was found, where ammonium chloride shows the most destabilizing properties and
sodium sulfate the most stabilizing. Dupeux et al. [257] correlated thermal stability
to higher crystallization success rates. This is in agreement with the generated data
presented in this manuscript. Higher glucose isomerase melting temperatures were
observed for experiments using sodium sulfate and ammonium sulfate whilst leading
to crystallization as determined with the phase diagrams. The order of melting
temperatures corresponds to protein solubility and stability behavior observed with
the phase diagrams.
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When comparing the cations sodium and ammonium, higher melting temperatures
were found for sodium. Thus, sodium stabilizes glucose isomerase more strongly
compared to ammonium. This can be correlated to glucose isomerase solubility and
stability phase behavior. For salts with sulfate as anion, sodium leads to bigger
crystals compared to ammonium. Hence, the solubility of glucose isomerase is higher
in the crystallization zone for ammonium sulfate compared to sodium sulfate. This
is in concert with ammonium being a weakly hydrated chaotropic agent [251] known
to increase solubility.
For salts with chloride as anion, sodium shows a smaller precipitation area with skin
formation compared to ammonium. Ammonium interacts more strongly with the
protein inducing destabilization of the native conformation which can be observed
by reduced thermal stability and macroscopically as skin formation [258].
The determined results imply higher stabilizing effects for sodium when compared
to ammonium which is in agreement with findings from Collins [251]. Sodium is a
strongly hydrated ion with kosmotropic properties, whereas ammonium is a weakly
hydrated ion with chaotropic properties.
When comparing the anions sulfate and chloride, higher melting temperatures were
observed for sulfate compared to chloride. Thus, sulfate stabilizes glucose isomerase
more strongly compared to chloride. This is in concert with findings from Arakawa
and Timasheff [259] that for sulfate preferential exclusion is higher compared to
chloride.
Melting temperatures were successfully correlated to glucose isomerase stability.
Sulfate is more stabilizing, leading to crystallization in combination with both inves-
tigated cations sodium and ammonium. In contrast, chloride is more destabilizing,
inducing larger precipitation zones and skin formation. Regarding the preferential
interaction theory, chloride preferentially interacts with the protein and leads to
protein destabilization and consequently to lower thermal stability.
Regarding the pH value, with decreasing distance to the proteins’ isoelectric point
the melting temperatures decreased for all investigated salt ionic strengths. The
number of protein surface charges of glucose isomerase decreases with decreasing
distance to its pI (A.4.1). Therefore, stabilizing electrostatic interactions between
proteins and water molecules are reduced. Hence, the hydration shell around the
protein is weakend and the native protein conformation is perturbed leading to lower
thermal stability as was found for all ionic strengths. This is also in agreement with
the determined macroscopic phase behavior of glucose isomerase.
It can be concluded that the anions and cations have a distinct impact on protein
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solubility and stability as investigated using melting temperature. Those findings
could successfully be correlated to protein phase behavior. Anions were found to
have a stronger effect on protein solubility and stability compared to cations which
is in agreement with literature [67, 251, 259]. Concluding from that, this is a
comparatively fast method to evaluate protein solubility and stability. Distinctions
between native (crystal, soluble, precipitate) and non-native (skin formation) phase
behavior can be made. Thus, melting temperatures can help to assess estimations
for protein phase behavior.
A.4.4. Aggregation Temperature
The thermal aggregation temperatures were examined to study glucose isomerase
stability. Low-salt and high-salt (2.29M - 4.00M ionic strength) conditions of
sodium sulfate, ammonium sulfate, sodium chloride, and ammonium chloride were
investigated for glucose isomerase using the Optim®2. The resolution limit of this
method was found to be around 36◦C resulting in problems to discriminate conditions
close to the isoelectric point of glucose isomerase.
The higher aggregation temperatures at low-salt conditions for all tested pH values
compared to high-salt conditions indicate a higher colloidal stability of glucose
isomerase. This is in concert with the results for the melting temperatures. Glucose
isomerase thermal stability is reduced by the addition of the investigated salts in the
given ionic strength and pH range.
The comparison of the cations sodium and ammonium, only possible for sulfate as
anion, shows higher aggregation temperatures for sodium compared to ammonium.
Thus, sodium cations stabilize glucose isomerase more strongly compared to ammo-
nium cations. This is in accordance to findings for melting temperature and glucose
isomerase phase behavior. Sodium, having a kosmotropic character, stabilizes glucose
isomerase more and leads to bigger crystals, whereas ammonium is chaotropic and
reduces crystal size.
The comparison of the anions sulfate and chloride, only possible for sodium as cation,
shows higher aggregation temperatures for sulfate. Thus, sulfate stabilized glucose
isomerase more strongly compared to chloride. This in concert with findings for
melting temperatures and glucose isomerase phase behavior.
The results for ammonium chloride showed large standard deviations for repeated
measurements indicating the existence of light scattering aggregates at the starting
conditions (data not shown). The results for ammonium chloride are in accordance
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with the observation concerning glucose isomerase phase behavior where ammo-
nium chloride led to evolving precipitation and skin formation in the investigated
ionic strength and pH range. Here, thermal aggregation temperatures support the
statements made by the evaluation of the melting temperatures.
A.5. Conclusions and Outlook
The present work shows that protein hydrophobicity and thermal stability measure-
ments can be used as tools for estimating protein stability. Protein phase behavior
was determined using a high-throughput methodology for generation of protein
phase diagrams. Protein phase behavior was investigated at a constant protein
concentration in dependence of precipitant ionic strength and pH value. Using for
different salt types, the influence of two anions and two cations on glucose isomerase
phase behavior was investigated. The results confirmed findings from literature [67,
251, 259], that anions influence protein phase behavior more strongly compared to
cations. Using hydrophobic interaction chromatography (HIC) and thermal stability
measurements, initially and completely soluble conditions were investigated.
Using retention behavior in HIC a deeper understanding of hydrophobic forces in
protein-protein interaction was generated. The differences in crystal form and size,
using sodium sulfate and ammonium sulfate, can be described by protein surface
hydrophobicity and thus estimated by HIC.
Melting temperatures and aggregation temperatures were measured to characterize
glucose isomerase thermal stability. Sulfate was found to have a less destabilizing effect
on glucose isomerase compared to chloride regarding conformational and colloidal
stability. Thermal stability measurements can be used to distinguish between native
(crystal, soluble, precipitate) and non-native (skin formation) phase behavior.
Using HIC experiments and thermal stability measurements, glucose isomerase
stability can be estimated in relation to variations of parameter settings. The
observed correlations should be verified for other biomolecules and variations of
parameters.
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Abstract
Fourier-Transform Infrared Spectroscopy (FTIR) is a well-established spectroscopic
method in the analysis of small molecules and protein secondary structure. However,
FTIR is not commonly applied for in-line monitoring of protein chromatography.
Here, the potential of in-line FTIR as a Process Analytical Technology (PAT) in
downstream processing was investigated in three case studies addressing the limits
of currently applied spectroscopic PAT methods. A first case study exploited the
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secondary structural differences of monoclonal antibodies (mAbs) and lysozyme to
selectively quantify the two proteins with Partial Least Squares Regression (PLS)
giving Root Mean Square Errors of Cross Validation (RMSECV) of 2.42 g/L and
1.67 g/L, respectively. The corresponding Q2 values are 0.92, 0.93 and, respectively,
0.99, indicating robust models in the calibration range. Second, a process separating
lysozyme and PEGylated lysozyme species was monitored giving an estimate of
the PEGylation degree of currently eluting species with RMSECV of 2.35 g/L for
lysozyme and 1.24 g/L for PEG with Q2 of 0.96 and 0.94, respectively. Finally,
Triton X-100 was added to a feed of lysozyme as a typical process-related impurity.
It was shown that the species could be selectively quantified from the FTIR 3D
field without PLS calibration. In summary, the proposed PAT tool has the potential
to be used as a versatile option for monitoring protein chromatography. It may
help to achieve a more complete implementation of the PAT initiative by mitigating
limitations of currently used techniques.
B.1. Introduction
Preparative chromatography of biopharmaceuticals is typically monitored by mea-
suring univariate signals such as pH, conductivity, pressure, and UV/Vis absorbance
at a given wavelength [214, 227]. Among these, especially single-wavelength UV/Vis
spectroscopy has been a staple for process monitoring of biopharmaceutical chro-
matography due to its linear response to protein concentration as well as its broad
dynamic range, sensitivity, and robustness. In spite of advantages, single-wavelength
UV/Vis absorption measurements generally do not allow for selective quantification
of multiple co-eluting proteins [260].
Even before the PAT initiative by the FDA in 2004 [261], research towards more
selective monitoring methods for preparative chromatography was conducted. But
the often small differences between biopharmaceutical product and protein as well as
non-protein contaminants make this a nontrivial task [34, 262]. As a possible solution,
fast at- or on-line analytical methods, such as analytical chromatography, have been
established. Discrete samples are taken from the process stream and analyzed on
the spot. This approach has been proposed for controlling capture [263–265] and
polishing steps [266, 267]. However, at- or on-line analytical chromatography is
complex in terms of equipment requiring a sampling module as well as an analytical
chromatography system close to the process stream. Furthermore, the sampling
and analysis time may be too long compared to the typical time frame available for
taking process decisions.
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An alternative approach exploits slight differences in UV/Vis absorption spectra of
different components to selectively quantify different species by chemometric methods
[34]. The approach yields results quickly enough to allow for real-time process
decisions in chromatography [268–270] and works for minute spectral differences
[271]. However, in the commonly measured spectral ranges, UV/Vis spectroscopy
lacks sensitivity towards relevant aspects of protein structure, notably the secondary
structure [140]. Furthermore, organic compounds are often not UV-active (e.g. sugars,
polyols, and Polyethylene Glycol (PEG) [272, 273]) or they may obscure the protein
signal (e.g. Triton X-100 [274] and benzyl alcohol [140]). Due to the high sensitivity,
UV/Vis absorption spectroscopy is also prone to detector saturation [34, 275].
FTIR allows to address several of these short-comings. Like UV/Vis spectroscopy,
FTIR is a non-destructive, quantitative, and quick method which can be performed
in-line [228–230]. FTIR measures the vibrational modes of samples and thereby
provides a spectroscopic fingerprint for different organic molecules. Proteins absorb
in the IR spectral range mainly due to vibrations of the polypeptide backbone [140,
231, 232]. Based on the backbone vibrations, FTIR grants insight into the secondary
structure of the measured proteins. In consequence, FTIR is a widely used method
for assessing the structural integrity of proteins during protein purification and
formulation [140]. Furthermore, FTIR was previously used as an at-line PAT tool in
downstream processing of biopharmaceuticals for quantifying product content, High
Molecular Weight species (HMW), and Host Cell Proteins (HCP) [276, 277].
In this work, in-line FTIR as a PAT tool for preparative protein purification was
implemented. An FTIR instrument was coupled to a lab-scale preparative chro-
matography system to perform the experiments. Three case studies were selected
to investigate potential applications of FTIR as a PAT tool. First, a mixture of
lysozyme and mAb was chosen due to the significant differences in secondary struc-
ture of the two proteins. While lysozyme mainly consists of alpha-helices (PDB ID
193L), mAb largely consists of beta-sheets (PDB ID 1HZH). The expected spectral
differences can be used to selectively quantify the two proteins by PLS regression.
Four linear-gradient elutions with varying gradient lengths were performed. Based on
the results, a PLS model for each protein was optimized. The error of the PLS model
was assessed by cross validation. Second, the preparative separation of PEGylated
lysozyme was monitored. In contrast to UV/Vis spectroscopy, PEG gives a distinct
signal in IR which can be used for quantification by PLS regression. Again, four linear
gradient elutions were performed for the calibration of two PLS models. Finally, the
potential to monitor process-related impurities using in-line FTIR was demonstrated
by adding Triton X-100 to a feed solution of lysozyme. Triton X-100 is employed for
virus inactivation in biopharmaceutical production and has to be removed from the
product [274, 278]. Based on an off-line calibration curve, mass-balancing of Triton
X-100 in the flow-through during product loading was performed.
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B.2. Materials and Methods
B.2.1. Experimental Setup
In-line FTIR measurements were performed using a Tensor 27 by Bruker Optics
(Ettlingen, Germany) connected to an ÄKTApurifier system by GE Healthcare (Little
Chalfort, UK). The chromatography system was equipped with a P-900 pump, a
P-960 sample pump, UV-900 UV/Vis cell, and a Frac-950 fraction collector (all
GE Healthcare). Unicorn 5.31 (GE Healthcare) was used to control the system.
The FTIR was equipped with a liquid nitrogen-cooled Mercury Cadmium Telluride
(MCT) detector and a BioATR II (Bruker Optics) with a flow-cell insert and a
seven-reflections silicon crystal. The instrument was controlled by OPUS 7.2 (Bruker
Optics).
In this setup, the eﬄuent stream from the column outlet was diverted through the
FTIR instrument and then back into the UV/Vis cell in the ÄKTApurifier system.
The flowpath is illustrated in Fig. B.1.. The delay volume between the FTIR and
the fraction collector was determined gravimetrically. As the flow rate was set in
the chromatographic methods, the measurement of the delay volume enables the
correlation of spectral data from the FTIR to collected fractions.
The interconnection between OPUS and Unicorn was achieved using a software
solution developed in-house consisting of a Matlab (The Mathworks, Natrick, MA,
United States) script and a VBScript in the built-in visual basic script engine of
OPUS. The custom software enables start of a measurement at a time defined
by Unicorn by sending a digital signal through the I/O port of the pump of the
ÄKTApurifier System. The signal is captured by a USB-6008 data acquisition device
(National Instruments, Austin, Tx, United States) controlled by Matlab which in
turn triggers the measurement in OPUS.
166
B.2. Materials and Methods
Buffer
source
Injection
Volume
Column UV/Visdetector
FTIR Fractioncollector
Figure B.1.: Schematic representation of the flow path in the custom chromatography setup,
solid lines represent the common flow path in the ÄKTApurifier while the dashed line represents
the modification.
B.2.2. Proteins and Buffers
All solutions were prepared using water purified by a PURELAB Ultra water purifi-
cation system by ELGA Labwater (High Wycombe, United Kingdom). Buffers were
filtered using a 0.2µm filter purchased from Sartorius (Göttingen, Germany) and
degassed by sonification before use. All buffers were pH-adjusted using 32% HCl
(Merck, Darmstadt, Germany).
Lysozyme was purchased from Hampton Research (Aliso Viejo, CA, United States).
mAb was provided by Lek Pharmaceuticals d.d. (Mengeš, Slovenia) as a virus-
inactivated Protein A eluate pool.
Preparative CEX chromatography runs in case studies I and III were conducted with
a 50mM sodium citrate buffer as equilibration buffer and with an added 500mM
NaCl as elution buffer. Both buffers were adjusted to pH 6.0. Sodium citrate tribasic
dihydrate was purchased from Sigma-Aldrich (St. Louis, MO, United States), sodium
chloride was purchased from Merck. For the CEX chromatography experiments in
case study II, a 25 mM sodium acetate buffer (pH 5.0) was used as equilibration
buffer. As elution buffer, a 25mM sodium acetate buffer with 1M NaCl (pH 5.0)
was used. Sodium acetate trihydrate was purchased from Sigma-Aldrich. Batch-
PEGylation of lysozyme was performed in a 25mM sodium phosphate buffer at
pH 7.2 using sodium phosphate monobasic dihydrate (Sigma-Aldrich) and di-sodium
hydrogen phosphate dihydrate (Merck).
Analytical cation-exchange chromatography was carried out at pH 8.0 using a 20mM
Tris (Merck) buffer for equilibration and a 20mM Tris buffer with 700mM NaCl
for elution.
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PEGylation of Lysozyme
The PEGylation protocol was adapted from [279]. Briefly, activated 5 kDA PEG was
purchased as Methoxy-PEG-propionaldehyde (mPEG-aldehyde, Sunbright ME-050
AL) from NOF Corporation (Tokyo, Japan). Sodium cyanoborohydride (NaCNBH3,
Sigma Aldrich) was added to the reaction buffer to a concentration of 20mM as
reducing agent. mPEG-aldehyde was added to a molar PEG-to-protein ratio of
6.67. After 3h, the mixture was diluted volumetrically 7-fold using the acetate
equilibration buffer and loaded onto the chromatography column.
B.2.3. Preparative Chromatography Experiments
For all chromatography experiments, FTIR spectra were recorded continuously in
the chromatography mode of OPUS with a resolution of 2 cm−1 in a range from 4000-
900 cm−1 without averaging multiple scans. In the given setup, each measurement
took 3.22 s. Background measurements at the beginning of chromatographic runs were
taken at the same resolution with 400 scans in equilibration buffer. All experiments
were conducted twice, once with protein injection and once with buffer only as a
blank run. The FTIR spectra from the blank runs were subsequently subtracted
from the protein runs to account for spectral effects by the gradient.
Case Study I: Selective Protein Quantification
For case study I, a HiTrap column by GE Healthcare prepacked with SP Sepharose
FF resin (Column Volume (CV) 5mL) was used. The column was loaded to a density
of 18.75 g/L, consisting of 12.5 g/L lysozyme and 6.25 g/L monoclonal antibody. The
flow rate for all experiments was set to 0.5mL/min. The column was equilibrated in
a low-salt buffer for 5CV before injection. The 50mL sample was injected using a
50mL superloop from GE Healthcare. Elution was carried out with a linear gradient
from 0-100% high-salt buffer with gradient lengths of 1CV , 2CV , 3CV , 4CV .
After elution, a high-salt wash of 8CV was performed for column regeneration. The
eﬄuent was collected over the complete injection and elution in 500µL fractions for
oﬄine analytics.
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Case Study II: Separation of PEGylated Lysozyme Species
The experiments with different PEGylated lysozyme species were conducted with
Toyopearl Gigacap S-650M resin prepacked in a MiniChrom column (CV 5mL) by
Tosoh (Griesheim, Germany). The column was loaded to a density of 50 g/L of
the heterogeneous batch PEGylation. The sample pump was run at 1mL/min for
loading. For the remaining chromatography run, the flow rate was set to 0.5mL/min.
The column was first equilibrated for 1CV , followed by an injection of 57.6CV
of sample solution. Linear-gradient elutions from 0-100% high-salt buffer were
conducted with gradients of 2CV , 3CV , 4CV , 5CV length, followed by a 2CV
high-salt rinse. The eﬄuent was collected from the beginning of the gradient until
the end of the high-salt rinse in 500µL fractions for oﬄine analytics.
In some of the collected fractions, unconjugated lysozyme started to precipitate after
elution probably due to the low pH, high salt concentration or low temperature [51,
279]. Fractions and the corresponding spectra showing signs of precipitation were
excluded from PLS model calibration.
Case Study III: Process-related Impurity
For the simulated process-related impurity experiments, a HiTrap column by GE
Healthcare prepacked with SP Sepharose FF resin (CV 5mL) was used. Triton
X-100 Biochemica was purchased from AppliChem GmbH (Darmstadt, Germany).
The column was loaded with 5mL of 25 g/L lysozyme and 10 g/L Triton X-100
solution [278]. The elution step was set to 2CV .
Reference samples were generated by diluting defined amounts of Triton X-100
in equilibration buffer at concentrations from 1.25 g/L to 10 g/L. To generate a
calibration curve, the samples were manually applied onto the ATR crystal. FTIR
measurements were performed with 400 scans for background and samples.
B.2.4. Analytical CEX Chromatography
As reference analytics for case study I, analytical CEX chromatography was performed
using a Dionex UltiMate 3000 liquid chromatography system by Thermo Fisher
Scientific (Waltham, MA, United States). The system was composed of a HPG-
3400RS pump, a WPS-3000TFC analytical autosampler, a TCC-3000RS column
thermostat, and a DAD3000RS detector. The system was controlled by Chromeleon
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6.80 (Thermo Fisher Scientific). Fractions from preparative CEX chromatography
were analyzed off-line on a Proswift SCX-1S 4.6x50mm column by Thermo Fisher
Scientific. A flow rate of 1.5mL/min was used. For each sample, the column was
first equilibrated for 1.8min with equilibration buffer. Next, 20µL sample was
injected into the system and washed for 0.5min with equilibration buffer. A linear
gradient was performed during the next 2min from 0-50% followed by a step to
100% elution buffer which was maintained for 2min.
For the experiments in case study II, a Vanquish UHPLC system (Thermo Fisher
Scientific) was used. The Vanquish UHPLC System consisted of a Diode Array
Detector HL, a Split Sampler FT, a Binary Pump F, and a Column Compartment
H including a preheater and post-column cooler (all Thermo Fisher Scientific). The
same buffers, column, and flow rate were used as for case study I. After injecting 5µL
of sample, the column was washed for 0.5min. Subsequently, a bilinear gradient was
performed from 0-50% elution buffer over 5min and 50-100% elution buffer over
1.75min. After the elution, a high-salt strip at 100% was run for 1min. Calibration
was performed by a dilution series of pure lysozyme. Since PEG does not absorb in
UV/Vis, solely lysozyme contributes to the absorption signal. Peak identification
with respect to the PEGylation degree was conducted using purified samples prepared
according to [273]. From the molar concentration of PEGylated lysozyme species,
the molar concentration of PEG was calculated.
B.2.5. Data analysis
All data analysis was performed in Matlab. For case studies I and II, the data
was first preprocessed and subsequently fitted with PLS-1 models by the SIMPLS
algorithm [280]. Preprocessing consisted of linearly interpolating off-line analytics to
be on the same time scale as the FTIR spectra. For case studies I and II, spectral
data above 2000 cm−1 resp. above 3100 cm−1 was discarded. Next, a Savitzky-Golay
filter with a second-order polynomial was applied on the spectra and optionally,
the first or second derivative was taken [281]. Cross-validation was performed by
excluding one chromatography run, calibrating a PLS model on the remaining runs,
and calculating a residual sum of squares on the excluded run. This procedure was
repeated until all runs had been excluded once. All residual sums of squares for
the different submodels were subsequently summed yielding the Predictive Residual
Sum of Squares (PRESS). The PRESS was scaled according to Wold et al. by the
number of samples and latent variables used in the PLS model [282]. Based on the
scaled PRESS, an optimization was performed using the built-in genetic algorithm
of Matlab for integers [283]. The genetic algorithm optimized the window width of
the Savitzky-Golay filter, the order of derivative, as well as the number of latent
variables for the PLS-1 model. The RMSECV was calculated from the PRESS by
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dividing by the total number of samples. The Q2 values were calculated by dividing
the PRESS by the summed squares of the response corrected to the mean [282].
For case study III, spectral data was smoothed both in direction of time and
wavenumber using a Savitzky-Golay filter with a second-order polynomial and a
frame length of 17 and 51, respectively. A linear baseline was calculated and
subtracted for each spectrum individually to account for a non-horizontal non-zero
baseline. The baseline subtraction was performed on the reference spectra as well as
on the spectra from the chromatography experiment. Based on the area under the
spectrum between wavenumbers 1007-1170 cm−1, a mass balance for Triton X-100 was
calculated from the spectral data of the chromatography run. The volume represented
by each spectrum was calculated from the recording time and the volumetric flow
rate of the experiment. Triton X-100 masses in each segment were calculated utilizing
the calibration curve and summed up over time.
B.3. Results and Discussion
In-line FTIR measurements were applied as a PAT tool for different preparative
chromatographic protein separations. In three different case studies, FTIR was used
for selective quantification of different species. First, background correction of the
FTIR chromatograms is discussed which was necessary for further data processing.
In a first case study, the capability of FTIR to measure differences in secondary
structure in-line and utilize the differences for selective quantification of mAb and
lysozyme was demonstrated. A second case study made use of the absorption of
PEG in IR to monitor the PEGylation degree of eluting PEGylated lysozyme species.
Finally, the third case study used the selectivity of FTIR to selectively quantify
Triton-X 100, a detergent used for viral inactivation.
B.3.1. Background Subtraction and Spectral Preprocessing
Background subtraction for in-line FTIR measurements is of major importance as
water has an absorption band around 1600 cm−1 (Fig. B.2. (A)) which coincides
with the most prominent protein band amide I. The spectral processing workflow is
illustrated in Fig. B.2. using data from case study I. Specifically the elution of mAb
and lysozyme using a 4CV gradient is shown. Most of the water absorption can be
eliminated by taking a background with the equilibration buffer at the beginning of
each chromatographic run. The water band is, however, also influenced by the salt
content of the buffer around 1650 cm−1. Salt gradients therefore cause a change in
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absorption over the run (Fig. B.2. (A), (B)). To reduce buffer effects, it is important
to find a suitable dynamic background correction. An approach based on reference
spectra matrices and chemometric correlations was not implemented due to the
overlap of water and protein bands [284]. Instead, an alternative approach was
chosen. Based on the retention time, a blank run without protein but including
the salt gradient was subtracted from the actual preparative run (Fig. B.2. (C)).
The resulting chromatogram provided a smooth baseline over the whole experiment.
After baseline correction, additional data preprocessing was performed. The single
scan spectra were smoothed by a Savitzky-Golay filter to reduce random noise
(Fig. B.2. (D)) and to take derivatives on the spectral data.
water band
protein bands
water band due to changing 
salt concentration
Figure B.2.: Work flow for data treatment of chromatography spectra illustrated with data
from case study I, 4CV run: background run – salt gradient without protein (A); raw spectra
of the run with protein (B); spectral data after the background has been subtracted (C); data
after smoothing by Savitzky-Golay algorithm (D).
B.3.2. Case Study I: Selective Protein Quantification
mAb and lysozyme feature significant differences in secondary structure. While
mAb consists largely of beta-sheets (PDB ID 1HZH), lysozyme mainly contains
alpha-helices (PDB ID 193L). These differences make the two proteins simple model
components to study the performance of in-line FTIR for selectively quantifying
proteins. The bands visible between 1200 cm−1 and 1700 cm−1 in Fig. B.2. (D) are
characteristic amide bands associated with the protein backbone [140, 231, 232].
Especially the amide I band is frequently used for assessing the secondary structure
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of proteins. For PLS calibration, all wavenumbers below 2000 cm−1 were taken into
account to include all protein bands without interference at the boundary due to the
Savitzky-Golay filter.
Based on four CEX runs, two PLS-1 models were optimized for selective quantification
of mAb and lysozyme, respectively. The resulting model parameters are listed in
Tab. B.1. Fig. B.3. shows a comparison from off-line analytics and the prediction
of PLS models. Both PLS models match peak maxima and peak widths well and
are able to discern the two components. For mAb, a root-mean-square error of
cross validation (RMSECV) of 2.42 g/L was reached. For lysozyme, the RMSECV
was 1.67 g/L. The corresponding Q2 values were 0.92 and 0.99, respectively. The
high Q2 values show, that a large part of the variation in the off-line concentration
measurements could be explained by the PLS model. The differentiation between
different proteins may however become more challenging for smaller differences
in secondary structure. Interestingly, the combination of Savitzky-Golay filtering
and PLS modeling allowed to reduce the measurement noise compared to single-
wavelength measurements. As shown by Fig. B.2. (C) and Fig. B.3., the measurement
noise in the IR spectra is higher than the noise observed in the PLS prediction. By
filtering and projecting the spectra to latent variables, random noise is reduced [281,
282]. Furthermore, 3.23 smeasurement time makes FTIR quick enough for monitoring
most practical preparative chromatography applications in real-time. In-line FTIR
spectroscopy allowed to cover high concentration ranges. The predicted concentration
of lysozyme during the 1CV run reaches 112 g/L without any interference from
detector saturation. The measurement setup therefore covers all concentrations
typically occurring in preparative protein chromatography.
In summary, the results show that FTIR in conjunction with PLS modeling can
differentiate in-line between proteins based on their secondary structure and has
the potential to be applied for real-time monitoring and control of preparative
chromatography.
Table B.1.: Model parameters for case studies I and II are listed below including the parame-
ters for the Savitzky-Golay filter and the latent variables of the PLS-1 model. Additionally,
the RMSECV for each model is listed.
Case study I Case study II
mAb lysozyme lysozyme PEG
Savitzky-Golay Window 215 21 101 361
Derivative 0 0 2 2
Latent variables 3 7 6 8
RMSECV (g l−1) 2.41 1.63 2.35 1.24
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Figure B.3.: Four chromatographic runs are shown for in-line FTIR measurements and
selective quantification of mAb and lysozyme. The red bars and lines refer to the mAb
off-line measurement and mAb PLS prediction, respectively. The blue bars and lines refer to
the lysozyme off-line measurement and lysozyme PLS prediction, respectively. The different
subplots show different gradient lengths: A 1CV , B 2CV , C 3CV , D 4CV .
B.3.3. Case Study II: Separation of PEGylated Lysozyme Species
In conventional chromatography systems, the separation of differently PEGylated
species cannot be monitored holistically as PEG does not absorb in UV. Contrary
to this, PEG produces a number of prominent bands in IR. A strong band around
1090 cm−1 with multiple shoulders is characteristic of C-O stretching [285]. Due to
symmetric CH2 stretching, PEG furthermore generates a doublet at 2884; 2922 cm−1.
Bands occurring between 1200 cm−1 and 1700 cm−1 are related to the protein back-
bone with some interference from PEG C-H bending.
Fig. B.4. shows a typical chromatographic separation of PEGylated lysozyme species.
During the elution, the ratio between PEG and protein bands decreases. First,
with a retention volume of 6.8mL, the absorption of the C-O band at 1090 cm−1
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(denoted as CO1 in Fig. B.4.) exceeds the absorption of amide I band (AI1). For
the second peak with a retention volume of 10.3mL, the absorption of the amide
I (AI2) is higher than for the C-O stretching band (CO2). The last peak does
not show characteristic PEG bands, i.e. consists of unconjugated lysozyme. The
order of elution followed a descending degree of PEGylation which is in line with
previous publications [273, 286, 287]. Based on the evaluation of IR absorption
AI1
AI2
AI3
AII3
AII2
AII1
CO2
CO1
Figure B.4.: Elution of PEGylated lysozyme species from a CEX column with a gradient
length of 5 CV. Bands visible between wavenumbers 1200-1700 cm−1 are the characteristic
amide bands associated with protein. The major protein bands amide I and amide II are
marked as AI and AII, respectively. The band at approximately 1100 cm−1 is characteristic of
PEG (C-O stretching, marked as CO). The subscript numerals refer to the elution order.
bands, it was decided to include all wavenumbers from 900-3100 cm−1 into PLS model
calibration. Initial PLS calibration on the concentration of the different PEGylated
lysozyme species showed that the conjugation did not cause large enough band shifts
to allow for selective quantification of the different PEGylated lysozyme species.
Instead, two PLS models were fitted on the total PEG resp. lysozyme concentration
independently. PEG concentration was calculated by weighting the off-line lysozyme
concentration according to the PEGylation degree. In Tab, B.1, the optimization
results are summarized. Fig. B.5. compares the PLS prediction with off-line analytics.
175
In-line FTIR for Process Monitoring of Chromatography
RMSECV values of 1.24 g/L and 2.35 g/L were reached for the PEG and lysozyme
concentration, respectively. The corresponding Q2 values were respectively 0.96 and
0.94 showing that the PLS models predicted the responses well. Based on the PEG
and lysozyme concentrations, a molar ratio could be calculated corresponding to
the current average PEGylation degree. To simplify visual interpretation, the molar
ratio was only plotted if the lysozyme concentration exceeded its RMSECV 3-fold.
Figure B.5.: Four chromatographic runs are shown for in-line FTIR measurements and
selective quantification of PEG and lysozyme. The red bars and lines refer to the PEG
off-line measurement and PEG PLS prediction, respectively. The blue bars and lines refer
to the lysozyme off-line measurement and lysozyme PLS prediction, respectively. Grey bars
correspond to measured protein concentrations on partially precipitated samples. Black dots
show the molar ratio between PEG and lysozyme, i.e. the current mean PEGylation degree.
The different subplots show different gradient lengths: A 2CV , B 3CV , C 4CV , D 5CV .
The predicted PEG and lysozyme concentrations accurately followed the concentra-
tions measured by off-line analytics. Furthermore, the molar ratio gives a suitable
tool for in-line monitoring of the elution of different PEG species. Interestingly,
the two PLS models are able to extend their prediction over the calibration range,
i.e. to perform a weak extrapolation. This can be seen as the PEG-to-lysozyme
ratio exceeds the value of two, which limits the calibration range spanned by off-line
analytics. Higher PEGylated species of lysozyme do however occur and could be
measured by the FTIR [273, 288].
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In summary, FTIR allows to monitor not only the protein and PEG concentration
but also the PEGylation degree during chromatographic separations.
B.3.4. Case Study III: Quantification of a Process-related
Triton X-100 is used for viral inactivation of biopharmaceuticals if pH treatment has
to be circumvented, e.g. for Factor VIII or pH-sensitive mAbs [274, 278]. To achieve
viral inactivation, Triton X-100 concentration needs to be above a minimal level.
Typically, a concentration of 1% (w/V) is used. Here, Triton X-100 concentration of
a mock virus inactivation batch was monitored during the subsequent load phase
onto a chromatographic column. During the chromatographic run, in-line FTIR
measurements were perform (Fig. B.6.).
Triton X-100
Figure B.6.: Triton X-100 as a process-related impurity can be seen in the flow-through of
the cation-exchange experiment from 5.5-11mL at 1090 cm−1.
In IR, Triton X-100 causes a characteristic band due to C-O stretching at 1090 cm−1.
By comparison of the blank run and the actual experiment, it was concluded that
Triton X-100 is not retained on the column and is mainly present in the flow-through.
The flow-through occurred between 5.5-11mL. As Triton X-100 and protein spectra
only weakly interfere with each other, the Triton X-100 content was measured by
simply correlating the band area of C-O stretching from 1007-1170 cm−1 to the
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Triton X-100 concentration. A linear regression for the calibration curve resulted
in a R2 > 0.9997. Based on the calibration curve, in-line mass-balancing could be
performed. The mass balance for Triton X-100 showed a recovery rate of 94.12% in
the flow-through. This shows that it is possible to selectively quantify Triton X-100
content during the chromatographic load phase.
B.4. Conclusion and Outlook
FTIR spectroscopy was successfully implemented in-line as a PAT tool for biopharma-
ceutical purification processes. It was demonstrated that FTIR is able to distinguish
and selectively quantify proteins in-line based on their secondary structure. Further-
more, FTIR presents a powerful tool for monitoring different chemical components
such as PEG or Triton X-100. Based on selective in-line quantification of PEG and
protein, PEGylation degrees could be measured in-line. Selective mass balancing
was performed on the process-related contaminant Triton X-100. In summary, FTIR
provides orthogonal information to the typically measured UV/Vis spectra. It there-
fore is potentially interesting for monitoring process attributes which have been
previously hidden. FTIR may help to achieve a more complete implementation of
the PAT initiative.
Future research should be directed towards making the setup more compatible with
the production environment. Challenges include the use of detectors without liquid
nitrogen cooling and the application of fiber optics for in-line process probes.
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C. Abbreviations and Symbols
Abbreviations
ABC Anything But Chromatography
AC Affinity chromatography
ADC Antibody drug conjugate
ASA Adaptive simulated annealing
ATPS Aqueous two-phase system
ATR Attenuated total reflection
AEX Anion exchange chromatography
BSA Bovine serum albumin
CEX Cation exchange chromatography
CHO Chinese hamster ovary
CSTR Continuous stirred tank reactor
CV Column volume
DF Diafiltration
DLVO Derjaguin, Landau, Verwey, Overbeek
DNA Deoxyribonucleic acid
DSP Downstream process development
DoE Design of experiment
ELISA Enzyme-linked immunosorbent Assay
EMA European Medicines Agency
Fc Fragment crystallizable
FDA Food and drug administration
FTIR Fourier-transform infrared spectroscopy
GMP Good manufacturing practice
GRM General rate model
GST Glutathione S-transferase
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HCCF Harvested cell culture fluid
HCP Host cell proteins
HIC Hydrophobic interaction chromatography
HIS Histidine
HMW High molecular weight impurities
HPLC High performance liquid chromatography
HT High-throughput
HTPD High-throughput process development
HTS High-throughput screening
IEX Ion exchange chromatography
IgG Immunglobulin G
LC Liquid chromatography
LGE Linear gradient elution
LM Levenberg-Marquardt
mAb Monoclonal antibody
MCA MultiChannel Arm
MCT Mercury Cadmium Telluride
MLR Multi linear regression
mPSE Modified polyethersulfone
MSMPR Mixed product removal reactor
MVDA Multivariate data analysis
NIPALS Nonlinear iterative partial last square
OFAT One-factor-at-a-time
PDB Protein data base
pKa Acid dissociation constant
PLS Partial least square
PAT Process analytical technologies
PCA Principle component analysis
PCCC Periodic counter current chromatography
PEG Polyethylene glycol
pI Isoelectric point
QbD Quality by design
QSAR Quantitative structure-activity relationship
PRESS Predictive residual sum of square
RMSECV Root mean square errors of validation
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RMSEP Root mean square errors of prediction
RP Reversed phase chromatography
SEC Size exclusion chromatography
SMA Steric mass action
TMP Transmembrane pressure
TFF Tangential flow filtration
UF Ultrafiltration
UHPLC Ultra-high performance chromatography
UV Ultraviolet
USP Upstream process development
VdW Van-der-Waals
Vis Visible
VLP Virus-like particles
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Symbols
ai Activity M
B Regression matrix -
ci Bulk phase concentration of species i M
cp Protein in solution M
cp,i Pore phase concentration of species i M
C Protein solubility in the Cohen equation M
C0 Protein solubility in the absence of PEG in the
Cohen equation
-
Dax Axial dispersion coefficient mm
2
s
Dp Pore diffusion coefficient mm
2
s
Ei Residues matrix of a PLS or PCA
F Electric force N
G Gibbs free energy J
h Ionic hydration number -
k Constant for hydration dependency of salts -
ke Coulomb constant NM
2
C2
kads Adsorption coefficient -
kdes Desorption coefficient -
keq Equilibrium coefficient -
kfilm,i Film transfer coefficient mms
kkin Kinetic coefficient -
K Equilibrium constant -
L Distance of the mirror mm
m PEG concentration %(w/w)
n Number of protein molecules -
P Protein molecules -
Pp Precipitate -
PEG One PEG molecule -
P T Principle component matrix -
pKa Acid dissociation constant at logarithmic scale
q Precipitated protein M
qi Stationary phase concentration of species i M
qp Charge of the species p C
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Q Principle component matrix -
r Radius mm
rp Particle radius of adsorbent mm
R Gas constant J
Kmol
S Entropy J
K
t Time s
T Temperature K
Tagg Aggregation temperature ◦C
Tm Melting temperature ◦C
u Flow velocity mm
s
U Potential energy J
H Enthalpy J
V Score matrix -
W Score matrix -
WB Bulk-like ordered water molecules -
x Space dimension mm
xi Amount fraction mol
X Matrix with original data during PCA -
z Distance between two particles m
β Number of bulk-like water molecules -
β0 Hydration number at infinite dilution of PEG and
protein
-
β1 Hydration number accounting for PEG Lmol
β2 Hydration number accounting for protein Lmol
ε Permittivity F
m
b Particle porosity -
γ Activity coefficient -
θ Characteristic binding charge -
Λ Total ligand density M
µi Chemical potential Jmol
ν Stoichiometric coefficient -
Ψ Electrostatic potential V
σ Shielding factor -
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